1 116HG Prader-Willi syndrome regulation Long ncRNA 116HG has been shown to play a role in the development of Prader–Willi syndrome (PWS) (Powell et al., 2013). chr15 N/A N/A N/A Human 116HG N/A 24624135 2 1B FGF-antisense transcripts endometriosis expression Mihalich et al, reported patients with endometriosis show low expression of 1B FGF-antisense transcripts, which correlates with endometrial cell proliferation N/A N/A N/A N/A Human 1B FGF-antisense transcripts N/A 23781896 3 4930503E24Rik ischemia/reperfusion expression Classification and validation of deregulated LncRNAs in ischemia/reperfusion-treated mouse livers. chr10 124469074 124524488 + Mus 4930503E24Rik; NR_028310.1 NR_028310.1 24312245 4 51A Alzheimer's disease regulation 51A expression drives a splicing shift of SORL1 from the synthesis of the canonical long protein variant 1 to an alternatively spliced protein form. This process, resulting in a decreased synthesis of SORL1 variant 1, is associated with an impaired processing of APP, leading to increase of A formation. chr19 58770915 58770934 - Human 51A NC_012749.1 22996644 5 5730458M16Rik Heart Failure expression Quantitative-PCR identified the relative expression of 5 significantly upregulated and 5 downregulated LncRNAs from 10 HF mice. Five LncRNAs were upregulated and 22 downregulated in HF hearts as compared with control hearts. N/A N/A N/A N/A Mus 5730458M16Rik AK020791.1 24205036 6 7SK AIDS Expression Stable expression of cdNIPP1 increased CDK9 phosphorylation on Thr(186) and the association of CDK9 with 7SK RNA. The stable expression of cdNIPP1 disrupted the interaction of Tat and PP1 and inhibited HIV-1 transcription. Expression of cdNIPP1 as a part of the HIV-1 genome inhibited HIV-1 replication. chr6 52860418 52860749 + Human RN7SK; 7SK NR_001445.2 21098020 7 7SK AIDS Interaction HIV-1 Tat assembles a multifunctional transcription elongation complex and stably associates with the 7SK snRNP. chr6 52860418 52860749 + Human RN7SK; 7SK NR_001445.2 20471949 8 7SK AIDS Interaction Tat efficiently replaces HEXIM1 on the 7SK snRNA in vivo and therefore, it promotes the disassembly of the 7SK/HEXIM/P-TEFb negative transcriptional regulatory snRNP to augment the nuclear level of active P-TEFb. The human 7SK snRNA carries a TAR RNA-like Tat-binding element that is essential for the normal transcriptional regulatory function of 7SK questions the viability of HIV therapeutic approaches based on small drugs blocking the Tat-binding site of HIV TAR. chr6 52860418 52860749 + Human RN7SK; 7SK NR_001445.2 20976203 9 7SK AIDS Interaction The 7SK-HMGA1 interaction not only adds an essential facet to the comprehension of transcriptional plasticity at the coupling of initiation and elongation, but also might provide a molecular link between HIV reprogramming of cellular gene expression-associated oncogenesis. chr6 52860418 52860749 + Human RN7SK; 7SK NR_001445.2 21087998 10 7SK AIDS Interaction The HIV-1 Tat protein also releases P-TEFb from the 7SK/HEXIM complex during viral infection to promote viral transcription and replication. chr6 52860418 52860749 + Human RN7SK; 7SK NR_001445.2 22377309 11 7SK cancer Interaction Together with the HEXIM proteins, 7SK RNA associates with and sequesters a fraction of cellular P-TEFb into a catalytically inactive complex. Active and inactive forms of P-TEFb are kept in a functional and dynamic equilibrium tightly linked to the transcriptional requirement of the cell. Importantly, cardiac hypertrophy and development of various types of human malignancies have been associated with increased P-TEFb activity, consequence of a disruption of this regulatory equilibrium. chr6 52860418 52860749 + Human RN7SK; 7SK NR_001445.2 22377309 12 7SK cardiac hypertrophy Interaction Together with the HEXIM proteins, 7SK RNA associates with and sequesters a fraction of cellular P-TEFb into a catalytically inactive complex. Active and inactive forms of P-TEFb are kept in a functional and dynamic equilibrium tightly linked to the transcriptional requirement of the cell. Importantly, cardiac hypertrophy and development of various types of human malignancies have been associated with increased P-TEFb activity, consequence of a disruption of this regulatory equilibrium. chr6 52860418 52860749 + Human RN7SK; 7SK NR_001445.2 22377309 13 7SK gastric cancer Expression Transfection of an siRNA directed against LARP7 (anti-LARP7 siRNA) into non-neoplastic gastric epithelial cells decreased 7sk levels by 72% relative to a control siRNA (P<0.01). chr6 52860418 52860749 + Human RN7SK; 7SK NR_001445.2 22488152 14 7SL AIDS Interaction 7SL RNA, but not the 54-kd signal recognition particle protein, is an abundant component of both infectious HIV-1 and minimal virus-like particles. chr14 50053298 50053596 + Human RN7SL1; 7SL; 7L1a; RN7SL; RNSRP1 NR_002715.1 16489186 15 7SL AIDS N/A 7SL RNA binding is a conserved feature of human anti-HIV-1 cytidine deaminases. chr14 50053298 50053596 + Human RN7SL1; 7SL; 7L1a; RN7SL; RNSRP1 NR_002715.1 20926562 16 7SL dermatomyositis Interaction Autoantibodies against signal recognition particle (SRP) are detected in patients with polymyositis/dermatomyositis (PM/DM). The SRP consists of 7SL RNA and 6 protein components. chr14 50053298 50053596 + Human RN7SL1; 7SL; 7L1a; RN7SL; RNSRP1 NR_002715.1 16142868 17 7SL Leishmania Expression Down-regulation of 7SL RNA expression and impairment of vesicular protein transport pathways by Leishmania infection of macrophages. chr14 50053298 50053596 + Human RN7SL1; 7SL; 7L1a; RN7SL; RNSRP1 NR_002715.1 15955815 18 7SL Leishmania Expression High-resolution melt analysis PCR (HRM PCR) for diagnosis of Old World Leishmania was developed using the 7SL RNA gene. Cutaneous leishmaniasis samples were analyzed. Sensitivity and specificity of HRM PCR were significantly better (P < 0.001) than those of internal transcribed spacer 1 PCR and similar to those of kinetoplast DNA PCR. chr14 50053298 50053596 + Human RN7SL1; 7SL; 7L1a; RN7SL; RNSRP1 NR_002715.1 20392923 19 7SL Leishmania N/A Leishmania 7SLRNA is an informative target for clinical and epidemiologic investigations of human leishmaniasis. chr14 50053298 50053596 + Human RN7SL1; 7SL; 7L1a; RN7SL; RNSRP1 NR_002715.1 20856851 20 7SL Leishmania N/A The 7SL RNA PCR has proven useful for direct diagnosis of Old World leishmaniasis, especially when combined with the RBD assay for species identification. chr14 50053298 50053596 + Human RN7SL1; 7SL; 7L1a; RN7SL; RNSRP1 NR_002715.1 20561310 21 7SL polymyositis Interaction Autoantibodies against signal recognition particle (SRP) are detected in patients with polymyositis/dermatomyositis (PM/DM). The SRP consists of 7SL RNA and 6 protein components. chr14 50053298 50053596 + Human RN7SL1; 7SL; 7L1a; RN7SL; RNSRP1 NR_002715.1 16142868 22 A130040M12Rik cancer Expression These results indicate that PSF is a major tumor-suppressor protein and VL30-1 RNA is a major tumor-promoter RNA in mice. chr11 86812765 86816129 - Mouse A130040M12Rik; VL30; CA782090; H3053C11 NR_002860.2 19805375 23 AC002511.1 enterovirus 72 infection expression A general consistency between the qPCR and microarray analysis results was confirmed in four lncRNAs (AP000688.29, AC002511.1, RP5-843L14.1, and RP4-620F22.3) in terms of regulation direction and significance. Specifically, a 3.31-fold down-regulation chr19 35940617 35942669 + Human FFAR2; FFA2R; GPR43 AC002511.1 23220233 24 ACTA2-AS1 lung adenocarcinoma expression Enhanced expression of long non-coding RNA ZXF1 promoted the invasion and metastasis in lung adenocarcinoma. chr10 88932747 88934927 + Human ACTA2-AS1; ZXF1; uc001kfo.1 XR_110433.4 24721325 25 ADAMTS9-AS2 glioma regulation A new tumor suppressor?LncRNA?ADAMTS9-AS2 is regulated by DNMT1 and inhibits migration of glioma cells. chr3 64684870 65011468 + Human ADAMTS9-AS2 NR_038264.1 24833086 26 AF086415 nasopharyngeal carcinoma expression Six lncRNAs (AF086415, AK095147, RP1-179N16.3, MUDENG, AK056098 and AK294004) were confirmed by qPCR. N/A N/A N/A N/A Human AF086415 AF086415.1 24379026 27 AFAP1-AS1 barrett's Esophagus expression Hypomethylation of Noncoding DNA Regions and Overexpression of the Long Noncoding RNA, AFAP1-AS1, in Barrett's Esophagus and Esophageal Adenocarcinoma. chr4 7755817 7780655 + Human AFAP1-AS1; AFAP1AS; AFAP1-AS NR_026892.1 23333711 28 AIR alcoholic liver disease Expression Up regulation in liver by DDC (Diethyl 1,4-dihydro-2,4,6,-trimethyl-3,5-pyridinedicarboxylate ). chr17 12741311 12859884 + Mouse Airn; Air; AI256653; AI597500; AW049873; D17Ertd663e; 2810051F02Rik; 2810434M15Rik; B930018I07Rik NR_002853.2 19362547 29 AIR chronic nonalcoholic liver disease Expression Up regulation in liver by DDC (Diethyl 1,4-dihydro-2,4,6,-trimethyl-3,5-pyridinedicarboxylate ). chr17 12741311 12859884 + Mouse Airn; Air; AI256653; AI597500; AW049873; D17Ertd663e; 2810051F02Rik; 2810434M15Rik; B930018I07Rik NR_002853.2 19362547 30 AIR hepatocelluar carcinoma Expression Up regulation in liver by DDC (Diethyl 1,4-dihydro-2,4,6,-trimethyl-3,5-pyridinedicarboxylate ). Furthermore, over expression of H19 and AIR was demonstrated in tumors formed in mice withdrawn for 9 months. chr17 12741311 12859884 + Mouse Airn; Air; AI256653; AI597500; AW049873; D17Ertd663e; 2810051F02Rik; 2810434M15Rik; B930018I07Rik NR_002853.2 19362547 31 AK023948 papillary thyroid carcinoma Expression Gene expression analysis indicated that AK023948 is significantly down-regulated in most PTC tumors. The putative noncoding RNA gene AK023948 is a candidate susceptibility gene for PTC. chr8 134067204 134070012 + Human PTCSC1; PTCSC; NCRNA00197 AK023948 19147577 32 AK028007 ischemia/reperfusion expression Classification and validation of deregulated LncRNAs in ischemia/reperfusion-treated mouse livers. N/A N/A N/A N/A Mus AK028007 AK028007.1 24312245 33 AK038798 Heart Failure expression Quantitative-PCR identified the relative expression of 5 significantly upregulated and 5 downregulated LncRNAs from 10 HF mice. Five LncRNAs were upregulated and 16 downregulated in HF hearts as compared with control hearts. N/A N/A N/A N/A Mus AK038798 AK038798.1 24205036 34 AK042766 Restless legs syndrome Expression A recent study suggested that the predisposition to RLS results from reduced expression of Meis1 mediated by intronic cis-regulatory elements. Intriguingly, in the developing mouse brain, Meis1 is co-expressed in the developing cerebellar granule cell layer along with a genomically-associated lncRNA AK042766 N/A N/A N/A N/A Mouse N/A AK042766 19696892 35 AK044955 Heart Failure expression Quantitative-PCR identified the relative expression of 5 significantly upregulated and 5 downregulated LncRNAs from 10 HF mice. Five LncRNAs were upregulated and 7 downregulated in HF hearts as compared with control hearts. N/A N/A N/A N/A Mus AK044955 AK044955.1 24205036 36 AK049728 Heart Failure expression Quantitative-PCR identified the relative expression of 5 significantly upregulated and 5 downregulated LncRNAs from 10 HF mice. Five LncRNAs were upregulated and 5 downregulated in HF hearts as compared with control hearts. N/A N/A N/A N/A Mus AK049728 AK049728.1 24205036 37 AK056098 nasopharyngeal carcinoma expression Six lncRNAs (AF086415, AK095147, RP1-179N16.3, MUDENG, AK056098 and AK294008) were confirmed by qPCR. N/A N/A N/A N/A Human AK056098 AK056098.1 24379026 38 AK095147 nasopharyngeal carcinoma expression Six lncRNAs (AF086415, AK095147, RP1-179N16.3, MUDENG, AK056098 and AK294005) were confirmed by qPCR. N/A N/A N/A N/A Human AK095147 AK095147.1 24379026 39 AK137898 Heart Failure expression Quantitative-PCR identified the relative expression of 5 significantly upregulated and 5 downregulated LncRNAs from 10 HF mice. Five LncRNAs were upregulated and 4 downregulated in HF hearts as compared with control hearts. N/A N/A N/A N/A Mus AK137898 AK137898.1 24205036 40 AK139328 Ischemia/Reperfusion regulation Silencing of Long Noncoding RNA AK139328 Attenuates Ischemia/Reperfusion Injury in Mouse Livers. N/A N/A N/A N/A Mus AK139328 AK139328.1 24312245 41 AK139328 ischemia/reperfusion expression Classification and validation of deregulated LncRNAs in ischemia/reperfusion-treated mouse livers. N/A N/A N/A N/A Mus AK139328 AK139328.1 24312245 42 AK143260 cardiac lineage regulation Boyer et al at Massachusetts Institute of Technology have begun to study lncRNAs important for heart development and have identified a novel lncRNA (AK143260) required for specification of the cardiac lineage in vitro chr18 61639653 61639653 + Mus Gm20748 AK143260.1 23104877 43 AK143294 ischemia/reperfusion expression Classification and validation of deregulated LncRNAs in ischemia/reperfusion-treated mouse livers. N/A N/A N/A N/A Mus AK143294 AK143294.1 24312245 44 AK143693 ischemia/reperfusion expression Classification and validation of deregulated LncRNAs in ischemia/reperfusion-treated mouse livers. N/A N/A N/A N/A Mus AK143693 AK143693.1 24312245 45 AK144081 Heart Failure expression Quantitative-PCR identified the relative expression of 5 significantly upregulated and 5 downregulated LncRNAs from 10 HF mice. Five LncRNAs were upregulated and 21 downregulated in HF hearts as compared with control hearts. N/A N/A N/A N/A Mus AK144081 AK144081.1 24205036 46 AK153778 Heart Failure expression Quantitative-PCR identified the relative expression of 5 significantly upregulated and 5 downregulated LncRNAs from 10 HF mice. Five LncRNAs were upregulated and 26 downregulated in HF hearts as compared with control hearts. N/A N/A N/A N/A Mus AK153778 AK153778.1 24205036 47 AK294004 nasopharyngeal carcinoma expression Six lncRNAs (AF086415, AK095147, RP1-179N16.3, MUDENG, AK056098 and AK294009) were confirmed by qPCR. chr11 69665563 69675397 - Human AK294004; ORAOV1; TAOS1 AK294004.1 24379026 48 Alg2 ischemia/reperfusion expression Classification and validation of deregulated LncRNAs in ischemia/reperfusion-treated mouse livers. chr4 47469833 47474369 - Mus Alg2; AK209601 AK209601.1 24312245 49 Alu lncRNAs Macular degeneration expression Biogenesis, metabolism, and functions of lncRNAs are otherwise interconnected with known pathogenic mechanisms N/A N/A N/A N/A Human Alu lncRNAs N/A 23791884 50 ANRIL atherosclerosis mutation Chr9p21 encodes the long non-coding RNA (ncRNA) antisense non-coding RNA in the INK4 locus (ANRIL). ANRIL expression is associated with the Chr9p21 genotype and correlated with atherosclerosis severity chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.4 N/A 23861667 51 ANRIL atherosclerosis regulation The large non-coding RNA ANRIL, which is associated with atherosclerosis, periodontitis and several forms of cancer, regulates ADIPOR1, VAMP3 and C11ORF10. chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.4 N/A 23813974 52 ANRIL cancer regulation The large non-coding RNA ANRIL, which is associated with atherosclerosis, periodontitis and several forms of cancer, regulates ADIPOR1, VAMP3 and C11ORF10. chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.4 N/A 23813974 53 ANRIL periodontitis regulation The large non-coding RNA ANRIL, which is associated with atherosclerosis, periodontitis and several forms of cancer, regulates ADIPOR1, VAMP3 and C11ORF10. chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.4 N/A 23813974 54 ANRIL prostat expression Recent studies have linked their mis-expression to diverse cancers (ANRIL: prostate cancer, XIST: female cancers, HOTAIR: breast cancer, KCNQ1OT1: colorectal cancer). chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.4 N/A 23660942 55 anti-NOS2A glioblastoma Expression anti-NOS2A is a lncRNA that is expressed in meningiomas and glioblastomas from a genomic locus that evolved by duplication of the NOS2A gene followed by internal DNA inversion. chr17 26083792 26127555 - Human NOS2; NOS; INOS; NOS2A; HEP-NOS NM_000625.4 18820242 56 anti-NOS2A Meningioma Expression anti-NOS2A is a lncRNA that is expressed in meningiomas and glioblastomas from a genomic locus that evolved by duplication of the NOS2A gene followed by internal DNA inversion. chr17 26083792 26127555 - Human NOS2; NOS; INOS; NOS2A; HEP-NOS NM_000625.4 18820242 57 AP000688.29 enterovirus 71 infection expression A general consistency between the qPCR and microarray analysis results was confirmed in four lncRNAs (AP000688.29, AC002511.1, RP5-843L14.1, and RP4-620F22.3) in terms of regulation direction and significance. Specifically, a 3.31-fold down-regulation (2.25-fold in microarray analysis) was observed in AP000688.29, 3.33-fold up-regulation (2.77-fold in microarray analysis) in AC002511.1, 2.29-fold up-regulation (2.40-fold in microarray analysis) in RP5-843L14.1, and 2.99-fold up-regulation (2.22-fold in microarray analysis) in RP4-620F22.3 N/A N/A N/A N/A Human N/A N/A 23220233 58 AP5M1 nasopharyngeal carcinoma expression Six lncRNAs (AF086415, AK095147, RP1-179N16.3, MUDENG, AK056098 and AK294007) were confirmed by qPCR. chr14 57268888 57290079 + Human AP5M1; Mu5; MuD; MUDENG; C14orf108 NR_026895.1 24379026 59 ASFMR1 fragile X syndrome Expression ASFMR1 is silenced in FXS patients and up regulated in pre-mutation carriers suggesting that a common process is responsible for regulating the expression these transcripts. chrX 146990949 147003676 - Human FMR1-AS1; FMR4; ASFMR1; FMR1AS; FMR1-AS NR_024499.1 17921506 60 ATP6V1G2-DDX39B dilated cardiomyopathy Mutation The haplotype block, NFKBIL1-ATP6V1G2-BAT1-MICB-MICA, within the class III-class I boundary region of the human major histocompatibility complex may control susceptibility to hepatitis C virus-associated dilated cardiomyopathy. chr6 31497996 31514625 - Human ATP6V1G2-DDX39B NR_037853.1 16101831 61 ATP6V1G2-DDX39B HCV Mutation The haplotype block, NFKBIL1-ATP6V1G2-BAT1-MICB-MICA, within the class III-class I boundary region of the human major histocompatibility complex may control susceptibility to hepatitis C virus-associated dilated cardiomyopathy. chr6 31497996 31514625 - Human ATP6V1G2-DDX39B NR_037853.1 16101831 62 ATXN8OS human spinocerebellar ataxia type 8 Expression RNA gain-of-function plays a significant role in SCA8: 1) CUG(exp) transcripts accumulate as ribonuclear inclusions that co-localize with MBNL1 in selected neurons in the brain. chr13 70681345 70713885 + Human ATXN8OS; SCA8; KLHL1AS; NCRNA00003 NR_002717.2 19680539 63 ATXN8OS human spinocerebellar ataxia type 8 Expression RNA gain-of-function plays a significant role in SCA8: 1) CUG(exp) transcripts accumulate as ribonuclear inclusions that co-localize with MBNL1 in selected neurons in the brain. chr13 70681345 70713885 + Human ATXN8OS; SCA8; KLHL1AS; NCRNA00003 NR_002717.2 19680539 64 ATXN8OS human spinocerebellar ataxia type 8 Expression Spinocerebellar ataxia type 8 (SCA8) involves bidirectional expression of CUG (ATXN8OS) and CAG (ATXN8) expansion transcripts. chr13 70681345 70713885 + Human ATXN8OS; SCA8; KLHL1AS; NCRNA00003 NR_002717.2 19229559 65 ATXN8OS human spinocerebellar ataxia type 8 Locus Patients show a trinucleotide (CUG) expansion in a noncoding RNA termed ataxin 8 opposite strand (ATXN8OS), an antisense transcript to the KLHL1 gene. chr13 70681345 70713885 + Human ATXN8OS; SCA8; KLHL1AS; NCRNA00003 NR_002717.2 16804541 66 ATXN8OS human spinocerebellar ataxia type 8 Mutation The ATXN8OS (CTA)n(CTG)n composite repeat expansion is transmitted in an autosomal dominant manner with reduced penetrance. chr13 70681345 70713885 + Human ATXN8OS; SCA8; KLHL1AS; NCRNA00003 NR_002717.2 20301445 67 ATXN8OS human spinocerebellar ataxia type 8 Mutation The low prevalence of SCA8 seems to be correlated with the low frequency of large (CTA/CTG)n copy number alleles in Chinese population. chr13 70681345 70713885 + Human ATXN8OS; SCA8; KLHL1AS; NCRNA00003 NR_002717.2 18841561 68 ATXN8OS Spinocerebellar ataxia type 8 mutation Genetic variation in lncRNA genes causes disease and influences susceptibility chr13 70681345 70713885 + Human ATXN8OS; SCA8; KLHL1AS; NCRNA00003 NR_002717.2 23791884 69 ATXN8OS Spinocerebellar ataxia type 8 Interaction ATXN8OS transcript contributes to SCA8 pathogenesis by altering the activity of MBNL/CELF alternative splicing proteins. chr13 70681345 70713885 + Human ATXN8OS; SCA8; KLHL1AS; NCRNA00003 NR_002717.2 20380817 70 ATXN8OS Spinocerebellar ataxia type 8 mutation Expansion repeats in the ATXN8OS lncRNA gene are partly responsible for the pathology of spinocerebellar ataxia type 8 through a toxic RNA gain-of-function mechanism that includes formation of ribonuclear inclusions in the cerebellum and deregulation of muscleblind-like splicing regulator 1-mediated alternative splicing chr13 70681345 70713885 + Human ATXN8OS; SCA8; KLHL1AS; NCRNA00003 NR_002717.2 22814587 71 B1 SINE RNA brain ischemia Expression SINE B2 was induced by global ischemia after 1 day in Mongolian gerbils. N/A N/A N/A N/A Gerbils N/A N/A 15016078 72 B1 SINE RNA infection of mouse minute virus Expression Increased levels of B1 and B2 SINE transcripts in mouse fibroblast cells due to minute virus of mice infection. N/A N/A N/A N/A Mouse N/A N/A 15351211 73 B2 SINE RNA deleterious effects in the somatic thymus tissue Epigenetics miR-468-mediated suppression of LSH leads to aberrant methylation of LINE1 and SINE B2. N/A N/A N/A N/A Mouse N/A N/A 19959559 74 B2 SINE RNA infection of chicken embryo lethal orphan adenovirus Interaction CELO protein Gam1 was able to mediate transcriptional activation of these B2 SINE-containing RNAs. Upregulation of B2-SINE-containing RNAs could be a novel contribution of Gam1 to CELO host cell infection. N/A N/A N/A N/A Mouse N/A N/A 12729754 75 B2 SINE RNA infection of mouse minute virus Expression Increased levels of B1 and B2 SINE transcripts in mouse fibroblast cells due to minute virus of mice infection. N/A N/A N/A N/A Mouse N/A N/A 15351211 76 B2 SINE RNA pain Expression Comt1 is differentially expressed among the strains, and this differential expression is cis-regulated. A B2 short interspersed nuclear element (SINE) was inserted in the 3'-untranslated region (3'-UTR) of Comt1 in 14 strains generating a common haplotype that correlates with gene expression. A haplotype, defined by a 3'-UTR B2 SINE element, regulates Comt1 expression and some mouse behaviors. N/A N/A N/A N/A Mouse N/A N/A 20659173 77 BACE1-AS Alzheimer's disease Expression Elevated levels of Ab, BACE1 proteins, as well as BACE1-AS have been detected in subjects with Alzheimer's disease (AD), suggesting that altered BACE1 expression plays a role in the pathogenesis of the disease. chr11 117162062 117162859 + Human BACE1-AS; BACE1AS; FJ573250; BACE1-AS1; NCRNA00177 NR_037803.1 18587408 78 BACE1-AS Alzheimer's disease Expression The BACE1-antisense transcript (BACE1-AS) is markedly upregulated in brain samples from AD patients and promotes the stability of the (sense) BACE1 transcript. chr11 117162062 117162859 + Human BACE1-AS; BACE1AS; FJ573250; BACE1-AS1; NCRNA00177 NR_037803.1 21785702 79 BACE1-AS Alzheimer's disease Interaction BACE1-AS is directly implicated in the increased abundance of A尾 1-42 in Alzheimer's disease. chr11 117162062 117162859 + Human BACE1-AS; BACE1AS; FJ573250; BACE1-AS1; NCRNA00177 NR_037803.1 18587408 80 BACE1-AS Alzheimer's disease Interaction BACE1-AS is directly implicated in the increased abundance of A尾 1-42 in Alzheimer's disease. chr11 117162062 117162859 + Human BACE1-AS; BACE1AS; FJ573250; BACE1-AS1; NCRNA00177 NR_037803.1 18587408 81 BACE1-AS Alzheimer's disease Interaction The BACE1-antisense transcript (BACE1-AS) regulates BACE1 mRNA and subsequently BACE1 protein expression in vitro and in vivo. BACE1 mRNA expression is under the control of a regulatory noncoding RNA that may drive Alzheimer's disease-associated pathophysiology. chr11 117162062 117162859 + Human BACE1-AS; BACE1AS; FJ573250; BACE1-AS1; NCRNA00177 NR_037803.1 18587408 82 BACE1-AS Alzheimer's disease expression BACE1 is one of two peptidases that carry out the initial proteolytic cleavage of APP, allowing it to accumulate in the brain. BACE1AS levels were found to be higher in human subjects with AD, and also in BACE1 transgenic mouse models of AD chr11 117162062 117162859 + Human BACE1-AS; BACE1AS; FJ573250; BACE1-AS1; NCRNA00177 NR_037803.1 22817756 83 BACE1-AS Alzheimer's disease expression BACE1-AS is elevated in brains of patients with AD, suggesting that the lncRNA is the driving force behind BACE1 dysregulation in AD chr11 117162062 117162859 + Human BACE1-AS; BACE1AS; FJ573250; BACE1-AS1; NCRNA00177 N/A 23562612 84 BACE1-AS Alzheimer's disease expression The expression of BACE1 antisense transcript (BACE1-AS) was linked to increased amyloid-β 1–42 in patients with Alzheimer’s disease and gave rise for a stabilizing function of the lncRNA. chr11 117162062 117162859 + Human BACE1-AS; BACE1AS; FJ573250; BACE1-AS1; NCRNA00177 NR_037803.1 24531795 85 BACE1-AS Alzheimer's disease expression he accumulation of this protein has been implicated in many neurological disorders and elevated levels of both BACE1 and BACE1-AS have been detected in subjects with Alzheimer's disease chr11 117162062 117162859 + Human BACE1-AS; BACE1AS; FJ573250; BACE1-AS1; NCRNA00177 NR_037803.1 22928560 86 BACE1-AS Alzheimer's disease regulation Genomic context links lncRNAs to disease genes/loci and related pathways chr11 117162062 117162859 + Human BACE1-AS; BACE1AS; FJ573250; BACE1-AS1; NCRNA00177 NR_037803.1 23791884 87 BACE1-AS Alzheimer's disease regulation In Alzheimer disease, the protein-coding gene BACE-1 (β-site amyloid precursor protein-cleaving enzyme) cleaves amyloid precursor protein (APP) to β-amyloid peptide (Aβ), the accumulation of which (amyloid plaques) is associated with disease. LncRNA BACE1-AS, located on the antisense strand to BACE1, binds complementarily to BACE1 mRNA, increases its stability, regulates BACE1 translation, and thereby the production of Aβ. chr11 117162062 117162859 + Human BACE1-AS; BACE1AS; FJ573250; BACE1-AS1; NCRNA00177 NR_037803.1 24667321 88 BACE1-AS Alzheimer's disease regulation It has been shown that misexpression of lncRNAs contributes to numerous diseases. For example, an lncRNA may influence the pathogenesis of Alzheimer's disease. The BACE1-AS can regulate BACE1 mRNA expression. BACE1 mRNA expression is under the control of a regulatory non-coding RNA that may drive Alzheimer's disease-associated pathophysiology chr11 117162062 117162859 + Human BACE1-AS; BACE1AS; FJ573250; BACE1-AS1; NCRNA00177 NR_037803.1 22535282 89 BACE1-AS Inclusion body myositis regulation Genomic context links lncRNAs to disease genes/loci and related pathways chr11 117162062 117162859 + Human BACE1-AS; BACE1AS; FJ573250; BACE1-AS1; NCRNA00177 NR_037803.1 23791884 90 BANCR melanoma N/A BRAF-regulated lncRNA 1 (BANCR) was identified as a recurrently overexpressed, previously unannotated 693-bp transcript on chromosome 9 with a potential functional role in melanoma cell migration. chr9 71911597 71921972 - Human BANCR; LINC00586 NR_047671.2 22581800 91 BANCR melanoma regulation This screen revealed a 693 bp novel lncRNA transcript, named BRAF-activated non-coding RNA (BANCR).Depletion of BANCR in melanoma cells resulted in profound migration defects, indicating a significant role of BANCR in regulation of melanoma cell motility. chr9 71911597 71921972 - Human BANCR; LINC00586 NR_047671.2 24115003 92 BANCR non-small cell lung cancer expression Downregulation of BRAF activated non-coding RNA is associated with poor prognosis for non-small cell lung cancer and promotes metastasis by affecting epithelial-mesenchymal transition. chr9 71911597 71921972 - Human BANCR; LINC00586 NR_047671.2 24655544 93 BC040587 osteosarcoma Mutation These CNAs (copy number alterations) in osteosarcoma often involve the noncoding RNAs LOC285194 and BC040587. N/A N/A N/A N/A Human N/A N/A 20048075 94 BCAR4 breast cancer Expression BCAR4 is expressed in 27% of primary breast tumors. Forced expression of BCAR4 in human ZR-75-1 and MCF7 breast cancer cells resulted in cell proliferation in the absence of estrogen and in the presence of various antiestrogens.BCAR4 may be a good target for treating antiestrogen-resistant breast cancer. chr16 11913687 11922689 - Human BCAR4 NR_024049.1 21506106 95 BCAR4 breast cancer Expression High BCAR4 mRNA levels were associated with poor MFS and overall survival, reflecting tumour aggressiveness. chr16 11913687 11922689 - Human BCAR4 NR_024049.1 20859285 96 BCAR4 breast cancer N/A Breast cancer anti-estrogen resistance 4 (BCAR4), caused OH-TAM resistance and anchorage-independent cell growth in ZR-75-1 cells. chr16 11913687 11922689 - Human BCAR4 NR_024049.1 16778085 97 BCAR4 breast cancer expression BCAR4 induces antioestrogen resistance but sensitises breast cancer to lapatinib. chr16 11913687 11922689 - Human BCAR4 NR_024049.1 22892392 98 BCYRN1 aging Expression In normal aging, BC200 levels in cortical areas were reduced by >60% between the ages of 49 and 86. In contrast, BC200 RNA was significantly up-regulated in AD brains, in comparison with age-matched normal brains. chr2 47562454 47562653 + Human BCYRN1; BC200; BC200a; LINC00004; NCRNA00004 NR_001568.1 17553964 99 BCYRN1 Alzheimer's disease Expression In normal aging, BC200 levels in cortical areas were reduced by >60% between the ages of 49 and 86. In contrast, BC200 RNA was significantly up-regulated in AD brains, in comparison with age-matched normal brains. chr2 47562454 47562653 + Human BCYRN1; BC200; BC200a; LINC00004; NCRNA00004 NR_001568.1 17553964 100 BCYRN1 Alzheimer's disease Expression Increased levels of BC200 were found in brain regions that are preferentially affected in AD. Further, in advanced stages of AD, BC200 was mis-localized and clustered in the perikaryon. These observations suggest that deregulation of these synaptic lncRNAs is involved in the synaptic and neural network dysfunction that is found in both early and later stages of AD. chr2 47562454 47562653 + Human BCYRN1; BC200; BC200a; LINC00004; NCRNA00004 NR_001568.1 20380817 101 BCYRN1 Alzheimer's disease expression BC200 levels in Brodmann's area 9 (the area of brain affected in AD) were found to be higher in age-matched AD brains compared with normal brains, and the relative levels of BC200 RNA in affected areas increased with the severity of AD. chr2 47562454 47562653 + Human BCYRN1; BC200; BC200a; LINC00004; NCRNA00004 N/A 23562612 102 BCYRN1 breast cancer Expression BC200 RNA was expressed in carcinomas of the breast, cervix, oesophagus, lung, ovary, parotid, and tongue, but not in corresponding normal tissues. chr2 47562454 47562653 + Human BCYRN1; BC200; BC200a; LINC00004; NCRNA00004 NR_001568.1 9422992 103 BCYRN1 breast cancer Expression In ductal carcinomas in situ, furthermore, significant BC200 (BCYRN1) expression was associated with high nuclear grade, suggesting that the presence of BC200 RNA in such tumors may be used as a prognostic indicator of tumor progression. chr2 47562454 47562653 + Human BCYRN1; BC200; BC200a; LINC00004; NCRNA00004 NR_001568.1 15240511 104 BCYRN1 cervical cancer Expression BC200 RNA was expressed in carcinomas of the breast, cervix, oesophagus, lung, ovary, parotid, and tongue, but not in corresponding normal tissues. chr2 47562454 47562653 + Human BCYRN1; BC200; BC200a; LINC00004; NCRNA00004 NR_001568.1 9422992 105 BCYRN1 lung cancer Expression BC200 RNA was expressed in carcinomas of the breast, cervix, oesophagus, lung, ovary, parotid, and tongue, but not in corresponding normal tissues. chr2 47562454 47562653 + Human BCYRN1; BC200; BC200a; LINC00004; NCRNA00004 NR_001568.1 9422992 106 BCYRN1 oesophagus cancer Expression BC200 RNA was expressed in carcinomas of the breast, cervix, oesophagus, lung, ovary, parotid, and tongue, but not in corresponding normal tissues. chr2 47562454 47562653 + Human BCYRN1; BC200; BC200a; LINC00004; NCRNA00004 NR_001568.1 9422992 107 BCYRN1 ovarian cancer Expression BC200 RNA was expressed in carcinomas of the breast, cervix, oesophagus, lung, ovary, parotid, and tongue, but not in corresponding normal tissues. chr2 47562454 47562653 + Human BCYRN1; BC200; BC200a; LINC00004; NCRNA00004 NR_001568.1 9422992 108 BCYRN1 parotid cancer Expression BC200 RNA was expressed in carcinomas of the breast, cervix, oesophagus, lung, ovary, parotid, and tongue, but not in corresponding normal tissues. chr2 47562454 47562653 + Human BCYRN1; BC200; BC200a; LINC00004; NCRNA00004 NR_001568.1 9422992 109 BCYRN1 tongue cancer Expression BC200 RNA was expressed in carcinomas of the breast, cervix, oesophagus, lung, ovary, parotid, and tongue, but not in corresponding normal tissues. chr2 47562454 47562653 + Human BCYRN1; BC200; BC200a; LINC00004; NCRNA00004 NR_001568.1 9422992 110 BDNF-AS depression regulation The lncRNA BDNF-AS is related to many neurological disorders, including Huntington's disease (HD), schizophrenia, and depression. chr11 27528399 27719718 + Human BDNF-AS; BDNF; BDNFOS; BDNF-AS1; ANTI-BDNF; NCRNA00049 N/A 23562612 111 BDNF-AS Huntington's disease regulation The lncRNA BDNF-AS is related to many neurological disorders, including Huntington's disease (HD), schizophrenia, and depression. chr11 27528399 27719718 + Human BDNF-AS; BDNF; BDNFOS; BDNF-AS1; ANTI-BDNF; NCRNA00049 N/A 23562612 112 BDNF-AS Huntington's disease regulation Thus, BDNF-AS inhibits BDNF transcription by recruiting EZH2 to the BDNF promoter region and in that way plays an important role in the development of HD. chr11 27528399 27719718 + Human BDNF-AS; BDNF; BDNFOS; BDNF-AS1; ANTI-BDNF; NCRNA00049 NR_002832.2 24624135 113 BDNF-AS psychiatric disease regulation Examples of recently discovered chromatin-bound long non-coding RNAs important for neuronal health and function include the brain-derived neurotrophic factor antisense transcript (Bdnf-AS) which regulates expression of the corresponding sense transcript, and LOC389023 which is associated with human-specific histone methylation signatures at the chromosome 2q14.1 neurodevelopmental risk locus by regulating expression of DPP10, an auxillary subunit for voltage-gated K(+) channels. chr11 27528399 27719718 + Human BDNF-AS; BDNF; BDNFOS; BDNF-AS1; ANTI-BDNF; NCRNA00049 N/A 23831425 114 BDNF-AS schizophrenia regulation The lncRNA BDNF-AS is related to many neurological disorders, including Huntington's disease (HD), schizophrenia, and depression. chr11 27528399 27719718 + Human BDNF-AS; BDNF; BDNFOS; BDNF-AS1; ANTI-BDNF; NCRNA00049 N/A 23562612 115 BDNF-AS1 obesity Locus This locus maps near key hypothalamic regulators of energy balance, may be associated with obesity. chr11 27528399 27719718 + Human BDNF-AS; BDNF; BDNFOS; BDNF-AS1; ANTI-BDNF; NCRNA00049 NR_002832.2 20935630 116 BDNF-AS1 obesity Mutation Association identified by GWAS (rs4074134, A118887G). chr11 27528399 27719718 + Human BDNF-AS; BDNF; BDNFOS; BDNF-AS1; ANTI-BDNF; NCRNA00049 NR_002832.2 19079260 117 BLACAT1 bladder cancer expression Theseguilty by association studies have found numerous bladder-cancer associated lncRNAs chr1 205404014 205425214 - Human BLACAT1; LINC00912; linc-UBC1 N/A 24006935 118 BOK-AS1 cancer expreesion The expression of BOKAS was found in testis and certain cancer tissues but not in other normal adult tissues. Overexpression of BOKAS was able to inhibit Bok-induced apoptosis in HeLa cells. chr2 241544384 241559143 - Human BOK-AS1; BOKAS; NAToB; BOK-AS; NCRNA00151 NR_033346.1 24757675 119 BOK-AS1 testicular cancer Expression A natural antisense transcript, BOKAS, regulates the pro-apoptotic activity of human Bok. The mRNA expression of BOKAS was only detected in testis and certain cancer tissues but not in other normal adult tissues examined. chr2 242483799 242498558 - Human BOK-AS1; BOKAS; NAToB; BOK-AS; NCRNA00151 NR_033346.1 19287972 120 BPESC1 blepharophimosis syndrome Mutation BPESC1 is disrupted by a balanced chromosomal translocation, t(3;4)(q23;p15.2), in a patient with BPES. chr3 138823027 138844009 + Human BPESC1; NCRNA00187 NR_026783.1 10995571 121 BX118339 West Syndrome Mutation A de novo balanced t(2;6)(p15;p22.3) in a patient with West Syndrome disrupts a lnc-RNA, BX118339. chr6 21486545 21512123 - Human LINC00581 22245136 122 BX118339 West Syndrome mutation Genetic variation in lncRNA genes causes disease and influences susceptibility chr6 21486545 21512123 - Human LINC00581 NR_103790.1 23791884 123 C15orf2 Angelman syndrome Expression C15orf2 and a novel noncoding transcript from the Prader-Willi/Angelman syndrome region show monoallelic expression in fetal brain. chr15 24920541 24928593 + Human NPAP1; C15orf2 NM_018958.2 17337158 124 C15orf2 Prader-Willi syndrome Expression C15orf2 and a novel noncoding transcript from the Prader-Willi/Angelman syndrome region show monoallelic expression in fetal brain. chr15 24920541 24928593 + Human NPAP1; C15orf2 NM_018958.2 17337158 125 C1QTNF9B-AS1 prostat Expression PCOTH, a novel gene overexpressed in prostate cancers, promotes prostate cancer cell growth through phosphorylation of oncoprotein TAF-Ibeta/SET. chr13 24463028 24466242 + Human C1QTNF9B-AS1; PCOTH BC073902 15930275 126 CASC2 endometrial cancer Mutation CASC2, in a region of common allelic loss at chromosome 10q26 is a novel candidate gene in human endometrial cancer. chr10 119806332 119969665 + Human CASC2; C10orf5 NR_026939.1 15024726 127 CBR3-AS1 carcinoma expression Upregulation of the long non-coding RNA PlncRNA-1 promotes esophageal squamous carcinoma cell proliferation and correlates with advanced clinical stage. chr21 37504065 37528606 - Human CBR3-AS1; PlncRNA-1 NR_038892.1 24337686 128 CBR3-AS1 prostat regulation Oncogene; putative therapeutic target chr21 37504065 37528606 - Human CBR3-AS1; PlncRNA-1 NR_038892.1 24373479 129 CBR3-AS1 prostat Interaction The prostate cancer-up-regulated long noncoding RNA PlncRNA-1 (CBR3-AS1) modulates apoptosis and proliferation through reciprocal regulation of androgen receptor. chr21 37504065 37528606 - Human CBR3-AS1; PlncRNA-1 NR_038892.1 22264502 130 CCAT1 colorectal cancer expression Recently, colon cancer associated transcript 1 (CCAT1) lncRNA was found to be expressed in colorectal cancer (CRC) tumors but not in normal tissue. chr8 128219629 128231724 - Human CCAT1 XR_108886.3 23416875 131 CCAT1 gastric cancer expreesion Another study reported that lncRNA CCAT1 was up-regulated in gastric carcinoma tissues, and its expression was closely related to the transcription factor c-Myc. chr8 128219629 128231724 - Human CCAT1 NR_108049.1 24833871 132 CCAT1 gastric cancer expreesion Level of lncRNA CCAT1 was markedly increased in gastric carcinoma tissue comparing with normal tissue, and overexpressed CCAT1 promoted cancer cell proliferation and migration chr8 128219629 128231724 - Human CCAT1 NR_108049.1 24757675 133 CCAT1 gastric cancer regulation Long noncoding RNA CCAT1, which could be activated by c-Myc, promotes the progression of gastric carcinoma. chr8 128219629 128231724 - Human CCAT1 XR_108886.3 23143645 134 CCAT2 CCAT2 expression CCAT2, a novel long non-coding RNA in breast cancer. chr8 N/A N/A N/A Human CCAT2; NCCP1; LINC00873 NR_109834.1 24077681 135 CCAT2 non-small cell lung cancer regulation CCAT2 is a lung adenocarcinoma-specific long non-coding RNA and promotes invasion of non-small cell lung cancer. chr8 127400399 127402150 + Human CCAT2; NCCP1; LINC00873 NR_109834.1 24504682 136 CCDC26 glioma mutation In the pooled analysis, the odds ratio for low-grade glioma associated with rs55705857 was 4.3 (P = 2.31 脳 10(-94)). rs55705857 maps to a highly evolutionarily conserved sequence within the long non-coding RNA CCDC26 raising the possibility of direct functionality. chr8 130433119 130761667 - Human CCDC26; RAM BC026098.1 23399484 137 CCND1 tumor regulation Binding to TLS protein induces TLS allosteric change, allowing interaction with cyclin D1, inhibiting CBP and p300 activity, and silencing cyclin D1 gene expression. chr11 69455873 69469242 + Human CCND1; BCL1; PRAD1; U21B31; D11S287E NM_053056.2 22996375 138 CCND1 promoter-derived lncRNAs TLS-associated pathological states expression Biogenesis, metabolism, and functions of lncRNAs are otherwise interconnected with known pathogenic mechanisms N/A N/A N/A N/A Human CCND1 promoter-derived lncRNAs N/A 23791884 139 CDKN2B-AS1 abdominal aortic aneurysm Mutation Genetic risk (rs10757278, A>G) for abdominal aortic aneurysm. chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.67 NR_003529.66 21146954 140 CDKN2B-AS1 acute lymphoblastic leukemia Expression Higher p15AS levels were often found in acute lymphoblastic (ALL) and myeloid leukemias (AML). chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.55 NR_003529.54 21874119 141 CDKN2B-AS1 acute lymphoblastic leukemia Expression Higher p15AS levels were often found in acute lymphoblastic (ALL) and myeloid leukemias (AML). chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.56 NR_003529.55 21874119 142 CDKN2B-AS1 acute lymphoblastic leukemia Mutation rs564398 (A>G), mapping to the CDKN2BAS locus that encodes for ANRIL antisense non-coding RNA, showed a statistically significant correlation with the ALL phenotype, with a risk pattern that was compatible with an overdominant model of disease susceptibility. chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.59 NR_003529.58 21414664 143 CDKN2B-AS1 Alzheimer's disease Mutation Recent studies showed that single nucleotide polymorphisms (rs3217992, A>G;rs1063192, C>T) mapping in the vicinity of ANRIL are linked to a wide spectrum of conditions, including cardiovascular disease, ischemic stroke, type 2 diabetes, frailty and Alzheimer's disease. chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.44 NR_003529.43 18761660 144 CDKN2B-AS1 Alzheimer's disease mutation Genetic variation in lncRNA genes causes disease and influences susceptibility chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.55 NR_003529.3 23791884 145 CDKN2B-AS1 aortic aneurysm Expression Significantly reduced expression of all INK4/ARF transcripts (p15(INK4b), p16(INK4a), ARF and ANRIL) was found in PBTL of individuals harboring a common SNP (rs10757278) associated with increased risk of coronary artery disease, stroke and aortic aneurysm. chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.22 NR_003529.21 19343170 146 CDKN2B-AS1 atherosclerosis mutation Genetic variation in lncRNA genes causes disease and influences susceptibility chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.55 NR_003529.3 23791884 147 CDKN2B-AS1 atherosclerosis Expression 9p21.3 may promote atherosclerosis by regulating expression of ANRIL, which in turn is associated with altered expression of genes controlling cellular proliferation pathways. chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.12 NR_003529.11 19592466 148 CDKN2B-AS1 atherosclerosis Expression ANRIL expression is associated with atherosclerosis risk. Expression of ANRIL transcripts was directly correlated with severity of atherosclerosis. chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.8 NR_003529.7 20056914 149 CDKN2B-AS1 atherosclerosis Expression Gene expression studies have found that expression levels of CDKN2A/CDKN2B/ANRIL are co-regulated and associated with the risk haplotype and atherosclerosis severity. chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.4 NR_003529.3 21550161 150 CDKN2B-AS1 atherosclerosis Expression abundantly expressed in atherosclerotic lesions. chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.36 NR_003529.35 20637465 151 CDKN2B-AS1 atherosclerosis Interaction ANRIL DQ485454 which is not genetically determined by the 9p21 genotype was significantly correlated with MTAP expression. chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.5 NR_003529.4 20637465 152 CDKN2B-AS1 atherosclerosis Locus A genetic susceptibility locus. chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.18 NR_003529.17 20956613 153 CDKN2B-AS1 atherosclerosis Mutation Genotypes of rs10757278 linked to increased risk of atherosclerotic diseases are also associated with decreased expression in PBTL of the INK4/ARF locus, near CDKN2B-AS1 locus. chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.10 NR_003529.9 19343170 154 CDKN2B-AS1 atherosclerosis Mutation Individuals homozygous for the atherosclerotic risk allele (rs3217992, A>G;rs1063192, C>T) show decreased expression of ANRIL. chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.61 NR_003529.60 21151960 155 CDKN2B-AS1 atherosclerosis Mutation The risk alleles for atherosclerosis-related phenotypes were consistently associated with a lower expression of ANRIL when evaluating exons 1-2. Common carotid artery stenosis was associated with a significantly lower (P<0.01) expression of ANRIL (exons 1-2). ANRIL knock-down in VSMC caused significant variation in expression of CDKN2A/B (P<0.05) and reduction of cell growth (P<0.05) in vitro. chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.40 NR_003529.39 22178423 156 CDKN2B-AS1 atherosclerosis Mutation/Expression Transcripts EU741058 and NR_003529 of antisense noncoding RNA in the INK4 locus (ANRIL) were significantly increased in carriers of the risk haplotype. chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.37 NR_003529.36 20056914 157 CDKN2B-AS1 basal cell carcinoma Locus A genetic susceptibility locus. chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.4 NR_003529.3 20956613 158 CDKN2B-AS1 basal cell carcinoma Mutation More recent GWAS also identified ANRIL as a risk locus (rs3217992, A>G;rs1063192, C>T) for gliomas and basal cell carcinomas in accordance with the princeps observation. chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.52 NR_003529.51 20956613 159 CDKN2B-AS1 breast cancer Expression Expression of ANRIL mainly coclustered with p14/ARF both in physiologic (various normal human tissues) and in pathologic conditions (human breast tumors). chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.21 NR_003529.20 17440112 160 CDKN2B-AS1 breast cancer Locus A genetic susceptibility locus. chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.4 NR_003529.3 20956613 161 CDKN2B-AS1 breast cancer Locus A locus associated with breast cancer. chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.30 NR_003529.29 20453838 162 CDKN2B-AS1 breast cancer Mutation More recently, additional GWAS identified ANRIL as a risk locus (rs3217992, A>G;rs1063192, C>T) for several cancers including breast cancer, nasopharyngeal carcinoma, basal cell carcinoma, and glioma. chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.53 NR_003529.52 20956613 163 CDKN2B-AS1 cancer Expression Down-regulated in cells were incubated in the presence of BLM for 24 h or irradiated. chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.41 NR_003529.40 22487937 164 CDKN2B-AS1 cancer Interaction RNA immunoprecipitation demonstrates that ANRIL binds to SUZ12 in vivo. Collectively, these results suggest a model in which ANRIL binds to and recruits PRC2 to repress the expression of p15(INK4B) locus. chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.62 NR_003529.61 21151178 165 CDKN2B-AS1 cancer expreesion High expression of ANRIL has been found in certain cancer tissues such as melanoma and prostate cancers? chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.44 NR_003529.3 24757675 166 CDKN2B-AS1 cancer locus Furthermore, genome wide association studies have identified the ANRIL gene as a risk locus for coronary disease, intracranial aneurism, type 2 diabetes and several cancers including glioma. chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.44 NR_003529.3 24624135 167 CDKN2B-AS1 cancer regulation It has also been shown that the tumor suppressor gene p15 is silenced by its natural antisense RNA, a lncRNA ANRIL. chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.44 NR_003529.3 24829860 168 CDKN2B-AS1 cancer expression ANRIL is a recently discovered long non-coding RNA encoded in the chromosome 9p21 region. This locus is a hotspot for disease-associated polymorphisms, and it has been consistently associated with cardiovascular disease, and more recently with several cancers, diabetes, glaucoma, endometriosis among other conditions. chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.4 NR_003529.54 23104877 169 CDKN2B-AS1 cancer expression Another lncRNA associated with human cancers is ANRIL, a long, antisense transcript found in the INK4a/Arf locus. ANRIL is overexpressed in human leukemias and prostate cancers, and its expression leads to epigenetic silencing of the nearby tumor suppressor p15 (Yu et al., 2008; Yap et al., 2010). chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.4 NR_003529.3 23473599 170 CDKN2B-AS1 cardiovascular disease mutation Aberrant ANRIL transcripts and mutations were associated with cardiovascular disease and cancer . chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.44 NR_003529.3 24531795 171 CDKN2B-AS1 cardiovascular disease Mutation Recent studies showed that single nucleotide polymorphisms (rs3217992, A>G;rs1063192, C>T) mapping in the vicinity of ANRIL are linked to a wide spectrum of conditions, including cardiovascular disease, ischemic stroke, type 2 diabetes, frailty and Alzheimer's disease. chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.49 NR_003529.48 20716961 172 CDKN2B-AS1 cardiovascular disease expression ANRIL is a recently discovered long non-coding RNA encoded in the chromosome 9p21 region. This locus is a hotspot for disease-associated polymorphisms, and it has been consistently associated with cardiovascular disease, and more recently with several cancers, diabetes, glaucoma, endometriosis among other conditions. chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.4 NR_003529.54 23104877 173 CDKN2B-AS1 cardiovascular disease mutation Aberrant ANRIL transcripts and mutations were associated with cardiovascular disease and cancer . chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.44 NR_003529.3 24531795 174 CDKN2B-AS1 cardiovascular disease regulation Recently, ANRIL, a multi-exonic lncRNA, has been shown to be implicated in epigenetic modulation in cardiac development and adult heart and also it has been associated with a locus implicated in cardiovascular disease. chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.55 NR_003529.3 24113581 175 CDKN2B-AS1 coronary artery disease Expression Significantly reduced expression of all INK4/ARF transcripts (p15(INK4b), p16(INK4a), ARF and ANRIL) was found in PBTL of individuals harboring a common SNP (rs10757278) associated with increased risk of coronary artery disease, stroke and aortic aneurysm. chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.24 NR_003529.23 19343170 176 CDKN2B-AS1 coronary artery disease Expression Whole blood RNA expression of the short variants of ANRIL was increased by 2.2-fold whereas expression of the long ANRIL variant was decreased by 1.2-fold in healthy subjects homozygous for the risk allele. chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.13 NR_003529.12 19592466 177 CDKN2B-AS1 coronary artery disease Expression Whole blood RNA expression of the short variants of ANRIL was increased by 2.2-fold whereas expression of the long ANRIL variant was decreased by 1.2-fold in healthy subjects homozygous for the risk allele. Expression levels of the long and short ANRIL variants were positively correlated with that of the cyclin-dependent kinase inhibitor, CDKN2B (p15) and TDGF1 (Cripto), respectively. chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.4 NR_003529.3 19592466 178 CDKN2B-AS1 coronary artery disease Mutation Sequence polymorphisms in a 58-kilobase (kb) interval on chromosome 9p21 confer a markedly increased risk (rs3217992, A>G;rs1063192, C>T) of coronary artery disease (CAD), the leading cause of death worldwide. chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.58 NR_003529.57 17554300 179 CDKN2B-AS1 coronary artery disease Mutation Susceptibility to coronary artery disease and diabetes is encoded by distinct, tightly linked SNPs (rs2891168, A>G) in the ANRIL locus on chromosome 9p. chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.19 NR_003529.18 18048406 180 CDKN2B-AS1 coronary artery disease expression However, overexpression of 1 ANRIL variant altered the expression of many genes involved in nuclear regulation and chromatin architecture, indicating diverse trans-regulatory effects that go beyond the cis-effects seen at 9p21. chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.55 NR_003529.54 23104877 181 CDKN2B-AS1 coronary disease Locus A genetic susceptibility locus chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.65 NR_003529.64 20956613 182 CDKN2B-AS1 coronary disease Mutation Common disease genome wide association studies (GWAS) have surprisingly identified the ANRIL gene as a genetic susceptibility locus (rs3217992, A>G;rs1063192, C>T) shared associated by coronary disease, intracranial aneurysm and also type 2 diabetes. chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.48 NR_003529.47 20956613 183 CDKN2B-AS1 coronary disease Mutation Risk SNPs (rs3217992, A>G;rs1063192, C>T) for coronary disease, stroke, diabetes, melanoma, and glioma were all associated with allelic expression of ANRIL. chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.4 NR_003529.3 20386740 184 CDKN2B-AS1 coronary disease Mutation Risk SNPs (rs3217992, A>G;rs1063192, C>T) for coronary disease, stroke, diabetes, melanoma, and glioma were all associated with allelic expression of CDKN2B-AS1. chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.28 NR_003529.27 20386740 185 CDKN2B-AS1 coronary disease locus Furthermore, genome wide association studies have identified the ANRIL gene as a risk locus for coronary disease, intracranial aneurism, type 2 diabetes and several cancers including glioma. chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.44 NR_003529.3 24624135 186 CDKN2B-AS1 coronary heart disease Locus CHD and periodontitis are genetically related by at least one susceptibility locus, which is possibly involved in ANRIL activity and independent of diabetes associated risk variants within this region. Elucidation of the interplay of ANRIL transcript variants and their involvement in increased susceptibility to the interactive diseases CHD and periodontitis promises new insight into the underlying shared pathogenic mechanisms of these complex common diseases. chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.33 NR_003529.32 19214202 187 CDKN2B-AS1 coronary heart disease Mutation Association of a genetic susceptibility locus (rs2891168, A>G;rs1333042, A>G;rs1333048, A>C). chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.14 NR_003529.13 19214202 188 CDKN2B-AS1 coronary heart disease mutation Association identified by GWAS (rs10757274, A>G;rs2383206, A>G). chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.4 NR_003529.3 17478681 189 CDKN2B-AS1 Diabetes mutation Genetic variation in lncRNA genes causes disease and influences susceptibility chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.55 NR_003529.3 23791884 190 CDKN2B-AS1 Diabetes Mutation Risk SNPs (rs3217992, A>G;rs1063192, C>T) for coronary disease, stroke, diabetes, melanoma, and glioma were all associated with allelic expression of CDKN2B-AS1. chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.26 NR_003529.25 20386740 191 CDKN2B-AS1 Diabetes expression ANRIL is a recently discovered long non-coding RNA encoded in the chromosome 9p21 region. This locus is a hotspot for disease-associated polymorphisms, and it has been consistently associated with cardiovascular disease, and more recently with several cancers, diabetes, glaucoma, endometriosis among other conditions. chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.4 NR_003529.54 23104877 192 CDKN2B-AS1 endometriosis Mutation The authors identified a significant association of endometriosis with rs10965235 (A>C, P = 5.57 x 10(-12), odds ratio = 1.44), which is located in CDKN2BAS on chromosome 9p21, encoding the cyclin-dependent kinase inhibitor 2B antisense RNA.the SNP showing the strongest association was located in intron 16 of CDKN2BAS and was implicated in regulating the expression of p15, p16 and p14. chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.35 NR_003529.34 20601957 193 CDKN2B-AS1 endometriosis expression ANRIL is a recently discovered long non-coding RNA encoded in the chromosome 9p21 region. This locus is a hotspot for disease-associated polymorphisms, and it has been consistently associated with cardiovascular disease, and more recently with several cancers, diabetes, glaucoma, endometriosis among other conditions. chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.4 NR_003529.54 23104877 194 CDKN2B-AS1 Esophageal squamous cell cancer regulation ANRIL inhibits p15INK4b through the TGFβ1 signaling pathway in human esophageal squamous cell carcinoma. chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.44 NR_003529.3 24747824 195 CDKN2B-AS1 familial and sporadic intracranial aneurysms Mutation All 6 index cases from IA families had the rs1333040-T allele (C>T) in CDKN2BAS. chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.29 NR_003529.28 20395613 196 CDKN2B-AS1 frailty Mutation Recent studies showed that single nucleotide polymorphisms (rs3217992, A>G;rs1063192, C>T) mapping in the vicinity of ANRIL are linked to a wide spectrum of conditions, including cardiovascular disease, ischemic stroke, type 2 diabetes, frailty and Alzheimer's disease. chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.43 NR_003529.42 17459456 197 CDKN2B-AS1 gastric cancer regulation Long noncoding RNA ANRIL indicates a poor prognosis of gastric cancer and promotes tumor growth by epigenetically silencing of miR-99a/miR-449a. chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.44 NR_003529.3 24810364 198 CDKN2B-AS1 Glaucoma mutation Genetic variation in lncRNA genes causes disease and influences susceptibility chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.55 NR_003529.3 23791884 199 CDKN2B-AS1 Glaucoma Mutation Genome-wide association study identifies susceptibility loci for open angle glaucoma at TMCO1 and CDKN2B-AS1 (rs4977756, A>G). chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.4 NR_003529.3 21532571 200 CDKN2B-AS1 Glaucoma expression ANRIL is a recently discovered long non-coding RNA encoded in the chromosome 9p21 region. This locus is a hotspot for disease-associated polymorphisms, and it has been consistently associated with cardiovascular disease, and more recently with several cancers, diabetes, glaucoma, endometriosis among other conditions. chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.4 NR_003529.54 23104877 201 CDKN2B-AS1 Glaucoma mutation CDKN2B-AS1 genotype-glaucoma feature correlations in primary open-angle glaucoma patients from the United States. chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.4 NR_003529.3 23111177 202 CDKN2B-AS1 glioma mutation Genetic variation in lncRNA genes causes disease and influences susceptibility chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.55 NR_003529.3 23791884 203 CDKN2B-AS1 glioma Locus A genetic susceptibility locus. chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.6 NR_003529.5 20956613 204 CDKN2B-AS1 glioma Mutation Association identified by GWAS. chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.11 NR_003529.10 19578367 205 CDKN2B-AS1 glioma Mutation More recent GWAS also identified ANRIL as a risk locus (rs3217992, A>G;rs1063192, C>T) for gliomas and basal cell carcinomas in accordance with the princeps observation. chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.51 NR_003529.50 20956613 206 CDKN2B-AS1 glioma Mutation Risk SNPs (rs3217992, A>G;rs1063192, C>T) for coronary disease, stroke, diabetes, melanoma, and glioma were all associated with allelic expression of ANRIL. chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.4 NR_003529.3 20386740 207 CDKN2B-AS1 glioma Mutation Risk SNPs (rs3217992, A>G;rs1063192, C>T) for coronary disease, stroke, diabetes, melanoma, and glioma were all associated with allelic expression of CDKN2B-AS1. chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.9 NR_003529.8 20386740 208 CDKN2B-AS1 glioma Mutation Variants (rs1412829, C>T) in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility. chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.32 NR_003529.31 19578366 209 CDKN2B-AS1 hereditary cutaneous malignant melanoma N/A Long ncRNA antisense non-coding RNA in the INK4 locus (ANRIL) has been associated to hereditary cutaneous malignant melanoma, prostate cancer and tumors of the neural system (Pasmant et al., 2011). chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.44 NR_003529.3 24624135 210 CDKN2B-AS1 intracranial aneurism locus Furthermore, genome wide association studies have identified the ANRIL gene as a risk locus for coronary disease, intracranial aneurism, type 2 diabetes and several cancers including glioma. chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.44 NR_003529.3 24624135 211 CDKN2B-AS1 intracranial aneurism mutation Genetic variation in lncRNA genes causes disease and influences susceptibility chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.55 NR_003529.3 23791884 212 CDKN2B-AS1 intracranial aneurism Locus A genetic susceptibility locus. chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.64 NR_003529.63 20956613 213 CDKN2B-AS1 intracranial aneurism Locus We also confirmed prior associations near CDKN2A-CDKN2B locus. chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.23 NR_003529.22 20364137 214 CDKN2B-AS1 intracranial aneurism Mutation Association identified by GWAS (rs1333040, C>T). chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.17 NR_003529.16 18997786 215 CDKN2B-AS1 intracranial aneurism Mutation Common disease genomewide association studies (GWAS) have surprisingly identified the ANRIL gene as a genetic susceptibility locus (rs3217992, A>G;rs1063192, C>T)shared associated by coronary disease, intracranial aneurysm and also type 2 diabetes. chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.38 NR_003529.37 20956613 216 CDKN2B-AS1 ischemic stroke regulation Regulation of CARD8 expression by ANRIL and association of CARD8 single nucleotide polymorphism rs2043211 (p.C10X) with ischemic stroke. chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.44 NR_003529.3 24385277 217 CDKN2B-AS1 leukemia regulation Gene silencing of INK4b-ARF-INK4a and p15/CDKN2B by recruitment of PRC1 and PRC2. chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.4 NR_003529.3 22996375 218 CDKN2B-AS1 melanoma Locus A genetic susceptibility locus. chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.7 NR_003529.6 20956613 219 CDKN2B-AS1 melanoma Mutation A large germline deletion (403231 bp) encompassing the INK4/ARF locus and the ANRIL lncRNA has been associated with hereditary cutaneous malignant melanoma (CMM) and neural system tumors (NST) syndrome. chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.46 NR_003529.45 21550244 220 CDKN2B-AS1 melanoma Mutation Association identified by GWAS. chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.4 NR_003529.3 17440112 221 CDKN2B-AS1 melanoma Mutation Risk SNPs (rs3217992, A>G;rs1063192, C>T) for coronary disease, stroke, diabetes, melanoma, and glioma were all associated with allelic expression of ANRIL. chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.57 NR_003529.56 20386740 222 CDKN2B-AS1 melanoma Mutation Risk SNPs (rs3217992, A>G;rs1063192, C>T) for coronary disease, stroke, diabetes, melanoma, and glioma were all associated with allelic expression of CDKN2B-AS1. chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.25 NR_003529.24 20386740 223 CDKN2B-AS1 myocardial infarction Mutation Association identified by GWAS. chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.4 NR_003529.3 17478679 224 CDKN2B-AS1 myocardial infarction Mutation association identified by GWAS (rs4977574, A>G). chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.16 NR_003529.15 19198609 225 CDKN2B-AS1 nasopharyngeal carcinoma Locus A genetic susceptibility locus. chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.4 NR_003529.3 20956613 226 CDKN2B-AS1 nasopharyngeal carcinoma Mutation A SNP rs1412829 (C49137T) at CDKN2A-CDKN2B gene cluster on 9p21 is associated with this disease. chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.4 NR_003529.3 20512145 227 CDKN2B-AS1 nasopharyngeal carcinoma Mutation More recently, additional GWAS identified ANRIL as a risk locus (rs3217992, A>G;rs1063192, C>T) for several cancers including breast cancer, nasopharyngeal carcinoma, basal cell carcinoma, and glioma. chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.54 NR_003529.53 20956613 228 CDKN2B-AS1 nasopharyngeal carcinoma mutation In recent years, GWAS has identified ANRIL as a risk locus for NPC and other cancers. chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.44 NR_003529.3 24817925 229 CDKN2B-AS1 neural system tumors syndrome Mutation A large germline deletion (403231 bp) encompassing the INK4/ARF locus and the ANRIL lncRNA has been associated with hereditary cutaneous malignant melanoma (CMM) and neural system tumors (NST) syndrome. chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.45 NR_003529.44 21550244 230 CDKN2B-AS1 Neurofibromatosis type 1 Mutation Single-nucleotide polymorphism rs2151280 (C>T, located in ANRIL) was statistically significantly associated with the number of PNFs (P < .001) in NF1 patients. In addition, allele T of rs2151280 was statistically significantly associated with reduced ANRIL transcript levels (P < .001), suggesting that modulation of ANRIL expression mediates PNF susceptibility. chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.47 NR_003529.46 22034633 231 CDKN2B-AS1 periodontitis Locus CHD and periodontitis are genetically related by at least one susceptibility locus, which is possibly involved in ANRIL activity and independent of diabetes associated risk variants within this region. Elucidation of the interplay of ANRIL transcript variants and their involvement in increased susceptibility to the interactive diseases CHD and periodontitis promises new insight into the underlying shared pathogenic mechanisms of these complex common diseases. chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.4 NR_003529.3 19214202 232 CDKN2B-AS1 periodontitis Mutation Association of a genetic susceptibility locus (rs2891168, A>G;rs1333042, A>G;rs1333048, A>C). chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.15 NR_003529.14 19214202 233 CDKN2B-AS1 peripheral artery disease Mutation SNP rs2383207 on ANRIL was most significantly associated with lower ABI. chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.39 NR_003529.38 22122968 234 CDKN2B-AS1 Plexiform neurofibroma mutation Genetic variation in lncRNA genes causes disease and influences susceptibility chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.55 NR_003529.3 23791884 235 CDKN2B-AS1 prostat regulation Gene silencing of INK4b-ARF-INK4a and p15/CDKN2B by recruitment of PRC1 and PRC2. chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.4 NR_003529.3 22996375 236 CDKN2B-AS1 prostat regulation ANRIL is an antisense lncRNA elevated in PCa that overlaps this locus, interacting directly with polycomb repressive complex 1 and histone H3K27 methylation to repress CDKN2A-CDKN2B expression chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.55 NR_003529.3 24146262 237 CDKN2B-AS1 prostat Interaction Here we report that chromobox 7 (CBX7) within the polycomb repressive complex 1 binds to ANRIL, and both CBX7 and ANRIL are found at elevated levels in prostate cancer tissues. chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.31 NR_003529.30 20541999 238 CDKN2B-AS1 prostat N/A Long ncRNA antisense non-coding RNA in the INK4 locus (ANRIL) has been associated to hereditary cutaneous malignant melanoma, prostate cancer and tumors of the neural system (Pasmant et al., 2011). chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.44 NR_003529.3 24624135 239 CDKN2B-AS1 prostat expression ANRIL is upregulated in prostate cancer and is required for the repression of the tumor suppressors INK4a/p16 and INK4b/p15 (Yap et al., 2010; Kotake et al., 2011). chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.44 NR_003529.3 24721780 240 CDKN2B-AS1 prostat expression ANRIL, also upregulated in prostate cancer, is required for the repression of the tumor suppressors INK4a/p16 and INK4b/p15. chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.4 NR_003529.3 23463798 241 CDKN2B-AS1 Stroke mutation Genetic variation in lncRNA genes causes disease and influences susceptibility chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.55 NR_003529.3 23791884 242 CDKN2B-AS1 Stroke Expression Significantly reduced expression of all INK4/ARF transcripts (p15(INK4b), p16(INK4a), ARF and ANRIL) was found in PBTL of individuals harboring a common SNP (rs10757278) associated with increased risk of coronary artery disease, stroke and aortic aneurysm. chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.34 NR_003529.33 19343170 243 CDKN2B-AS1 Stroke Mutation Risk SNPs (rs3217992, A>G;rs1063192, C>T) for coronary disease, stroke, diabetes, melanoma, and glioma were all associated with allelic expression of ANRIL. chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.4 NR_003529.3 20386740 244 CDKN2B-AS1 Stroke Mutation Risk SNPs (rs3217992, A>G;rs1063192, C>T) for coronary disease, stroke, diabetes, melanoma, and glioma were all associated with allelic expression of CDKN2B-AS1. chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.27 NR_003529.26 20386740 245 CDKN2B-AS1 Stroke Mutation Variants (rs3217992, A>G;rs1063192, C>T) on chromosome 9p21.3 correlated with ANRIL expression contribute to stroke risk and recurrence in a large prospective stroke population. chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.60 NR_003529.59 22034006 246 CDKN2B-AS1 Stroke expression Levels of CDKN2B-AS1/ANRIL in human carotid atherosclerotic plaques and peripheral blood T lymphocytes are linked to rates of ischemic and hemorrhagic stroke. chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.55 NR_003529.3 24145019 247 CDKN2B-AS1 tumor regulation ANRIL, GAS5 and lincRNA-p23 are involved in the escape of growth suppression by regulating tumor suppressor genes (ANRIL) or apoptosis regulators. chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.44 NR_003529.3 24667321 248 CDKN2B-AS1 tumor N/A Long ncRNA antisense non-coding RNA in the INK4 locus (ANRIL) has been associated to hereditary cutaneous malignant melanoma, prostate cancer and tumors of the neural system (Pasmant et al., 2011). chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.44 NR_003529.3 24624135 249 CDKN2B-AS1 type 2 diabetes Locus A genetic susceptibility locus. chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.63 NR_003529.62 20956613 250 CDKN2B-AS1 type 2 diabetes Mutation Association identified by GWAS. chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.4 NR_003529.3 17463249 251 CDKN2B-AS1 type 2 diabetes Mutation Common disease genomewide association studies (GWAS) have surprisingly identified the ANRIL gene as a genetic susceptibility locus (rs3217992, A>G;rs1063192, C>T) shared associated by coronary disease, intracranial aneurysm and also type 2 diabetes. chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.50 NR_003529.49 20956613 252 CDKN2B-AS1 type 2 diabetes Mutation Recent studies showed that single nucleotide polymorphisms (rs3217992, A>G;rs1063192, C>T) mapping in the vicinity of ANRIL are linked to a wide spectrum of conditions, including cardiovascular disease, ischemic stroke, type 2 diabetes, frailty and Alzheimer's disease. chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.66 NR_003529.65 17463248 253 CDKN2B-AS1 type 2 diabetes Mutation Risk SNPs (rs3217992, A>G;rs1063192, C>T) for coronary disease, stroke, diabetes, melanoma, and glioma were all associated with allelic expression of ANRIL. chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.4 NR_003529.3 20386740 254 CDKN2B-AS1 type 2 diabetes Mutation Susceptibility to coronary artery disease and diabetes is encoded by distinct, tightly linked SNPs (rs2891168, A>G) in the ANRIL locus on chromosome 9p. chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.20 NR_003529.19 18048406 255 CDKN2B-AS1 type 2 diabetes locus Furthermore, genome wide association studies have identified the ANRIL gene as a risk locus for coronary disease, intracranial aneurism, type 2 diabetes and several cancers including glioma. chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.44 NR_003529.3 24624135 256 CDKN2B-AS10 Stroke expression Genetic variants that affect the expression of the ANRIL transcript have been correlated with stroke risk and recurrence in a large prospective study chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.55 NR_003529.63 22817756 257 CDKN2B-AS11 Stroke mutation Moreover, genome-wide association studies have demonstrated that the 9p21 genomic locus is a hotspot for the risk of stroke, glioma, plexiform neurofibroma and other disorders chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.55 NR_003529.64 22814587 258 CDKN2B-AS12 glioma mutation Moreover, genome-wide association studies have demonstrated that the 9p21 genomic locus is a hotspot for the risk of stroke, glioma, plexiform neurofibroma and other disorders chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.55 NR_003529.65 22814587 259 CDKN2B-AS13 plexiform neurofibroma mutation Moreover, genome-wide association studies have demonstrated that the 9p21 genomic locus is a hotspot for the risk of stroke, glioma, plexiform neurofibroma and other disorders chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.55 NR_003529.66 22814587 260 CDKN2B-AS2 coronary heart disease mutation Interestingly, genome wide association studies (GWAS) identified several variants in the intergenic region encompassing ANRIL to be associated with several diseases such as coronary heart disease, intracranial aneurysm, many type of cancers and T2D chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.55 NR_003529.55 22928560 261 CDKN2B-AS3 intracranial aneurism mutation Interestingly, genome wide association studies (GWAS) identified several variants in the intergenic region encompassing ANRIL to be associated with several diseases such as coronary heart disease, intracranial aneurysm, many type of cancers and T3D chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.55 NR_003529.56 22928560 262 CDKN2B-AS4 cancer mutation Interestingly, genome wide association studies (GWAS) identified several variants in the intergenic region encompassing ANRIL to be associated with several diseases such as coronary heart disease, intracranial aneurysm, many type of cancers and T4D chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.55 NR_003529.57 22928560 263 CDKN2B-AS5 type 2 diabetes mutation Interestingly, genome wide association studies (GWAS) identified several variants in the intergenic region encompassing ANRIL to be associated with several diseases such as coronary heart disease, intracranial aneurysm, many type of cancers and T5D chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.55 NR_003529.58 22928560 264 CDKN2B-AS6 neuroblastoma expression Disruptions to the expression of ANRIL have accordingly been associated with the development of several cancer types, including neuroblastoma , acute lymphocytic leukaemia, melanoma and prostate chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.55 NR_003529.59 22817756 265 CDKN2B-AS7 acute lymphoblastic leukemia expression Disruptions to the expression of ANRIL have accordingly been associated with the development of several cancer types, including neuroblastoma , acute lymphocytic leukaemia, melanoma and prostate chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.55 NR_003529.60 22817756 266 CDKN2B-AS8 melanoma expression Disruptions to the expression of ANRIL have accordingly been associated with the development of several cancer types, including neuroblastoma , acute lymphocytic leukaemia, melanoma and prostate chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.55 NR_003529.61 22817756 267 CDKN2B-AS9 prostat expression Disruptions to the expression of ANRIL have accordingly been associated with the development of several cancer types, including neuroblastoma , acute lymphocytic leukaemia, melanoma and prostate chr9 21994790 22121096 + Human CDKN2B-AS1; ANRIL; p15AS; CDKN2BAS; CDKN2B-AS; NCRNA00089; RP11-145E5.55 NR_003529.62 22817756 268 CECR3 cat eye syndrome N/A Cat eye syndrome chromosome region, candidate 3 chr22 17737750 17747623 - Human CECR3 NR_038398.2 11381032 269 CECR9 cat eye syndrome N/A Cat eye syndrome chromosome region, candidate 9 chr22 17809924 17810122 + Human CECR9 N/A 11381032 270 CHL1-AS2 adolescent idiopathic scoliosis Mutation We found strongest evidence of association with chromosome 3p26.3 SNPs (rs1400180,A>C) in the proximity of the CHL1 gene (P < 8*10^(-8) for rs1400180). chr3 237441 239090 - Human CHL1-AS2 XM_931148.3 21216876 271 CHRF cardiac hypertrophy regulation The Long Noncoding RNA CHRF Regulates Cardiac Hypertrophy by Targeting miR-489. N/A N/A N/A N/A Human CHRF N/A 24557880 272 CRNDE colorectal cancer Expression An uncharacterized gene locus (Chr16:hCG_1815491), now named colorectal neoplasia differentially expressed (gene symbol CRNDE), is activated early in colorectal neoplasia. chr16 54952775 54963079 - Human CRNDE; LINC00180; NCRNA00180 NR_034105.2 22393467 273 CTBP1-AS prostat regulation Oncogene chr4 1210120 1218591 + Human CTBP1-AS; PCAT10 NR_104331.1 24373479 274 CTBP1-AS prostat regulation The prostate cancer-associated ncRNA transcript 1 lncRNA PCAT1, SchlAP1 (second chromosome locus associated with prostate-1), and CTBP1-AS indicate cancer cell invasiveness and metastasis in prostate cancer progression. chr4 1210120 1218591 + Human CTBP1-AS; PCAT10 NR_104331.1 24531795 275 D4Z4 Facioscapulohumeral muscular dystrophy mutation The genetic lesion involved in FSHD is unusual as it does not target a protein-coding gene, but rather affects the copy number of the 3.3 kb macrosatellite D4Z4 mapping at the subtelomeric region of chromosome 4 (4q35). N/A N/A N/A N/A Human D4Z4 N/A 24685002 276 DANCR bone diseases expression These data suggest that ANCR is an essential mediator of osteoblast differentiation, thus offering a new target for the development of therapeutic agents to treat bone diseases. chr4 53578621 53580305 + Human DANCR;ANCR; SNHG13; KIAA0114 NR_024031.1 23438432 277 DAOA-AS1 bipolar disorder Mutation Polymorphisms at the G72/G30 gene locus, on 13q33, are associated with bipolar disorder in two independent pedigree series. chr13 106111404 106158030 - Human DAOA-AS1; G35; DAOAAS; DAOA-AS NR_040247.6 12647258 278 DAOA-AS1 panic disorder N/A Panic disorder associated. chr13 106111404 106158030 - Human DAOA-AS1; G32; DAOAAS; DAOA-AS NR_040247.3 15477870 279 DAOA-AS1 schizophrenia Expression Markers of the G72/G30 genes are associated with schizophrenia in a non-Caucasian population. chr13 106111404 106158030 - Human DAOA-AS1; G36; DAOAAS; DAOA-AS NR_040247.7 15194506 280 DAOA-AS1 schizophrenia Mutation Meta-analysis revealed that there is weak evidence of association between the G72/G30 genes and schizophrenia. chr13 106111404 106158030 - Human DAOA-AS1; G34; DAOAAS; DAOA-AS NR_040247.5 17179078 281 DAOA-AS1 schizophrenia Mutation Significant associations of schizophrenia with the A allele of rs947267 (A>C,P=0.012) and haplotype A-A-G (rs2391191-rs947267-rs778294) (P=0.008) were found in early-onset schizophrenic patients. chr13 106111404 106158030 - Human DAOA-AS1; G33; DAOAAS; DAOA-AS NR_040247.4 17179866 282 DAOA-AS1 schizophrenia Mutation Transmission disequilibrium analysis revealed a significant association between the rs947267 polymorphism (A>C) and schizophrenia (P=0.016), with the A allele more commonly transmitted to patients. chr13 106111404 106158030 - Human DAOA-AS1; G38; DAOAAS; DAOA-AS NR_040247.9 16791105 283 DAOA-AS1 schizophrenia Mutation rs778294 (A>G) and rs947267 (A>C), were found to be associated with the risk of schizophrenia. chr13 106111404 106158030 - Human DAOA-AS1; G30; DAOAAS; DAOA-AS NR_040247.1 17651942 284 DAOA-AS1 schizophrenia N/A Association with schizophrenia. chr13 106111404 106158030 - Human DAOA-AS1; G31; DAOAAS; DAOA-AS NR_040247.2 15271585 285 DAOA-AS1 schizophrenia N/A G72/G30 (DAOA-AS1) are important candidate genes for explaining schizophrenia in the Han Chinese population. chr13 106111404 106158030 - Human DAOA-AS1; G37; DAOAAS; DAOA-AS NR_040247.8 15653269 286 DAOA-AS1 schizophrenia N/A G72/G30 genes are involved in conferring susceptibility to schizophrenia. chr13 106111404 106158030 - Human DAOA-AS1; G30; DAOAAS; DAOA-AS NR_040247.1 16402132 287 DAPK1 Pancreatic ductal adenocarcinoma Expression Differential expression chr9 90112756 90323549 + Human DAPK1; DAPK NM_004938.2 22078386 288 DBE-T Facioscapulohumeral muscular dystrophy expression As a result, this region becomes more prone to transcription and gives rise to the activatory lncRNA DBE-T. DBE-T is mainly produced in FSHD patients and mediates the aberrant activation of the FSHD locus. chr4 190985657 190995609 + Human DBE-T JQ639078.1 24685002 289 DBE-T Facioscapulohumeral muscular dystrophy regulation Epigenetic deregulation of lncRNAs genes is associated with disease chr4 190985657 190995609 + Human DBE-T JQ639078.1 23791884 290 DBE-T Facioscapulohumeral muscular dystrophy mutation The activatory long non-coding RNA DBE-T reveals the epigenetic etiology of facioscapulohumeral muscular dystrophy. chr4 190985657 190995609 + Human DBE-T JQ639078.1 22710800 291 DBE-T Facioscapulohumeral muscular dystrophy regulation In contrast, in FSHD patients, a deletion of D4Z4 repeats results in cis production of the DBE-T lncRNA that binds to protein complexes, reorganizes the chromatin state of the FSHD locus, and reactivates the repressed 4q35 genes. chr4 190985657 190995609 + Human DBE-T JQ639078.1 24667321 292 DGCR5 DiGeorge syndrome Expression The DiGeorge syndrome-associated noncoding RNA, DGCR5, is repressed by REST through a proximal upstream binding site. chr22 18958027 18982141 + Human DGCR5; LINC00037; NCRNA00037 NR_002733.2 19050060 293 DGCR5 DiGeorge syndrome mutation DGCR5 is disrupted by the patient ADU breakpoint. chr22 18958027 18982141 + Human DGCR5; LINC00037; NCRNA00039 NR_002733.4 8659529 294 DGCR5 Huntington's disease expression Interestingly, many of these lncRNAs contain genomic binding sites for the transcriptional repressor REST, a key mediator of transcriptional changes in HD, including the known REST target lncRNA, DGCR5. chr22 18958027 18982141 + Human DGCR5; LINC00037; NCRNA00037 NR_002733.2 23346095 295 DGCR5 velocardiofacial syndrome N/A Association chr22 18958027 18982141 + Human DGCR5; LINC00037; NCRNA00038 NR_002733.3 20380817 296 DISC2 affective disorders N/A DISC2 is a likely susceptibility locus for both schizophrenia and affective disorders. chr1 231950372 231954263 - Human DISC2; DISC1OS; DISC1-AS1; NCRNA00022 NR_002227.9 15478311 297 DISC2 Autism spectrum disorder regulation Genomic context links lncRNAs to disease genes/loci and related pathways chr1 231950372 231954263 - Human DISC2; DISC1OS; DISC1-AS1; NCRNA00021 NR_002227.2 23791884 298 DISC2 Autism spectrum disorder Locus The disruption of the DISC genomic locus, which encodes both the DISC1 protein-coding gene and the DISC2 lncRNA, has been linked in a number of genetic analyses to the risk of developing schizophrenia, schizophrenia, bipolar disorder, major depression, and autistic spectrum disorders. chr1 231950372 231954263 - Human DISC2; DISC1OS; DISC1-AS1; NCRNA00015 NR_002227.2 19606485 299 DISC2 Autism spectrum disorder regulation DISC1 is regulated by its lncRNA, DISC6, which may also represent an excellent candidate for susceptibility to these disorders. chr1 231950372 231954263 - Human DISC2; DISC1OS; DISC1-AS1; NCRNA00015 NR_002227.2 22817756 300 DISC2 bipolar disorder regulation Genomic context links lncRNAs to disease genes/loci and related pathways chr1 231950372 231954263 - Human DISC2; DISC1OS; DISC1-AS1; NCRNA00021 NR_002227.2 23791884 301 DISC2 bipolar disorder Locus The disruption of the DISC genomic locus, which encodes both the DISC1 protein-coding gene and the DISC2 lncRNA, has been linked in a number of genetic analyses to the risk of developing schizophrenia, schizophrenia, bipolar disorder, major depression, and autistic spectrum disorders. chr1 231950372 231954263 - Human DISC2; DISC1OS; DISC1-AS1; NCRNA00016 NR_002227.3 17912248 302 DISC2 bipolar disorder regulation DISC1 is regulated by its lncRNA, DISC4, which may also represent an excellent candidate for susceptibility to these disorders. chr1 231950372 231954263 - Human DISC2; DISC1OS; DISC1-AS1; NCRNA00015 NR_002227.2 22817756 303 DISC2 depression Locus The disruption of the DISC genomic locus, which encodes both the DISC1 protein-coding gene and the DISC2 lncRNA, has been linked in a number of genetic analyses to the risk of developing schizophrenia, schizophrenia, bipolar disorder, major depression, and autistic spectrum disorders. chr1 231950372 231954263 - Human DISC2; DISC1OS; DISC1-AS1; NCRNA00019 NR_002227.6 17912248 304 DISC2 Major depression regulation Genomic context links lncRNAs to disease genes/loci and related pathways chr1 231950372 231954263 - Human DISC2; DISC1OS; DISC1-AS1; NCRNA00021 NR_002227.2 23791884 305 DISC2 Major depression regulation DISC1 is regulated by its lncRNA, DISC5, which may also represent an excellent candidate for susceptibility to these disorders. chr1 231950372 231954263 - Human DISC2; DISC1OS; DISC1-AS1; NCRNA00015 NR_002227.2 22817756 306 DISC2 schizophrenia Locus The disruption of the DISC genomic locus, which encodes both the DISC1 protein-coding gene and the DISC2 lncRNA, has been linked in a number of genetic analyses to the risk of developing schizophrenia, schizophrenia, bipolar disorder, major depression, and autistic spectrum disorders. chr1 231950372 231954263 - Human DISC2; DISC1OS; DISC1-AS1; NCRNA00017 NR_002227.4 20380817 307 DISC2 schizophrenia regulation DISC1 is regulated by its lncRNA, DISC3, which may also represent an excellent candidate for susceptibility to these disorders. chr1 231950372 231954263 - Human DISC2; DISC1OS; DISC1-AS1; NCRNA00015 NR_002227.2 22817756 308 DISC2 schizophrenia Mutation The Disrupted in Schizophrenia (DISC) locus on human chromosome 1q42 has been strongly implicated by genetic studies as a susceptibility locus for major mental illnesses.DISC2, a putative noncoding transcript partially antisense to DISC1, is not conserved. chr1 231950372 231954263 - Human DISC2; DISC1OS; DISC1-AS1; NCRNA00021 NR_002227.8 12573262 309 DISC2 schizophrenia regulation Genomic context links lncRNAs to disease genes/loci and related pathways chr1 231950372 231954263 - Human DISC2; DISC1OS; DISC1-AS1; NCRNA00021 NR_002227.2 23791884 310 DISC2 schizophrenia Locus DISC2 should be considered a formal candidate gene for susceptibility to psychiatric illness (schizophrenia). chr1 231950372 231954263 - Human DISC2; DISC1OS; DISC1-AS1; NCRNA00020 NR_002227.7 10814723 311 DISC2 schizophrenia Locus The disruption of the DISC genomic locus, which encodes both the DISC1 protein-coding gene and the DISC2 lncRNA, has been linked in a number of genetic analyses to the risk of developing schizophrenia, schizophrenia, bipolar disorder, major depression, and autistic spectrum disorders. chr1 231950372 231954263 - Human DISC2; DISC1OS; DISC1-AS1; NCRNA00018 NR_002227.5 17912248 312 DISC2 schizophrenia N/A DISC1 and DISC2 should be considered formal candidate genes for susceptibility to psychiatric illness. chr1 231950372 231954263 - Human DISC2; DISC1OS; DISC1-AS1; NCRNA00020 NR_002227.7 10814723 313 DISC2 schizophrenia N/A DISC2 is a likely susceptibility locus for both schizophrenia and affective disorders. chr1 231950372 231954263 - Human DISC2; DISC1OS; DISC1-AS1; NCRNA00023 NR_002227.10 15478311 314 DISC2 schizophrenia regulation DISC1 is regulated by its lncRNA, DISC2, which may also represent an excellent candidate for susceptibility to these disorders. chr1 231950372 231954263 - Human DISC2; DISC1OS; DISC1-AS1; NCRNA00015 NR_002227.2 22817756 315 DLEU1 chronic lymphocytic leukemia Locus In 13q14.3, where several tumor suppressor genes, including the miRNA genes miR-16-1 and miR-15a, are co-regulated by the two long non-coding RNA genes DLEU1 and DLEU2 that span the critical region. chr13 50656414 50679433 + Human DLEU1; BCMS; DLB1; LEU1; LEU2; XTP6; DLEU2; LINC00021; NCRNA00023 NR_002605.3 19347735 316 DLEU1 chronic lymphocytic leukemia Mutation Frequently deleted in B-cell chronic lymphocytic leukemia. chr13 50656414 50679433 + Human DLEU1; BCMS; DLB1; LEU1; LEU2; XTP6; DLEU2; LINC00021; NCRNA00022 NR_002605.2 11161783 317 DLEU1 chronic lymphocytic leukemia N/A Leu1 and Leu2 genes are strong candidates as tumor suppressor gene(s) involved in B-CLL leukemogenesis. chr13 50656414 50679433 + Human DLEU1; BCMS; DLB1; LEU1; LEU2; XTP6; DLEU2; LINC00021; NCRNA00021 NR_002605.1 9395242 318 DLEU2 chronic lymphocytic leukemia Expression The microRNAs miR-15a and miR-16-1 are downregulated in multiple tumor types and are frequently deleted in chronic lymphocytic leukemia (CLL), myeloma and mantle cell lymphoma. DLEU2 negatively regulates the G1 Cyclins E1 and D1 through miR-15a/miR-16-1 and provide evidence that these oncoproteins are subject to miR-15a/miR-16-1-mediated repression under normal conditions. We also demonstrate that DLEU2 overexpression blocks cellular proliferation and inhibits the colony-forming ability of tumor cell lines in a miR-15a/miR-16-1-dependent way. chr13 50556688 50699677 - Human DLEU2; 1B4; DLB2; LEU2; BCMSUN; RFP2OS; MIR15AHG; TRIM13OS; LINC00022; NCRNA00022 NR_002612.1 19591824 319 DLEU2 chronic lymphocytic leukemia Locus In 13q14.3, where several tumor suppressor genes, including the miRNA genes miR-16-1 and miR-15a, are co-regulated by the two long non-coding RNA genes DLEU1 and DLEU2 that span the critical region. chr13 50556688 50699677 - Human DLEU2; 1B4; DLB2; LEU2; BCMSUN; RFP2OS; MIR15AHG; TRIM13OS; LINC00022; NCRNA00025 NR_002612.4 19347735 320 DLEU2 chronic lymphocytic leukemia Mutation B-cell chronic lymphocytic leukemia: frequent chromosomal imbalance. chr13 50556688 50699677 - Human DLEU2; 1B4; DLB2; LEU2; BCMSUN; RFP2OS; MIR15AHG; TRIM13OS; LINC00022; NCRNA00027 NR_002612.6 11072235 321 DLEU2 chronic lymphocytic leukemia Mutation Frequently deleted in B-cell chronic lymphocytic leukemia. chr13 50556688 50699677 - Human DLEU2; 1B4; DLB2; LEU2; BCMSUN; RFP2OS; MIR15AHG; TRIM13OS; LINC00022; NCRNA00030 NR_002612.9 11161783 322 DLEU2 chronic lymphocytic leukemia N/A Leu1 and Leu2 genes are strong candidates as tumor suppressor gene(s) involved in B-CLL leukemogenesis. chr13 50556688 50699677 - Human DLEU2; 1B4; DLB2; LEU2; BCMSUN; RFP2OS; MIR15AHG; TRIM13OS; LINC00022; NCRNA00029 NR_002612.8 9395242 323 DLEU2 lymphocytic leukemia Locus Dleu2 is an antisense transcript that encompasses the Kcnrg and Trim13 genes, as well as two microRNA genes, Mirn16-1 and Mirn15a, which have been previously identified in lymphocytic leukemia. chr13 50556688 50699677 - Human DLEU2; 1B4; DLB2; LEU2; BCMSUN; RFP2OS; MIR15AHG; TRIM13OS; LINC00022; NCRNA00024 NR_002612.3 18562676 324 DLEU2 lymphoma Expression The microRNAs miR-15a and miR-16-1 are downregulated in multiple tumor types and are frequently deleted in chronic lymphocytic leukemia (CLL), myeloma and mantle cell lymphoma. DLEU2 negatively regulates the G1 Cyclins E1 and D1 through miR-15a/miR-16-1 and provide evidence that these oncoproteins are subject to miR-15a/miR-16-1-mediated repression under normal conditions. We also demonstrate that DLEU2 overexpression blocks cellular proliferation and inhibits the colony-forming ability of tumor cell lines in a miR-15a/miR-16-1-dependent way. chr13 50556688 50699677 - Human DLEU2; 1B4; DLB2; LEU2; BCMSUN; RFP2OS; MIR15AHG; TRIM13OS; LINC00022; NCRNA00023 NR_002612.2 19591824 325 DLEU2 lymphoma Mutation mantle-cell lymphoma: frequent chromosomal imbalance. chr13 50556688 50699677 - Human DLEU2; 1B4; DLB2; LEU2; BCMSUN; RFP2OS; MIR15AHG; TRIM13OS; LINC00022; NCRNA00028 NR_002612.7 11072235 326 DLEU2 myeloma Expression The microRNAs miR-15a and miR-16-1 are downregulated in multiple tumor types and are frequently deleted in chronic lymphocytic leukemia (CLL), myeloma and mantle cell lymphoma. DLEU2 negatively regulates the G1 Cyclins E1 and D1 through miR-15a/miR-16-1 and provide evidence that these oncoproteins are subject to miR-15a/miR-16-1-mediated repression under normal conditions. We also demonstrate that DLEU2 overexpression blocks cellular proliferation and inhibits the colony-forming ability of tumor cell lines in a miR-15a/miR-16-1-dependent way. chr13 50556688 50699677 - Human DLEU2; 1B4; DLB2; LEU2; BCMSUN; RFP2OS; MIR15AHG; TRIM13OS; LINC00022; NCRNA00026 NR_002612.5 19591824 327 DLG2AS schizophrenia Locus These results suggest that PSZA11q14 may be considered a candidate gene for schizophrenia acting as an antisense regulator of DLG-2, which controls assembling functional N-methyl-D-aspartate (NMDA) receptors. chr11 84594424 84604599 + Human DLG2-AS1; SZ-1; DLG2AS; DLG2-AS; PSZA11q14 13130513 328 DLX6-AS1 Split Hand/Split Foot malformation disorder Interaction The lncRNA EVF2, which recruits the transcription factor Dlx2 to activate the protein coding genes DLX5 and DLX6 that are associated with the Split Hand/ Split Foot malformation disorder. chr7 96597827 96643377 - Human DLX6-AS1; Evf-2; DLX6AS; DLX6-AS; NCRNA00212 NR_015448.1 20930520 329 DMPK myotonic dystrophy type 1 Mutation The mutant DMPK transcript causes myotonic dystrophy type 1 (DM1), which is encoded by a protein-coding gene containing a CUG expansion repeat in its 3'-untranslated region. chr19 46272975 46285815 - Human DLG2-AS1; SZ-1; DLG2AS; DLG2-AS; PSZA11q14 19909263 330 DMPK 3'UTR Heart Failure expression it is clear that Nkx2-5 is a genetic modifier of myotonic muscular dystrophy RNA toxicity and indicates important functionality of this 3'UTR, independent of its mRNA, in heart dysfunction. chr19 46272975 46285815 - Human DLG2-AS1; SZ-1; DLG2AS; DLG2-AS; PSZA11q14 23104877 331 DNM3OS ovarian cancer Locus pri-miR-199a2 within the human Dnm3os gene. The regulation of MIR199A2/214 expression may be used as a potential therapeutic approach in EOC (epithelial ovarian cancer) patients. chr1 172107724 172113975 - Human DNM3OS; DNM3-AS1; MIR199A2HG NR_038397.1 20400975 332 DQ786243 Crohn's disease regulation LncRNA DQ786243 affects Treg related CREB and Foxp3 expression in Crohn's disease. N/A N/A N/A N/A Human DQ786243 N/A 24289115 333 Dreh hepatocelluar carcinoma regulation Further experiments showed that Dreh can specifically bind to vimentin, a type III intermediate filament and the major cytoskeletal component of mesenchymal cells and then inhibit HCC metastasis by modifying the expression and reorganization of vimentin. chr17 64767111 64767931 + Mus Dreh NR_105051.1 24296588 334 Dreh hepatocelluar carcinoma regulation lncRNA-Dreh could bind to the intermediate filament protein vimentin, repress its expression, and thus change the cytoskeleton structure and inhibit tumor metastasis. It acts as a tumor suppressor in the development of HBV-HCC, which inhibits HCC growth and metastasis?in vitro?and?in vivo. These findings support a role of lncRNA-Dreh in tumor suppression and survival prediction of HCC patients. chr17 64767111 64767931 + Mus Dreh NR_105051.1 24757675 335 DSCAM-AS1 adolescent idiopathic scoliosis Mutation Other top associations in our GWAS were with SNPs (rs2222973, C>T) in the DSCAM gene. chr21 41755010 41757285 + Human DSCAM-AS1; M41 NR_038896.1 21216876 336 DSCAM-AS1 breast cancer Expression M41 (DSCAM-AS1) mRNA is expressed at a statistically significantly higher level in human breast cancer specimens than in normal human breast and benign lesions. chr21 41755010 41757285 + Human DSCAM-AS1; M41 NR_038896.1 12177779 337 ENSG00000135253.9 Hereditary Haemorrhagic Telangiectasia expression Top 42 long non-coding RNAs (q<0.001) differentially expressed in HHT telangiectasia. chr7 128502505 128550773 - Human ENSG00000135253.9 N/A 24603890 338 ENSG00000147753.5 Hereditary Haemorrhagic Telangiectasia expression Top 42 long non-coding RNAs (q<0.001) differentially expressed in HHT telangiectasia. chrY 6317509 6325947 + Human ENSG00000147753.5 N/A 24603890 339 ENSG00000196096.3 Hereditary Haemorrhagic Telangiectasia expression Top 42 long non-coding RNAs (q<0.001) differentially expressed in HHT telangiectasia. chr2 214141276 214148929 - Human ENSG00000196096.3 N/A 24603890 340 ENSG00000197251.3 Hereditary Haemorrhagic Telangiectasia expression Top 42 long non-coding RNAs (q<0.001) differentially expressed in HHT telangiectasia. chr6 33553883 33561115 - Human ENSG00000197251.3 N/A 24603890 341 ENSG00000203325.3 Hereditary Haemorrhagic Telangiectasia expression Top 42 long non-coding RNAs (q<0.001) differentially expressed in HHT telangiectasia. chr1 32517892 32539075 - Human ENSG00000203325.3 N/A 24603890 342 ENSG00000206129.3 Hereditary Haemorrhagic Telangiectasia expression Top 42 long non-coding RNAs (q<0.001) differentially expressed in HHT telangiectasia. chr18 53670844 53858493 - Human ENSG00000206129.3 N/A 24603890 343 ENSG00000215231.3 Hereditary Haemorrhagic Telangiectasia expression Top 42 long non-coding RNAs (q<0.001) differentially expressed in HHT telangiectasia. chr5 5034472 5070117 + Human ENSG00000215231.3 N/A 24603890 344 ENSG00000215374.4 Hereditary Haemorrhagic Telangiectasia expression Top 42 long non-coding RNAs (q<0.001) differentially expressed in HHT telangiectasia. chr8 7159133 7212876 - Human ENSG00000215374.4 N/A 24603890 345 ENSG00000215808.2 Hereditary Haemorrhagic Telangiectasia expression Top 42 long non-coding RNAs (q<0.001) differentially expressed in HHT telangiectasia. chr1 238643684 238649323 - Human ENSG00000215808.2 N/A 24603890 346 ENSG00000226496.1 Hereditary Haemorrhagic Telangiectasia expression Top 42 long non-coding RNAs (q<0.001) differentially expressed in HHT telangiectasia. chr21 42513427 42520060 - Human ENSG00000226496.1 N/A 24603890 347 ENSG00000229563.1 Hereditary Haemorrhagic Telangiectasia expression Top 42 long non-coding RNAs (q<0.001) differentially expressed in HHT telangiectasia. chrX 45364633 45489447 + Human ENSG00000229563.1 N/A 24603890 348 ENSG00000230133.1 Hereditary Haemorrhagic Telangiectasia expression Top 42 long non-coding RNAs (q<0.001) differentially expressed in HHT telangiectasia. chr20 24180403 24205224 + Human ENSG00000230133.1 N/A 24603890 349 ENSG00000230544.1 Hereditary Haemorrhagic Telangiectasia expression Top 42 long non-coding RNAs (q<0.001) differentially expressed in HHT telangiectasia. chr13 114586640 114588308 + Human ENSG00000230544.1 N/A 24603890 350 ENSG00000231133.1 Hereditary Haemorrhagic Telangiectasia expression Top 42 long non-coding RNAs (q<0.001) differentially expressed in HHT telangiectasia. chr20 61727150 61733631 - Human ENSG00000231133.1 N/A 24603890 351 ENSG00000231185.2 Hereditary Haemorrhagic Telangiectasia expression Top 42 long non-coding RNAs (q<0.001) differentially expressed in HHT telangiectasia. chr5 141704858 142051566 + Human ENSG00000231185.2 N/A 24603890 352 ENSG00000232021.2 Hereditary Haemorrhagic Telangiectasia expression Top 42 long non-coding RNAs (q<0.001) differentially expressed in HHT telangiectasia. chr4 109088681 109177992 + Human ENSG00000232021.2 N/A 24603890 353 ENSG00000232046.1 Hereditary Haemorrhagic Telangiectasia expression Top 42 long non-coding RNAs (q<0.001) differentially expressed in HHT telangiectasia. chr2 66801162 66957289 + Human ENSG00000232046.1 N/A 24603890 354 ENSG00000232956.3 Hereditary Haemorrhagic Telangiectasia expression Top 42 long non-coding RNAs (q<0.001) differentially expressed in HHT telangiectasia. chr7 45022622 45026560 - Human ENSG00000232956.3 N/A 24603890 355 ENSG00000233154.1 Hereditary Haemorrhagic Telangiectasia expression Top 42 long non-coding RNAs (q<0.001) differentially expressed in HHT telangiectasia. chr1 116966346 117021464 - Human ENSG00000233154.1 N/A 24603890 356 ENSG00000233251.3 Hereditary Haemorrhagic Telangiectasia expression Top 42 long non-coding RNAs (q<0.001) differentially expressed in HHT telangiectasia. chr2 56400669 56412905 - Human ENSG00000233251.3 N/A 24603890 357 ENSG00000235285.1 Hereditary Haemorrhagic Telangiectasia expression Top 42 long non-coding RNAs (q<0.001) differentially expressed in HHT telangiectasia. chr13 44720606 44732358 - Human ENSG00000235285.1 N/A 24603890 358 ENSG00000237036.3 Hereditary Haemorrhagic Telangiectasia expression Top 42 long non-coding RNAs (q<0.001) differentially expressed in HHT telangiectasia. chr10 31596646 31608810 - Human ENSG00000237036.3 N/A 24603890 359 ENSG00000237548.1 Hereditary Haemorrhagic Telangiectasia expression Top 42 long non-coding RNAs (q<0.001) differentially expressed in HHT telangiectasia. chr9 124646915 124725998 - Human ENSG00000237548.1 N/A 24603890 360 ENSG00000240453.1 Hereditary Haemorrhagic Telangiectasia expression Top 42 long non-coding RNAs (q<0.001) differentially expressed in HHT telangiectasia. chr1 745489 753092 - Human ENSG00000240453.1 N/A 24603890 361 ENSG00000241269.1 Hereditary Haemorrhagic Telangiectasia expression Top 42 long non-coding RNAs (q<0.001) differentially expressed in HHT telangiectasia. chr7 5459458 5462753 + Human ENSG00000241269.1 N/A 24603890 362 ENSG00000245910.3 Hereditary Haemorrhagic Telangiectasia expression Top 42 long non-coding RNAs (q<0.001) differentially expressed in HHT telangiectasia. chr8 67833919 67838633 - Human ENSG00000245910.3 N/A 24603890 363 ENSG00000248176.1 Hereditary Haemorrhagic Telangiectasia expression Top 42 long non-coding RNAs (q<0.001) differentially expressed in HHT telangiectasia. chr4 29119930 29204392 + Human ENSG00000248176.1 N/A 24603890 364 ENSG00000249364.1 Hereditary Haemorrhagic Telangiectasia expression Top 42 long non-coding RNAs (q<0.001) differentially expressed in HHT telangiectasia. chr5 66675206 67101066 + Human ENSG00000249364.1 N/A 24603890 365 ENSG00000249772.1 Hereditary Haemorrhagic Telangiectasia expression Top 42 long non-coding RNAs (q<0.001) differentially expressed in HHT telangiectasia. chr5 80409204 80410671 - Human ENSG00000249772.1 N/A 24603890 366 ENSG00000250195.1 Hereditary Haemorrhagic Telangiectasia expression Top 42 long non-coding RNAs (q<0.001) differentially expressed in HHT telangiectasia. chr4 139741108 139933800 - Human ENSG00000250195.1 N/A 24603890 367 ENSG00000250608.1 Hereditary Haemorrhagic Telangiectasia expression Top 42 long non-coding RNAs (q<0.001) differentially expressed in HHT telangiectasia. chr3 131043936 131100319 - Human ENSG00000250608.1 N/A 24603890 368 ENSG00000254154.3 Hereditary Haemorrhagic Telangiectasia expression Top 42 long non-coding RNAs (q<0.001) differentially expressed in HHT telangiectasia. chr1 177897923 178007142 - Human ENSG00000254154.3 N/A 24603890 369 ENSG00000255471.1 Hereditary Haemorrhagic Telangiectasia expression Top 42 long non-coding RNAs (q<0.001) differentially expressed in HHT telangiectasia. chr11 86603256 86636079 - Human ENSG00000255471.1 N/A 24603890 370 ENSG00000256218.1 Hereditary Haemorrhagic Telangiectasia expression Top 42 long non-coding RNAs (q<0.001) differentially expressed in HHT telangiectasia. chr12 5475214 5476940 - Human ENSG00000256218.1 N/A 24603890 371 ENSG00000259150.1 Hereditary Haemorrhagic Telangiectasia expression Top 42 long non-coding RNAs (q<0.001) differentially expressed in HHT telangiectasia. chr15 26360960 26378184 + Human ENSG00000259150.1 N/A 24603890 372 ENSG00000259334.1 Hereditary Haemorrhagic Telangiectasia expression Top 42 long non-coding RNAs (q<0.001) differentially expressed in HHT telangiectasia. chr14 24391456 24403777 - Human ENSG00000259334.1 N/A 24603890 373 ENSG00000259484.1 Hereditary Haemorrhagic Telangiectasia expression Top 42 long non-coding RNAs (q<0.001) differentially expressed in HHT telangiectasia. chr15 57151866 57210697 - Human ENSG00000259484.1 N/A 24603890 374 ENSG00000259758.1 Hereditary Haemorrhagic Telangiectasia expression Top 42 long non-coding RNAs (q<0.001) differentially expressed in HHT telangiectasia. chr8 141530255 141539600 - Human ENSG00000259758.1 N/A 24603890 375 ENSG00000263753.1 Hereditary Haemorrhagic Telangiectasia expression Top 42 long non-coding RNAs (q<0.001) differentially expressed in HHT telangiectasia. chr18 5232875 5246507 + Human ENSG00000263753.1 N/A 24603890 376 ENSG00000264772.1 Hereditary Haemorrhagic Telangiectasia expression Top 42 long non-coding RNAs (q<0.001) differentially expressed in HHT telangiectasia. chr17 7466604 7485342 + Human ENSG00000264772.1 N/A 24603890 377 ENSG00000266952.1 Hereditary Haemorrhagic Telangiectasia expression Top 42 long non-coding RNAs (q<0.001) differentially expressed in HHT telangiectasia. chr18 61880317 61927290 - Human ENSG00000266952.1 N/A 24603890 378 ENSMUST00000022467 Heart Failure expression Quantitative-PCR identified the relative expression of 5 significantly upregulated and 5 downregulated LncRNAs from 10 HF mice. Five LncRNAs were upregulated and 28 downregulated in HF hearts as compared with control hearts. N/A N/A N/A N/A Mus ENSMUST00000022467 N/A 24205036 379 ENSMUST00000041159 Heart Failure expression Quantitative-PCR identified the relative expression of 5 significantly upregulated and 5 downregulated LncRNAs from 10 HF mice. Five LncRNAs were upregulated and 31 downregulated in HF hearts as compared with control hearts. N/A N/A N/A N/A Mus ENSMUST00000041159 N/A 24205036 380 ENSMUST00000117372 Heart Failure expression Quantitative-PCR identified the relative expression of 5 significantly upregulated and 5 downregulated LncRNAs from 10 HF mice. Five LncRNAs were upregulated and 30 downregulated in HF hearts as compared with control hearts. N/A N/A N/A N/A Mus ENSMUST00000117372 N/A 24205036 381 ENSMUST00000117393 Heart Failure expression Quantitative-PCR identified the relative expression of 5 significantly upregulated and 5 downregulated LncRNAs from 10 HF mice. Five LncRNAs were upregulated and 15 downregulated in HF hearts as compared with control hearts. N/A N/A N/A N/A Mus ENSMUST00000117393 N/A 24205036 382 ENSMUST00000119855 Heart Failure expression Quantitative-PCR identified the relative expression of 5 significantly upregulated and 5 downregulated LncRNAs from 10 HF mice. Five LncRNAs were upregulated and 24 downregulated in HF hearts as compared with control hearts. N/A N/A N/A N/A Mus ENSMUST00000119855 N/A 24205036 383 ENSMUST00000120925 Heart Failure expression Quantitative-PCR identified the relative expression of 5 significantly upregulated and 5 downregulated LncRNAs from 10 HF mice. Five LncRNAs were upregulated and 14 downregulated in HF hearts as compared with control hearts. N/A N/A N/A N/A Mus ENSMUST00000120925 N/A 24205036 384 ENSMUST00000127230 Heart Failure expression Quantitative-PCR identified the relative expression of 5 significantly upregulated and 5 downregulated LncRNAs from 10 HF mice. Five LncRNAs were upregulated and 8 downregulated in HF hearts as compared with control hearts. N/A N/A N/A N/A Mus ENSMUST00000127230 N/A 24205036 385 ENSMUST00000127429 Heart Failure expression Quantitative-PCR identified the relative expression of 5 significantly upregulated and 5 downregulated LncRNAs from 10 HF mice. Five LncRNAs were upregulated and 27 downregulated in HF hearts as compared with control hearts. N/A N/A N/A N/A Mus ENSMUST00000127429 N/A 24205036 386 ENSMUST00000130025 Heart Failure expression Quantitative-PCR identified the relative expression of 5 significantly upregulated and 5 downregulated LncRNAs from 10 HF mice. Five LncRNAs were upregulated and 17 downregulated in HF hearts as compared with control hearts. Mus ENSMUST00000130025 N/A 24205036 387 ENSMUST00000142855 Heart Failure expression Quantitative-PCR identified the relative expression of 5 significantly upregulated and 5 downregulated LncRNAs from 10 HF mice. Five LncRNAs were upregulated and 6 downregulated in HF hearts as compared with control hearts. N/A N/A N/A N/A Mus ENSMUST00000142855 N/A 24205036 388 ENSMUST00000143888 Heart Failure expression Quantitative-PCR identified the relative expression of 5 significantly upregulated and 5 downregulated LncRNAs from 10 HF mice. Five LncRNAs were upregulated and 9 downregulated in HF hearts as compared with control hearts. N/A N/A N/A N/A Mus ENSMUST00000143888 N/A 24205036 389 ENSMUST00000151138 ischemia/reperfusion expression Classification and validation of deregulated LncRNAs in ischemia/reperfusion-treated mouse livers. N/A N/A N/A N/A Mus ENSMUST00000151138 N/A 24312245 390 ENSMUST00000160947 Heart Failure expression Quantitative-PCR identified the relative expression of 5 significantly upregulated and 5 downregulated LncRNAs from 10 HF mice. Five LncRNAs were upregulated and 23 downregulated in HF hearts as compared with control hearts. N/A N/A N/A N/A Mus ENSMUST00000160947 N/A 24205036 391 ENSMUST00000167632 Heart Failure expression Quantitative-PCR identified the relative expression of 5 significantly upregulated and 5 downregulated LncRNAs from 10 HF mice. Five LncRNAs were upregulated and 20 downregulated in HF hearts as compared with control hearts. N/A N/A N/A N/A Mus ENSMUST00000167632 N/A 24205036 392 ENST00000513542 Ventricular septal defects expression Furthermore, our established filtering pipeline indicated an association of two lncRNAs, ENST00000513542 and RP11-473L15.2, with VSD. N/A N/A N/A N/A Human ENST00000513542 N/A 24147006 393 EPB41L4A-AS1 cancer Expression Ectopic expression of TIGA1 (EPB41L4A-AS1) inhibited not only tumor cell proliferation but also anchorage-independent growth of cancer cell lines. chr5 111496223 111498198 + Human EPB41L4A-AS1; TIGA1; C5orf26; NCRNA00219 NR_015370.2 16973895 394 ESCCAL-1 Esophageal squamous cell cancer expression In addition, we confirmed another two upregulated lncRNAs that are differentially expressed in ESCC and that we have named ESCCAL-1, and ESCCAL-5. N/A N/A N/A N/A Human ESCCAL-1 N/A 24222893 395 ESCCAL-5 Esophageal squamous cell cancer expression In addition, we confirmed another two upregulated lncRNAs that are differentially expressed in ESCC and that we have named ESCCAL-1, and ESCCAL-5. N/A N/A N/A N/A Human ESCCAL-5 N/A 24222893 396 ESRG embryonal carcinoma Expression HESRG was expressed strongly and diffusively in the nuclei of tumor cells in intracranial germinoma and embryonal carcinoma as well as in human embryonic stem cells.In embryonal carcinoma, 6 of 9 showed intensive (3+) immunostaining and 3 of 9 showed moderate (2+) immunostaining. chr3 54666151 54673884 - Human ESRG; HESRG NR_027122.1 21861197 397 ESRG intracranial aneurism Expression HESRG was expressed strongly and diffusively in the nuclei of tumor cells in intracranial germinoma and embryonal carcinoma as well as in human embryonic stem cells.In germinomas, 25 of 31 showed intensive (3+) expression, four cases showed moderate (2+) immunostaining and the remaining 2 cases showed weak (1+) immunostaining. chr3 54666151 54673884 - Human ESRG; HESRG NR_027122.1 21861197 398 FADS1 lipid metabolism disorder regulation The expression of FADS, and its lncRNA, reverse D5-desaturase, were found to be reciprocally regulated by the dietary fat content in animal models chr11 61567097 61584529 - Human FADS1; D5D; TU12; FADS6; FADSD5; LLCDL1 NM_013402.4 22817756 399 Fendrr Heart Failure expression The tissue-specific lncRNA Fendrr is an essential regulator of heart and body wall development in the mouse. chr8 121054882 121083032 - Mus Fendrr; 1110050K14Rik NR_045471.1 23369715 400 FGF10-AS1 Ventricular septal defects expression Furthermore, our established filtering pipeline indicated an association of two lncRNAs, ENST00000513542 and RP11-473L15.2, with VSD. chr5 44388834 44414091 + Human FGF10-AS1; RP11-473L15.2 NR_108034.1 24147006 401 FMR4 fragile X syndrome regulation Genomic context links lncRNAs to disease genes/loci and related pathways chrX 146990949 147003676 - Human FMR1-AS1; FMR4; ASFMR1; FMR1AS; FMR1-AS NR_024499.1 23791884 402 FMR4 fragile X syndrome Expression A novel RNA transcript with antiapoptotic function is silenced in fragile X syndrome. chrX 146990949 147003676 - Human FMR1-AS1; FMR4; ASFMR1; FMR1AS; FMR1-AS NR_024499.1 18213394 403 FMR4 fragile X syndrome Expression FMR4 is also silenced in FXS patients because of a CGG expansion repeat in the 5鈥?untranslated region (UTR) of the FMR1 gene and up regulated in pre-mutation carriers chrX 146990949 147003676 - Human FMR1-AS1; FMR4; ASFMR1; FMR1AS; FMR1-AS NR_024499.1 18213394 404 FMR4 Fragile X-associated tremor and ataxia syndrome regulation Genomic context links lncRNAs to disease genes/loci and related pathways chrX 146990949 147003676 - Human FMR1-AS1; FMR4; ASFMR1; FMR1AS; FMR1-AS NR_024499.1 23791884 405 FMR5 Fragile X syndrome expression Comprehensive analysis of the transcriptional landscape of the human FMR1 gene reveals two new long noncoding RNAs differentially expressed in Fragile X syndrome and Fragile X-associated tremor/ataxia syndrome. N/A N/A N/A N/A Human FMR5 N/A 24005575 406 FMR5 Fragile X-associated tremor and ataxia syndrome expression Comprehensive analysis of the transcriptional landscape of the human FMR1 gene reveals two new long noncoding RNAs differentially expressed in Fragile X syndrome and Fragile X-associated tremor/ataxia syndrome. N/A N/A N/A N/A Human FMR5 N/A 24005575 407 FMR6 Fragile X syndrome expression Comprehensive analysis of the transcriptional landscape of the human FMR1 gene reveals two new long noncoding RNAs differentially expressed in Fragile X syndrome and Fragile X-associated tremor/ataxia syndrome. N/A N/A N/A N/A Human FMR6 N/A 24005575 408 FMR6 Fragile X-associated tremor and ataxia syndrome expression Comprehensive analysis of the transcriptional landscape of the human FMR1 gene reveals two new long noncoding RNAs differentially expressed in Fragile X syndrome and Fragile X-associated tremor/ataxia syndrome. N/A N/A N/A N/A Human FMR6 N/A 24005575 409 GAS5 autoimmune disease Expression Increased lncRNA Gas5 activity in immune cells could suppress GR-induced transcriptional activity and contribute to the development of autoimmune disease. chr1 173833039 173837125 - Human GAS5; SNHG2; NCRNA00034 NR_002578.6 20124551 410 GAS5 B-cell neoplasms expression HOTAIR long non-coding RNA is a negative prognostic factor not only in primary tumors, but also in the blood of colorectal cancer patients. chr1 173833039 173837125 - Human GAS5; SNHG2; NCRNA00034 NR_002578.2 24583225 411 GAS5 breast cancer Expression GAS5, a non-protein-coding RNA, controls apoptosis and is downregulated in breast cancer. chr1 173833039 173837125 - Human GAS5; SNHG2; NCRNA00030 NR_002578.2 18836484 412 GAS5 breast cancer Expression Gas5 has also been linked with breast cancer because Gas5 transcript levels are significantly reduced compared to unaffected normal breast epithelia. chr1 173833039 173837125 - Human GAS5; SNHG2; NCRNA00035 NR_002578.7 20673990 413 GAS5 breast cancer regulation GAS5?lncRNA?promoted the apoptosis of triple-negative and oestrogen receptor-positive cells but only dual PI3K/mTOR inhibition was able to enhance GAS5 levels in all cell types. Reduced GAS5 expression attenuates apoptosis induction by classical chemotherapeutic agents in breast cancer cells, providing an explanation for the relationship between GAS5 expression and breast cancer patient prognosis.? chr1 173833039 173837125 - Human GAS5; SNHG2; NCRNA00034 NR_002578.2 24789445 414 GAS5 cancer regulation Pickard et al. showed that GAS5 promotes apoptosis of prostate cells after irradiation with UV, and low GAS5 expression therefore reduces the effectiveness of chemotherapeutic agents. chr1 173833039 173837125 - Human GAS5; SNHG2; NCRNA00034 NR_002578.2 24757675 415 GAS5 kidney cancer expression Tumour suppressor chr1 173833039 173837125 - Human GAS5; SNHG2; NCRNA00034 NR_002578.2 24373479 416 GAS5 lymphoma Mutation Chromosomal translocations affecting the 1q25 locus containing the Gas5 gene have been detected in melanoma, B-cell lymphoma, and prostate and breast cancer. chr1 173833039 173837125 - Human GAS5; SNHG2; NCRNA00031 NR_002578.3 18836484 417 GAS5 lymphoma Mutation The GAS5 (growth arrest-specific transcript 5) gene fuses to BCL6 as a result of t(1;3)(q25;q27) in a patient with B-cell lymphoma. chr1 173833039 173837125 - Human GAS5; SNHG2; NCRNA00036 NR_002578.8 18406879 418 GAS5 melanoma Mutation Chromosomal translocations affecting the 1q25 locus containing the Gas5 gene have been detected in melanoma, B-cell lymphoma, and prostate and breast cancer. chr1 173833039 173837125 - Human GAS5; SNHG2; NCRNA00032 NR_002578.4 18836484 419 GAS5 prostat expression Tumour suppressor; putative oncogene host chr1 173833039 173837125 - Human GAS5; SNHG2; NCRNA00034 NR_002578.2 24373479 420 GAS5 prostat Mutation Chromosomal translocations affecting the 1q25 locus containing the Gas5 gene have been detected in melanoma, B-cell lymphoma, and prostate and breast cancer. chr1 173833039 173837125 - Human GAS5; SNHG2; NCRNA00033 NR_002578.5 18836484 421 GAS5 systemic lupus erythaematosus N/A The Gas5 transcript has been linked with increased susceptibility to systemic lupus erythaematosus in mouse models, presumably as a result of its effect on the immunosuppressant role of glucocorticoids chr1 161035166 161035166 + mouse Gas5; Gas-5 22817756 422 GAS5 tumor regulation ANRIL, GAS5 and lincRNA-p23 are involved in the escape of growth suppression by regulating tumor suppressor genes (ANRIL) or apoptosis regulators. chr1 173833039 173837125 - Human GAS5; SNHG2; NCRNA00034 NR_002578.2 24667321 423 GAS5 tumor regulation Binding to GR as a decoy and blocking transcriptional induction by GR, induces growth arrest and apoptosis. chr1 173833039 173837125 - Human GAS5; SNHG2; NCRNA00034 NR_002578.2 22996375 424 GAS5 tumor regulation Our own work suggests that while RoR (Zhang et al., 2013a) may function as an oncogene through suppression of p53 in response to DNA damage, loc285194 (Liu et al., 2013) and GAS5 (Zhang et al., 2013b) may play a tumor suppressive role through the “competitive endogenous RNA” (CeRNA) mechanism (Salmena et al., 2011). chr1 173833039 173837125 - Human GAS5; SNHG2; NCRNA00034 NR_002578.2 24721780 425 GDNFOS Alzheimer's disease Expression The findings of novel GDNF and GDNFOS isoforms and differences in tissue expression patterns dysregulated in AD brains may further reveal the role of endogenous GDNF in human brain diseases. chr5 37873821 37874827 + Human GDNF-AS1; GDNFOS XR_158787.1 22081608 426 GHET1 gastric cancer regulation Long non-coding RNA GHET1 promotes gastric carcinoma cell proliferation by increasing c-Myc mRNA stability. chr7 N/A N/A N/A Human GHET1 N/A 24397586 427 Gm12839 Heart Failure expression Quantitative-PCR identified the relative expression of 5 significantly upregulated and 5 downregulated LncRNAs from 10 HF mice. Five LncRNAs were upregulated and 29 downregulated in HF hearts as compared with control hearts. chr4 115582038 115583127 - Mus Gm12839; OTTMUSG00000008630 NR_033575.1 24205036 428 Gm20748 cardiovascular disease expression Here, we identified Braveheart (Bvht), a heart-associated lncRNA in mouse. Using multiple embryonic stem cell (ESC) differentiation strategies, we show that Bvht is required for progression of nascent mesoderm toward a cardiac fate. chr18 61639653 61647503 + Mus Gm20748; Bvht NR_045420.1 23352431 429 Gm6644 Heart Failure expression Quantitative-PCR identified the relative expression of 5 significantly upregulated and 5 downregulated LncRNAs from 10 HF mice. Five LncRNAs were upregulated and 12 downregulated in HF hearts as compared with control hearts. chr1 55443695 55445063 - Mus Gm6644; Akr1b3p; EG626009 NR_028277 24205036 430 GNAS-AS1 pseudohypoparathyroidism type Ib Mutation Deletion of the nespas causes pseudohypoparathyroidism Type Ib. chr20 57393973 57393973 - Human GDNF-AS1; GDNFOS XR_158787.1 20444925 431 H19 adrenocortical carcinomas Epigenetics This disease has been associated with structural abnormalities at the 11p15 locus, which harbors the IGF2 gene as well as the genes coding for insulin, H19, and p57kip2. chr11 2016406 2019065 - Human H19; ASM; BWS; WT2; ASM1; PRO2605; D11S813E; LINC00008; NCRNA00040 NR_002196.33 22019903 432 H19 atherosclerosis Epigenetics The most pronounced differences of atherosclerotic plaques in DNA methylation levels were registered for a site which is located in CpG-island of imprinted gene H19. chr11 2016406 2019065 - Human H19; ASM; BWS; WT2; ASM1; PRO2605; D11S813E; LINC00008; NCRNA00044 NR_002196.37 21954592 433 H19 Beckwith-Wiedemann syndrome Epigenetics Allelic methylation of H19 and IGF2 in the Beckwith-Wiedemann syndrome. chr11 2016406 2019065 - Human H19; ASM; BWS; WT2; ASM1; PRO2605; D11S813E; LINC00008; NCRNA00021 NR_002196.14 7987305 434 H19 Beckwith-Wiedemann syndrome Epigenetics Epigenetic alterations of H19 and LIT1 distinguish patients with Beckwith-Wiedemann syndrome with cancer and birth defects. chr11 2016406 2019065 - Human H19; ASM; BWS; WT2; ASM1; PRO2605; D11S813E; LINC00008; NCRNA00015 NR_002196.8 11813134 435 H19 Beckwith-Wiedemann syndrome Epigenetics Mosaicism for 11p15 UPD and hypermethylation of the H19 gene in blood cells were associated with an increased risk of tumour. chr11 2016406 2019065 - Human H19; ASM; BWS; WT2; ASM1; PRO2605; D11S813E; LINC00008; NCRNA00027 NR_002196.20 11436121 436 H19 Beckwith-Wiedemann syndrome Locus The H19 locus acts in vivo as a tumor suppressor. chr11 2016406 2019065 - Human H19; ASM; BWS; WT2; ASM1; PRO2605; D11S813E; LINC00008; NCRNA00063 NR_002196.56 18719115 437 H19 Beckwith-Wiedemann syndrome Mutation Microdeletions in the human H19 DMR result in loss of IGF2 imprinting and Beckwith-Wiedemann syndrome. chr11 2016406 2019065 - Human H19; ASM; BWS; WT2; ASM1; PRO2605; D11S813E; LINC00008; NCRNA00051 NR_002196.44 15314640 438 H19 biparental complete hydatidiform moles Epigenetics H19 is abnormally methylated on the maternal alleles in BiCHMs. chr11 2016406 2019065 - Human H19; ASM; BWS; WT2; ASM1; PRO2605; D11S813E; LINC00008; NCRNA00008 NR_002196.1 12783848 439 H19 bladder cancer expression Prognostic marker low-risk marker Oncogene targeted therapy agent chr11 2016406 2019065 - Human H19; ASM; BWS; WT2; ASM1; PRO2605; D11S813E; LINC00008; NCRNA00021 NR_002196.1 24373479 440 H19 bladder cancer regulation Control of imprinting breast, cervix, oesophagus prostate, endometrial, colon chr11 2016406 2019065 - Human H19; ASM; BWS; WT2; ASM1; PRO2605; D11S813E; LINC00008; NCRNA00021 NR_002196.1 24499465 441 H19 bladder cancer Expression The imprinted H19 gene is a marker of early recurrence in human bladder carcinoma. chr11 2016406 2019065 - Human H19; ASM; BWS; WT2; ASM1; PRO2605; D11S813E; LINC00008; NCRNA00012 NR_002196.5 11193051 442 H19 bladder cancer Mutation A significantly decreased risk of bladder cancer was found for the rs2839698 TC genotype but not for CC homozygotes.The rs2839698 TC genotype was especially associated with a reduced risk of developing non-muscle-invasive disease. Borderline significantly chr11 2016406 2019065 - Human H19; ASM; BWS; WT2; ASM1; PRO2605; D11S813E; LINC00008; NCRNA00032 NR_002196.25 18262338 443 H19 bladder cancer Mutation An SNP polymorphism in the non-protein-encoding H19 gene is associated with a decreased risk of developing non-muscle-invasive bladder cancer. A significantly decreased risk of bladder cancer was found for the rs2839698 TC genotype, but not for CC homozygotes. chr11 2016406 2019065 - Human H19; ASM; BWS; WT2; ASM1; PRO2605; D11S813E; LINC00008; NCRNA00060 NR_002196.53 18262338 444 H19 bladder cancer N/A Bladder tumors may be successfully treated by intravesical instillation of the double promoter vector H19-DTA-P4-DTA. chr11 2016406 2019065 - Human H19; ASM; BWS; WT2; ASM1; PRO2605; D11S813E; LINC00008; NCRNA00033 NR_002196.26 21162716 445 H19 bladder cancer N/A The H19 non-coding RNA is essential for human tumor growth. chr11 2016406 2019065 - Human H19; ASM; BWS; WT2; ASM1; PRO2605; D11S813E; LINC00008; NCRNA00026 NR_002196.19 17786216 446 H19 bladder cancer expression Theseguilty by association studies have found numerous bladder-cancer associated lncRNAs chr11 2016406 2019065 - Human H19; ASM; BWS; WT2; ASM1; PRO2605; D11S813E; LINC00008; NCRNA00040 N/A 24006935 447 H19 bladder cancer regulation Control of imprinting. Containing miRNA miR-675. chr11 2016406 2019065 - Human H19; ASM; BWS; WT2; ASM1; PRO2605; D11S813E; LINC00008; NCRNA00040 NR_002196.1 22996375 448 H19 bladder cancer regulation Upregulated H19 contributes to bladder cancer cell proliferation by regulating ID2 expression. chr11 2016406 2019065 - Human H19; ASM; BWS; WT2; ASM1; PRO2605; D11S813E; LINC00008; NCRNA00040 NR_002196.1 23354591 449 H19 bladder cancer regulation Upregulated H19 contributes to bladder cancer cell proliferation by regulating ID2 expression. chr11 2016406 2019065 - Human H19; ASM; BWS; WT2; ASM1; PRO2605; D11S813E; LINC00008; NCRNA00040 NR_002196.1 23399020 450 H19 breast cancer Expression Down-regulation of H19 significantly decreases breast and lung cancer cell clonogenicity and anchorage-independent growth. In addition, c-Myc and H19 expression shows strong association in primary breast and lung carcinomas. chr11 2016406 2019065 - Human H19; ASM; BWS; WT2; ASM1; PRO2605; D11S813E; LINC00008; NCRNA00049 NR_002196.42 16707459 451 H19 breast cancer Expression H19 RNA and insulin-like growth factor II mRNA were up-regulated significantly in non-neoplastic WAP-CRD-BP mammary tissue. chr11 2016406 2019065 - Human H19; ASM; BWS; WT2; ASM1; PRO2605; D11S813E; LINC00008; NCRNA00014 NR_002196.7 14729626 452 H19 breast cancer Expression Overexpression of an ectopic H19 gene enhances the tumorigenic properties of breast cancer cells. chr11 2016406 2019065 - Human H19; ASM; BWS; WT2; ASM1; PRO2605; D11S813E; LINC00008; NCRNA00013 NR_002196.6 12419837 453 H19 breast cancer Expression the transcript is stabilized in breast cancer cells and overexpressed in human breast tumors.91H expression is upregulated in breast cancer. chr11 2016406 2019065 - Human H19; ASM; BWS; WT2; ASM1; PRO2605; D11S813E; LINC00008; NCRNA00009 NR_002196.2 18794369 454 H19 breast cancer Mutation Different SNPs in LSP1 and H19 and in minor genes probably were associated with BC risk. chr11 2016406 2019065 - Human H19; ASM; BWS; WT2; ASM1; PRO2605; D11S813E; LINC00008; NCRNA00043 NR_002196.36 21996731 455 H19 breast cancer Mutation rs2107425 (C>T) near H19 was significantly associated with shorter metastasis-free survival in uni- and multi-variate analysis , with the more aggressive minor allele displaying a recessive trait. chr11 2016406 2019065 - Human H19; ASM; BWS; WT2; ASM1; PRO2605; D11S813E; LINC00008; NCRNA00058 NR_002196.51 21748294 456 H19 breast cancer regulation Control of imprinting. Containing miRNA miR-675. chr11 2016406 2019065 - Human H19; ASM; BWS; WT2; ASM1; PRO2605; D11S813E; LINC00008; NCRNA00040 NR_002196.1 22996375 457 H19 cancer Expression H19 expression was found in the hepatic metastases of 64 of 80 patients. High expression (higher staining grades) of H19 in the metastases was found in 43 of 80 patients. However, H19 expression status in the hepatic metastases did not correlate with either the length of time to development of metastasis or overall survival. chr11 2016406 2019065 - Human H19; ASM; BWS; WT2; ASM1; PRO2605; D11S813E; LINC00008; NCRNA00048 NR_002196.41 16189152 458 H19 cancer Expression The human H19 gene is frequently overexpressed in myometrium and stroma during pathological endometrial proliferative events. chr11 2016406 2019065 - Human H19; ASM; BWS; WT2; ASM1; PRO2605; D11S813E; LINC00008; NCRNA00053 NR_002196.46 15618002 459 H19 cervical cancer Mutation High incidence of loss of heterozygosity and abnormal imprinting of H19 and IGF2 genes in invasive cervical carcinomas. chr11 2016406 2019065 - Human H19; ASM; BWS; WT2; ASM1; PRO2605; D11S813E; LINC00008; NCRNA00020 NR_002196.13 8570220 460 H19 choricarcinoma regulation Control of imprinting. Containing miRNA miR-675. chr11 2016406 2019065 - Human H19; ASM; BWS; WT2; ASM1; PRO2605; D11S813E; LINC00008; NCRNA00040 NR_002196.1 22996375 461 H19 chronic myeloproliferative disorders Expression Reduced expression of H19 in bone marrow cells from chronic myeloproliferative disorders. chr11 2016406 2019065 - Human H19; ASM; BWS; WT2; ASM1; PRO2605; D11S813E; LINC00008; NCRNA00010 NR_002196.3 12682647 462 H19 colon cancer Expression DT-A was preferentially expressed in liver metastases after being transfected with H19 or IGF2-P3 promoter-driven DT-A expression plasmids, causing a very significant inhibition of tumor growth as a result of its cytotoxic effect. chr11 2016406 2019065 - Human H19; ASM; BWS; WT2; ASM1; PRO2605; D11S813E; LINC00008; NCRNA00052 NR_002196.45 15521051 463 H19 colon cancer Locus Oncofetal H19-derived miR-675 regulates tumor suppressor RB in human colorectal cancer. chr11 2016406 2019065 - Human H19; ASM; BWS; WT2; ASM1; PRO2605; D11S813E; LINC00008; NCRNA00025 NR_002196.18 19926638 464 H19 colon cancer N/A Regional therapy with DTA-H19 vector suppresses growth of colon adenocarcinoma metastases in the rat liver. chr11 2016406 2019065 - Human H19; ASM; BWS; WT2; ASM1; PRO2605; D11S813E; LINC00008; NCRNA00042 NR_002196.35 21874233 465 H19 colon cancer regulation Control of imprinting. Containing miRNA miR-675. chr11 2016406 2019065 - Human H19; ASM; BWS; WT2; ASM1; PRO2605; D11S813E; LINC00008; NCRNA00040 NR_002196.1 22996375 466 H19 Congenital hyperinsulinism Expression In agreement with the loss of the maternal chromosome, the level of expression of a maternally expressed tumor suppressor gene, H19, was greatly reduced compared to the level of expression of the paternally expressed growth promoter gene, IGF2. chr11 2016406 2019065 - Human H19; ASM; BWS; WT2; ASM1; PRO2605; D11S813E; LINC00008; NCRNA00017 NR_002196.10 11395395 467 H19 Esophageal squamous cell cancer regulation Long non-coding RNA 91H contributes to the occurrence and progression of esophageal squamous cell carcinoma by inhibiting IGF2 expression. chr11 2016406 2019065 - Human H19; ASM; BWS; WT2; ASM1; PRO2605; D11S813E; LINC00008; NCRNA00009 NR_002196.1 24706416 468 H19 Esophageal squamous cell cancer regulation Control of imprinting. Containing miRNA miR-675. chr11 2016406 2019065 - Human H19; ASM; BWS; WT2; ASM1; PRO2605; D11S813E; LINC00008; NCRNA00040 NR_002196.1 22996375 469 H19 gastric cancer expreesion Overexpression of?lncRNA?H19 enhances carcinogenesis and metastasis of gastric cancer. chr11 2016406 2019065 - Human H19; ASM; BWS; WT2; ASM1; PRO2605; D11S813E; LINC00008; NCRNA00021 NR_002196.1 24810858 470 H19 gastric cancer regulation Using real-time RT-PCR, flow cytometry, RNA immunoprecipitation and other methods, Yang et al confirmed that H19 expression in gastric cancer accelerated cell proliferation. chr11 2016406 2019065 - Human H19; ASM; BWS; WT2; ASM1; PRO2605; D11S813E; LINC00008; NCRNA00021 NR_002196.1 24833871 471 H19 gastric cancer regulation c-Myc-induced, long, noncoding H19 affects cell proliferation and predicts a poor prognosis in patients with gastric cancer. chr11 2016406 2019065 - Human H19; ASM; BWS; WT2; ASM1; PRO2605; D11S813E; LINC00008; NCRNA00021 NR_002196.1 24671855 472 H19 germ cell tumor Epigenetics IGF2/H19 methylation status in GCTs might reflect preservation of the physiologic imprinting erasure in PGCs rather than a loss of imprinting in a sense that is accepted for somatic tumors. chr11 2016406 2019065 - Human H19; ASM; BWS; WT2; ASM1; PRO2605; D11S813E; LINC00008; NCRNA00057 NR_002196.50 16001432 473 H19 gestational choriocarcinoma Expression Prominent expression of H19 was found in placental site trophoblastic tumor and gestational choriocarcinoma. chr11 2016406 2019065 - Human H19; ASM; BWS; WT2; ASM1; PRO2605; D11S813E; LINC00008; NCRNA00023 NR_002196.16 8188082 474 H19 gestational trophoblastic diseases Expression LOI, deregulation of IGF2 promoters, and the altered expression levels of IGF2 and H19 genes might be associated with the progression of GTD. chr11 2016406 2019065 - Human H19; ASM; BWS; WT2; ASM1; PRO2605; D11S813E; LINC00008; NCRNA00011 NR_002196.4 12648595 475 H19 glioblastoma Expression Another study performed in CD133+ and CD133- glioblastoma derived primary cell lines revealed levels of H19 expression that were relatively high and low, respectively. chr11 2016406 2019065 - Human H19; ASM; BWS; WT2; ASM1; PRO2605; D11S813E; LINC00008; NCRNA00050 NR_002196.43 20380817 476 H19 glioma regulation Epigenetic deregulation of lncRNAs genes is associated with disease chr11 2016406 2019065 - Human H19; ASM; BWS; WT2; ASM1; PRO2605; D11S813E; LINC00008; NCRNA00021 NR_002196.1 23791884 477 H19 glioma regulation Long non-coding RNA H19 promotes glioma cell invasion by deriving miR-675. chr11 2016406 2019065 - Human H19; ASM; BWS; WT2; ASM1; PRO2605; D11S813E; LINC00008; NCRNA00021 NR_002196.1 24466011 478 H19 growth restriction Epigenetics A loss of methylation at H19. chr11 2016406 2019065 - Human H19; ASM; BWS; WT2; ASM1; PRO2605; D11S813E; LINC00008; NCRNA00059 NR_002196.52 20104244 479 H19 hematopoiesis Expression Down-regulation of the IGF-2/H19 locus during normal and malignant hematopoiesis is independent of the imprinting pattern. chr11 2016406 2019065 - Human H19; ASM; BWS; WT2; ASM1; PRO2605; D11S813E; LINC00008; NCRNA00054 NR_002196.47 15645136 480 H19 hepatocelluar carcinoma expression Dysregulation and functional roles of lncRNAs in HCC chr11 2016406 2019065 - Human H19; ASM; BWS; WT2; ASM1; PRO2605; D11S813E; LINC00008; NCRNA00021 NR_002196.1 24183851 481 H19 hepatocelluar carcinoma Expression We found that imbalances in levels of IGF2 and H19 transcripts were correlated with advanced tumor stage and poor outcome in HCC patients. chr11 2016406 2019065 - Human H19; ASM; BWS; WT2; ASM1; PRO2605; D11S813E; LINC00008; NCRNA00055 NR_002196.48 15736456 482 H19 hepatocelluar carcinoma N/A The H19 non-coding RNA is essential for human tumor growth. chr11 2016406 2019065 - Human H19; ASM; BWS; WT2; ASM1; PRO2605; D11S813E; LINC00008; NCRNA00024 NR_002196.17 17786216 483 H19 hepatocelluar carcinoma expreesion Overexpression of H19 was found in hepatocellular carcinoma.? chr11 2016406 2019065 - Human H19; ASM; BWS; WT2; ASM1; PRO2605; D11S813E; LINC00008; NCRNA00021 NR_002196.1 24757675 484 H19 hepatocelluar carcinoma regulation Epigenetic activation of the MiR-200 family contributes to H19-mediated metastasis suppression in hepatocellular carcinoma. chr11 2016406 2019065 - Human H19; ASM; BWS; WT2; ASM1; PRO2605; D11S813E; LINC00008; NCRNA00040 NR_002196.1 23222811 485 H19 hyperhomocysteinemia Epigenetics The effect of hyperhomocysteinemia on H19 DMD methylation was tissue-specific. hyperhomocysteinemia produces tissue-specific changes in H19 DMD methylation and increased vascular expression of H19 in adult mice. chr11 2016406 2019065 - Human H19; ASM; BWS; WT2; ASM1; PRO2605; D11S813E; LINC00008; NCRNA00065 NR_002196.58 15899898 486 H19 infertility Expression H19 expression was lower in the infertility group as compared to the control group. chr11 2016406 2019065 - Human H19; ASM; BWS; WT2; ASM1; PRO2605; D11S813E; LINC00008; NCRNA00062 NR_002196.55 20042264 487 H19 kidney cancer regulation Tumour suppressor; tumour suppressor host chr11 2016406 2019065 - Human H19; ASM; BWS; WT2; ASM1; PRO2605; D11S813E; LINC00008; NCRNA00021 NR_002196.1 24373479 488 H19 liver cancer Epigenetics H19 ICR showed loss-of-imprinting in two steps and allelic histone marker signature during tumorigenesis showed similarity with ES cells. chr11 2016406 2019065 - Human H19; ASM; BWS; WT2; ASM1; PRO2605; D11S813E; LINC00008; NCRNA00034 NR_002196.27 21163252 489 H19 liver cancer regulation Control of imprinting breast, cervix, oesophagus prostate, endometrial, colon chr11 2016406 2019065 - Human H19; ASM; BWS; WT2; ASM1; PRO2605; D11S813E; LINC00008; NCRNA00021 NR_002196.1 24499465 490 H19 liver cancer regulation Control of imprinting. Containing miRNA miR-675. chr11 2016406 2019065 - Human H19; ASM; BWS; WT2; ASM1; PRO2605; D11S813E; LINC00008; NCRNA00040 NR_002196.1 22996375 491 H19 lung cancer Expression Down-regulation of H19 significantly decreases breast and lung cancer cell clonogenicity and anchorage-independent growth. In addition, c-Myc and H19 expression shows strong association in primary breast and lung carcinomas. chr11 2016406 2019065 - Human H19; ASM; BWS; WT2; ASM1; PRO2605; D11S813E; LINC00008; NCRNA00029 NR_002196.22 16707459 492 H19 lung cancer regulation Control of imprinting breast, cervix, oesophagus prostate, endometrial, colon chr11 2016406 2019065 - Human H19; ASM; BWS; WT2; ASM1; PRO2605; D11S813E; LINC00008; NCRNA00021 NR_002196.1 24499465 493 H19 lung cancer regulation Control of imprinting. Containing miRNA miR-675. chr11 2016406 2019065 - Human H19; ASM; BWS; WT2; ASM1; PRO2605; D11S813E; LINC00008; NCRNA00040 NR_002196.1 22996375 494 H19 Marek's disease Mutation The mutant CVI/rpp38 was not only reactive with MAb H19 in IFA but also in immunoprecipitation. chr11 2016406 2019065 - Human H19; ASM; BWS; WT2; ASM1; PRO2605; D11S813E; LINC00008; NCRNA00018 NR_002196.11 10696440 495 H19 Medulloblastoma regulation Epigenetic deregulation of lncRNAs genes is associated with disease chr11 2016406 2019065 - Human H19; ASM; BWS; WT2; ASM1; PRO2605; D11S813E; LINC00008; NCRNA00021 NR_002196.1 23791884 496 H19 Medulloblastoma Epigenetics A study of medulloblastomas and medulloblastoma cell lines showed partial loss of imprinting (LOI) and biallelic expression of H19. chr11 2016406 2019065 - Human H19; ASM; BWS; WT2; ASM1; PRO2605; D11S813E; LINC00008; NCRNA00041 NR_002196.34 20380817 497 H19 melanoma Expression The study of 4 sensitive and 2 resistant cell lines allowed the identification of 4 genes (RCC1, IFI16, hox2 and h19) preferentially transcribed in sensitive ((IFN-alpha therapy) cells and 2 (SHB and PKC-zeta) preferentially expressed in resistant cells. chr11 2016406 2019065 - Human H19; ASM; BWS; WT2; ASM1; PRO2605; D11S813E; LINC00008; NCRNA00016 NR_002196.9 11437411 498 H19 melanoma Mutation Although the IGF2 and H19 genotypes/haplotypes were not significantly associated with melanoma, two of the most severe cases (very early onset or multiple melanomas) showed to be heterozygous for both genes. chr11 2016406 2019065 - Human H19; ASM; BWS; WT2; ASM1; PRO2605; D11S813E; LINC00008; NCRNA00056 NR_002196.49 20483645 499 H19 melanoma Expression H19 RNA downregulation stimulated melanogenesis in melasma. chr11 2016406 2019065 - Human H19; ASM; BWS; WT2; ASM1; PRO2605; D11S813E; LINC00008; NCRNA00036 NR_002196.29 19968822 500 H19 Meningioma regulation Epigenetic deregulation of lncRNAs genes is associated with disease chr11 2016406 2019065 - Human H19; ASM; BWS; WT2; ASM1; PRO2605; D11S813E; LINC00008; NCRNA00021 NR_002196.1 23791884 501 H19 Meningioma Epigenetics An examination of meningiomas (World Health Organization grades I-III) demonstrated more robustly that the imprinting status of H19 is perturbed with LOI in a significant number of these tumors. chr11 2016406 2019065 - Human H19; ASM; BWS; WT2; ASM1; PRO2605; D11S813E; LINC00008; NCRNA00045 NR_002196.38 20380817 502 H19 Mullerian aplasia Epigenetics Methylation of H19 and its imprinted control region (H19 ICR1) in Mullerian aplasia. chr11 2016406 2019065 - Human H19; ASM; BWS; WT2; ASM1; PRO2605; D11S813E; LINC00008; NCRNA00035 NR_002196.28 21458801 503 H19 myeloproliferative polycythaemia vera Expression Expression of the imprinted tumour-suppressor gene H19 is tightly regulated during normal haematopoiesis and is reduced in haematopoietic precursors of patients with the myeloproliferative disease polycythaemia vera. chr11 2016406 2019065 - Human H19; ASM; BWS; WT2; ASM1; PRO2605; D11S813E; LINC00008; NCRNA00019 NR_002196.12 10640993 504 H19 neural tube defects Epigenetics The methylation levels of H19 DMR1 in the NTD and control groups are 73.3%卤15.9 and 58.3%卤11.2, respectively. Hyper-methylation of the H19 DMR1 may be correlated with the occurrence of NTDs. chr11 2016406 2019065 - Human H19; ASM; BWS; WT2; ASM1; PRO2605; D11S813E; LINC00008; NCRNA00039 NR_002196.32 22234160 505 H19 neuroblastoma regulation Epigenetic deregulation of lncRNAs genes is associated with disease chr11 2016406 2019065 - Human H19; ASM; BWS; WT2; ASM1; PRO2605; D11S813E; LINC00008; NCRNA00021 NR_002196.1 23791884 506 H19 obesity Epigenetics Insulin-like Growth Factor 2/H19 Methylation at Birth and Risk of Overweight and Obesity in Children. chr11 2016406 2019065 - Human H19; ASM; BWS; WT2; ASM1; PRO2605; D11S813E; LINC00008; NCRNA00037 NR_002196.30 22341586 507 H19 ovarian cancer Expression H19 RNA was detected in 90% of patients with OCAF (Ovarian cancer ascites fluid ) as determined by ISH. Intratumoral injection of DTA-H19 into ectopically developed tumors caused 40% inhibition of tumor growth. chr11 2016406 2019065 - Human H19; ASM; BWS; WT2; ASM1; PRO2605; D11S813E; LINC00008; NCRNA00038 NR_002196.31 19656414 508 H19 pheochromocytoma Mutation Tumor DNA from the index patient revealed loss of heterozygosity (LOH) at 11q23, causing loss of the wild-type paternal SDHD allele and LOH affecting maternal 11p15, including H19. chr11 2016406 2019065 - Human H19; ASM; BWS; WT2; ASM1; PRO2605; D11S813E; LINC00008; NCRNA00046 NR_002196.39 21937622 509 H19 Pituitary adenoma regulation Epigenetic deregulation of lncRNAs genes is associated with disease chr11 2016406 2019065 - Human H19; ASM; BWS; WT2; ASM1; PRO2605; D11S813E; LINC00008; NCRNA00021 NR_002196.1 23791884 510 H19 Prader-Willi syndrome regulation Epigenetic deregulation of lncRNAs genes is associated with disease chr11 2016406 2019065 - Human H19; ASM; BWS; WT2; ASM1; PRO2605; D11S813E; LINC00008; NCRNA00021 NR_002196.1 23791884 511 H19 pre-eclampsia Mutation LOI of H19 can be identified in pre-eclamptic placentas and is associated with maternal blood pressures, which implies the involvement of H19 gene LOI in the pathogenesis of pre-eclampsia and its potential relationship with the severity of the disease. chr11 2016406 2019065 - Human H19; ASM; BWS; WT2; ASM1; PRO2605; D11S813E; LINC00008; NCRNA00064 NR_002196.57 19570415 512 H19 prostat expression Putative susceptibility and diagnostic marker chr11 2016406 2019065 - Human H19; ASM; BWS; WT2; ASM1; PRO2605; D11S813E; LINC00008; NCRNA00021 NR_002196.1 24373479 513 H19 Silver-Russell syndrome Epigenetics The major finding (~44%) is a hypomethylation of the imprinting control region 1 (ICR1) in 11p15.5 affecting the expression of H19 and IGF2. 4-10% of the patients carry a maternal UPD of chromosome 7 (UPD(7)mat). chr11 2016406 2019065 - Human H19; ASM; BWS; WT2; ASM1; PRO2605; D11S813E; LINC00008; NCRNA00031 NR_002196.24 21150838 514 H19 Silver-Russell syndrome Mutation Epigenetic mutations of the imprinted IGF2-H19 domain in Silver-Russell syndrome chr11 2016406 2019065 - Human H19; ASM; BWS; WT2; ASM1; PRO2605; D11S813E; LINC00008; NCRNA00028 NR_002196.21 19066168 515 H19 trophoblastic tumor Expression Prominent expression of H19 was found in placental site trophoblastic tumor and gestational choriocarcinoma. chr11 2016406 2019065 - Human H19; ASM; BWS; WT2; ASM1; PRO2605; D11S813E; LINC00008; NCRNA00022 NR_002196.15 8188082 516 H19 tumor Epigenetics In recent years, we have extensively investigated the expression of the H19 gene in a number of human cancers and explored the role of H19 RNA in tumor development. chr11 2016406 2019065 - Human H19; ASM; BWS; WT2; ASM1; PRO2605; D11S813E; LINC00008; NCRNA00040 NR_002196.1 23429271 517 H19 tumor regulation Oncofetal H19 RNA promotes tumor metastasis. chr11 2016406 2019065 - Human H19; ASM; BWS; WT2; ASM1; PRO2605; D11S813E; LINC00008; NCRNA00021 NR_002196.1 24703882 518 H19 tumor expression H19, a lncRNA with oncogenic properties, is upregulated in a wide range of tumours. chr11 2016406 2019065 - Human H19; ASM; BWS; WT2; ASM1; PRO2605; D11S813E; LINC00008; NCRNA00040 N/A 23660942 519 H19 Wiedemann-Beckwith syndrome Epigenetics Genetic analyses of the patient's blood showed hypermethylation at the H19 locus on chromosome 11p. chr11 2016406 2019065 - Human H19; ASM; BWS; WT2; ASM1; PRO2605; D11S813E; LINC00008; NCRNA00030 NR_002196.23 21058226 520 H19 Wilms' tumor Epigenetics 37% of patients with Wilms' tumor were H19 epimutations. chr11 2016406 2019065 - Human H19; ASM; BWS; WT2; ASM1; PRO2605; D11S813E; LINC00008; NCRNA00047 NR_002196.40 22470196 521 H19 Wilms' tumor Epigenetics Gain of methylation at the H19 DMR is an early event in Wilms' tumorigenesis that is independent of chromosomal losses. chr11 2016406 2019065 - Human H19; ASM; BWS; WT2; ASM1; PRO2605; D11S813E; LINC00008; NCRNA00061 NR_002196.54 16179496 522 HAR1A Alzheimer's disease N/A Schizophrenia spectrum disorders and AD have also been linked with the rheelin (RELN) gene and its antisense transcript HAR1 chr20 61732644 61735737 + Human HAR1A; HAR1F; LINC00064; NCRNA00064 NR_003244.1 22817756 523 HAR1A Huntington's disease Expression HAR1, a deeply conserved genomic region consisting of a cis-antisense pair of structured lncRNAs (HAR1F and HAR1R) (2, 23) located ~80 kb from the neural microRNA, miR-124-3. HAR1 levels are significantly lower in the striatum of HD patients. chr20 61732644 61735737 + Human HAR1A; HAR1F; LINC00064; NCRNA00064 NR_003244.1 20179156 524 HAR1A Huntington's disease regulation HAR1 has also been implicated in HD, where the transcriptional repressor RE-1-silencing transcription factor (REST) enters pathologically into the nucleus, leading to the repression of several important neuronal genes. chr20 61732644 61735737 + Human HAR1A; HAR1F; LINC00064; NCRNA00064 N/A 23562612 525 HAR1A schizophrenia N/A Schizophrenia spectrum disorders and AD have also been linked with the rheelin (RELN) gene and its antisense transcript HAR1 chr20 61732644 61735737 + Human HAR1A; HAR1F; LINC00064; NCRNA00064 NR_003244.1 22817756 526 HAR1B Alzheimer's disease N/A Schizophrenia spectrum disorders and AD have also been linked with the rheelin (RELN) gene and its antisense transcript HAR1 chr20 61726845 61733671 - Human HAR1B; HAR1R; LINC00065; NCRNA00065 NR_003245.1 22817756 527 HAR1B Huntington's disease Expression HAR1, a deeply conserved genomic region consisting of a cis-antisense pair of structured lncRNAs (HAR1F and HAR1R) (2, 23) located ~80 kb from the neural microRNA, miR-124-3. HAR1 levels are significantly lower in the striatum of HD patients. chr20 61726845 61733671 - Human HAR1B; HAR1R; LINC00065; NCRNA00065 NR_003245.1 20179156 528 HAR1B Huntington's disease regulation HAR1 has also been implicated in HD, where the transcriptional repressor RE-1-silencing transcription factor (REST) enters pathologically into the nucleus, leading to the repression of several important neuronal genes. chr20 61726845 61733671 - Human HAR1B; HAR1R; LINC00065; NCRNA00065 N/A 23562612 529 HAR1B schizophrenia N/A Schizophrenia spectrum disorders and AD have also been linked with the rheelin (RELN) gene and its antisense transcript HAR1 chr20 61726845 61733671 - Human HAR1B; HAR1R; LINC00065; NCRNA00065 NR_003245.1 22817756 530 HCP5 AIDS Expression A total of 245 HIV patients were included in the study. A good correlation between HLA-B*5701 and HCP5 was observed (negative and positive predictive values of 100% and 93%, respectively). chr6 31430957 31433586 + Human HCP5; P5-1; 6S2650E; D6S2650E NR_040662.1 20534626 531 HCP5 AIDS Mutation A polymorphism (rs2395029, G824T) in the HCP5 gene associated with HLA-B*5701 does not restrict HIV-1 in vitro. chr6 31430957 31433586 + Human HCP5; P5-1; 6S2650E; D6S2650E NR_040662.1 19935381 532 HCP5 AIDS Mutation HCP5 genotyping could serve as a simple screening tool for ABC-HSR. chr6 31430957 31433586 + Human HCP5; P5-1; 6S2650E; D6S2650E NR_040662.1 18684101 533 HEIH hepatocelluar carcinoma expreesion Dr. Yang and his colleagues found that one lncRNA, named lncRNA-HEIH, was overexpressed in HCC tissue compared with normal liver tissues using microarray. chr5 180829954 180831618 - Human HEIH; HCCAT2; LINC-HEIH; LINC00848; lncRNA-HEIH NR_045680.1 24757675 534 HELLPAR extravillous trophoblast mutation We identified a novel long intergenic noncoding RNA (lincRNA) transcript of 205,012 bases with (peri)nuclear expression in the extravillous trophoblast using strand-specific RT-PCR complemented with RACE and FISH. chr12 101,115,493 101,320,504 + Human LINC-HELLP JX088243.1 23093777 535 HIF1A-AS1 kidney cancer Expression The antitumor DNA topoisomerase I (Top1) inhibitor camptothecin (CPT) increases the cellular levels of two antisense lncRNAs at the 5' (5'aHIF-1 alpha) and 3' (3'aHIF-1 alpha) ends of the human HIF1A-AS1 gene. chr14 62147759 62162536 - Human HIF1A-AS1; 5'aHIF-1A 21897117 536 HIF1A-AS1 kidney cancer expression Diagnostic and discriminative marker chr14 62147759 62162536 - Human HIF1A-AS1; 5'aHIF-1A NR_047116.1 24373479 537 HIF1A-AS1 renal cancer Expression overexpressed in human renal cancer and during hypoxia. chr14 62147759 62162536 - Human HIF1A-AS1; 5'aHIF-1A 9923855 538 HIF1A-AS2 kidney cancer expression Diagnostic and discriminative marker chr14 61747039 61749089 - Human HIF1A-AS2; aHIF; 3'aHIF-1A NR_045406.1 24373479 539 HI-LNC25 type 2 diabetes regulation Depletion of HI-LNC25, a 尾 cell-specific lncRNA, downregulated GLIS3 mRNA, thus exemplifying a gene regulatory function of islet lncRNAs. Finally, selected islet lncRNAs were dysregulated in type 2 diabetes or mapped to genetic loci underlying diabetes susceptibility. N/A N/A N/A N/A Human N/A N/A 23040067 540 HLA-AS1 AIDS Mutation HIV-1 disease-influencing effects associated with ZNRD1, HCP5 and HLA-C alleles are attributable mainly to either HLA-A10 or HLA-B*57 alleles. chr1 220961451 221139391 + Human HLA-AS1 N/A 18982067 541 HLA-AS1 liver injury Mutation HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. chr1 220961451 221139391 + Human HLA-AS1 N/A 19483685 542 HLA-AS1 multiple sclerosis Mutation We identified significant effects on MS susceptibility of HLA-A*2 , and two coding polymorphisms in the MOG gene after full conditioning on HLA-DRB1. chr1 220961451 221139391 + Human HLA-AS1 N/A 17971048 543 HLA-AS1 psoriasis Mutation HLA-Cw*0602 associates more strongly to psoriasis in the Swedish population than variants of the novel 6p21.3 gene PSORS1C3. chr1 220961451 221139391 + Human HLA-AS1 N/A 15848982 544 HNF1A-AS1 adenocarcinoma regulation Long non-coding RNA HNF1A-AS1 regulates proliferation and migration in oesophageal adenocarcinoma cells. chr12 121407641 121410095 - Human HNF1A-AS1; C12orf27; NCRNA00262 N/A 24000294 545 HNF1A-AS1 oesophageal adenocarcinoma regulation Long non-coding RNA HNF1A-AS1 regulates proliferation and migration in oesophageal adenocarcinoma cells. chr14 62147759 62162536 - Human HIF1A-AS1; 5'aHIF-1A NR_047116.1 24000294 546 HOTAIR B-cell neoplasms expression HOTAIR long non-coding RNA is a negative prognostic factor not only in primary tumors, but also in the blood of colorectal cancer patients. chr12 54356096 54362515 - Human HOTAIR; HOXAS; HOXC-AS4; HOXC11-AS1; NCRNA00080 NR_047517.1 24583225 547 HOTAIR breast cancer regulation Epigenetically silences gene expression via LSD1/CoREST & PRC2; metastasis chr12 54356096 54362515 - Human HOTAIR; HOXAS; HOXC-AS4; HOXC11-AS1; NCRNA00080 NR_047517.1 24499465 548 HOTAIR breast cancer Expression A subsequent study revealed that HOTAIR is overexpressed in approximately one quarter of human breast cancers. chr12 54356096 54362515 - Human HOTAIR; HOXAS; HOXC-AS4; HOXC11-AS1; NCRNA00080 NR_047517.9 20930520 549 HOTAIR breast cancer Expression Elevated expression of HOTAIR is observed in primary and metastatic breast cancer. chr12 54356096 54362515 - Human HOTAIR; HOXAS; HOXC-AS4; HOXC11-AS1; NCRNA00073 NR_047517.2 21925379 550 HOTAIR breast cancer Expression HOTAIR expression level in primary tumors is a powerful predictor of eventual metastasis and death. chr12 54356096 54362515 - Human HOTAIR; HOXAS; HOXC-AS4; HOXC11-AS1; NCRNA00072 NR_047517.1 20393566 551 HOTAIR breast cancer Expression HOTAIR is increased in expression in primary breast tumours and metastases, and HOTAIR expression level in primary tumours is a powerful predictor of eventual metastasis and death. chr12 54356096 54362515 - Human HOTAIR; HOXAS; HOXC-AS4; HOXC11-AS1; NCRNA00075 NR_047517.4 20393566 552 HOTAIR breast cancer Expression HOTAIR showed positive association with 'hang Serum Response'. chr12 54356096 54362515 - Human HOTAIR; HOXAS; HOXC-AS4; HOXC11-AS1; NCRNA00086 NR_047517.15 19182780 553 HOTAIR breast cancer Expression Recently, augmented levels of HOTAIR in primary breast tumors were shown to correlate with breast cancer invasiveness and metastasis. chr12 54356096 54362515 - Human HOTAIR; HOXAS; HOXC-AS4; HOXC11-AS1; NCRNA00087 NR_047517.16 20393566 554 HOTAIR breast cancer Expression The lncRNA HOTAIR is a strong predictor of metastasis in breast tumors and its over-expression in various breast carcinoma cell lines promotes invasion. chr12 54356096 54362515 - Human HOTAIR; HOXAS; HOXC-AS4; HOXC11-AS1; NCRNA00079 NR_047517.8 21903344 555 HOTAIR breast cancer expression For example, HOTAIR is remarkably overexpressed in breast tumors and the expression of HOTAIR in primary breast tumors is a strong prognosis marker of patient outcomes such as metastasis and patient survival chr12 54356096 54362515 - Human HOTAIR; HOXAS; HOXC-AS4; HOXC11-AS1; NCRNA00080 NR_047517.1 24721780 556 HOTAIR breast cancer expression HOTAIR was proposed as a diagnostic marker in breast and colorectal cancer. Its depletion resulted in reduced invasiveness, and its expression level correlated with differentially regulated genes of the PRC2 complex. chr12 54356096 54362515 - Human HOTAIR; HOXAS; HOXC-AS4; HOXC11-AS1; NCRNA00080 NR_047517.1 24531795 557 HOTAIR breast cancer expression In approximately one-quarter of human breast cancers, HOTAIR is highly induced, while its elevated levels are also predictive of metastasis and disease progression in other cancers, such as colon, colorectal, gastrointestinal, pancreatic and liver cancer. chr12 54356096 54362515 - Human HOTAIR; HOXAS; HOXC-AS4; HOXC11-AS1; NCRNA00080 NR_047517.1 24667321 558 HOTAIR breast cancer expression Overexpression of the HOTAIR transcript, a cis-lncRNA associated with the HOXD gene cluster, has been associated with hepatocellular carcinoma [32], colorectal cancer [33] and breast cancer [13] by deregulation of HOXD cluster genes chr12 54356096 54362515 - Human HOTAIR; HOXAS; HOXC-AS4; HOXC11-AS1; NCRNA00086 NR_047517.15 22817756 559 HOTAIR breast cancer expression Recent studies have linked their mis-expression to diverse cancers (ANRIL: prostate cancer, XIST: female cancers, HOTAIR: breast cancer, KCNQ1OT3: colorectal cancer). chr12 54356096 54362515 - Human HOTAIR; HOXAS; HOXC-AS4; HOXC11-AS1; NCRNA00086 N/A 23660942 560 HOTAIR breast cancer expression The wellstudied lincRNA, HOTAIR, is highly expressed in breast cancer metastases, and its overexpression in various breast carcinoma cell lines promotes invasion chr12 54356096 54362515 - Human HOTAIR; HOXAS; HOXC-AS4; HOXC11-AS1; NCRNA00086 NR_047517.15 22535282 561 HOTAIR breast cancer regulation Gene silencing by interacting with PRC2 and LSD1/CoREST complexes. chr12 54356096 54362515 - Human HOTAIR; HOXAS; HOXC-AS4; HOXC11-AS1; NCRNA00072 NR_047517.1 22996375 562 HOTAIR breast cancer regulation On a more mechanistic level, recent studies have revealed the contribution of lncRNAs as proto-oncogenes, e.g. GAGE6, as tumor suppressor genes, e.g. 鈥榩15 antisense RNA and lincP21' (36,91), as drivers of metastatic transformation, e.g. HOTAIR in breast cancer, and as regulators of alternative splicing, e.g. MALAT1 chr12 54356096 54362515 - Human HOTAIR; HOXAS; HOXC-AS4; HOXC11-AS1; NCRNA00086 NR_047517.15 22492512 563 HOTAIR breast cancer regulation Gupta et al found that lncRNA HOTAIR overexpression was a strong predictor of breast tumor metastasis. chr12 54356096 54362515 - Human HOTAIR; HOXAS; HOXC-AS4; HOXC11-AS1; NCRNA00080 NR_047517.1 24829860 564 HOTAIR breast cancer regulation Gene silencing by interacting with PRC2 and LSD1/CoREST complexes. chr12 54356096 54362515 - Human HOTAIR; HOXAS; HOXC-AS4; HOXC11-AS1; NCRNA00072 NR_047517.1 22996375 565 HOTAIR cancer Epigenetics Epigenetically silences gene expression at many loci by recruitment of LSD1/CoREST/REST and PRC2 repressive chromatin modifying complexes. Oncogene: promotes tumour metastasis. chr12 54356096 54362515 - Human HOTAIR; HOXAS; HOXC-AS4; HOXC11-AS1; NCRNA00078 NR_047517.7 21256239 566 HOTAIR cancer Epigenetics Long noncoding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. chr12 54356096 54362515 - Human HOTAIR; HOXAS; HOXC-AS4; HOXC11-AS1; NCRNA00082 NR_047517.11 20393566 567 HOTAIR cancer Expression HOTAIR is causally involved in tumor progression. It is significantly overexpressed in metastatic breast cancer. chr12 54356096 54362515 - Human HOTAIR; HOXAS; HOXC-AS4; HOXC11-AS1; NCRNA00077 NR_047517.6 22045689 568 HOTAIR cancer expreesion Overexpression of HOTAIR was found in breast and colon cancers and was associated with metastasis and poor prognosis. chr12 54356096 54362515 - Human HOTAIR; HOXAS; HOXC-AS4; HOXC11-AS1; NCRNA00080 NR_047517.1 24757675 569 HOTAIR cancer expression Long Non-coding RNA HOTAIR Is Targeted and Regulated by miR-141 in Human Cancer Cells. chr12 54356096 54362515 - Human HOTAIR; HOXAS; HOXC-AS4; HOXC11-AS1; NCRNA00080 NR_047517.1 24616104 570 HOTAIR cancer regulation Forced expression of HOTAIR in epithelial cancer cells altered the localization of PRC2 on chromatin. Genome-wide studies revealed PRC2 localization more resembling occupancy in embryonic fibroblasts.? chr12 54356096 54362515 - Human HOTAIR; HOXAS; HOXC-AS4; HOXC11-AS1; NCRNA00080 NR_047517.1 24829860 571 HOTAIR cancer expression HOTAIR overexpression has been linked to increased invasiveness and poorer outcomes in several human cancers. chr12 54356096 54362515 - Human HOTAIR; HOXAS; HOXC-AS4; HOXC11-AS1; NCRNA00072 NR_047517.1 23473599 572 HOTAIR cancer expression HOTAIR overexpression is associated with poor prognosis in breast (Gupta et al. 2010), liver (Z. Yang et al. 2011), colorectal (Kogo et al. 2011), gastrointestinal (Niinuma et al. 2012), and pancreatic (Kim et al. 2012) cancers and is proposed to increase tumor invasiveness and metastasis (Gupta et al. 2010). chr12 54356096 54362515 - Human HOTAIR; HOXAS; HOXC-AS4; HOXC11-AS1; NCRNA00072 NR_047517.1 23463798 573 HOTAIR cancer expression It is overexpressed in various carcinomas including breast cancer. chr12 54356096 54362515 - Human HOTAIR; HOXAS; HOXC-AS4; HOXC11-AS1; NCRNA00072 NR_047517.1 23463798 574 HOTAIR cervical cancer expreesion Overexpression of?long?noncoding?RNA?HOTAIR predicts a poor prognosis in patients with cervical cancer. chr12 54356096 54362515 - Human HOTAIR; HOXAS; HOXC-AS4; HOXC11-AS1; NCRNA00080 NR_047517.1 24748337 575 HOTAIR colon cancer expression In approximately one-quarter of human breast cancers, HOTAIR is highly induced, while its elevated levels are also predictive of metastasis and disease progression in other cancers, such as colon, colorectal, gastrointestinal, pancreatic and liver cancer. chr12 54356096 54362515 - Human HOTAIR; HOXAS; HOXC-AS4; HOXC11-AS1; NCRNA00080 NR_047517.1 24667321 576 HOTAIR colorectal cancer expression HOTAIR was proposed as a diagnostic marker in breast and colorectal cancer. Its depletion resulted in reduced invasiveness, and its expression level correlated with differentially regulated genes of the PRC2 complex. chr12 54356096 54362515 - Human HOTAIR; HOXAS; HOXC-AS4; HOXC11-AS1; NCRNA00080 NR_047517.1 24531795 577 HOTAIR colorectal cancer Epigenetics Long noncoding RNA HOTAIR regulates polycomb-dependent chromatin modification and is associated with poor prognosis in colorectal cancers.patients with high HOTAIR expression had a relatively poorer prognosis. chr12 54356096 54362515 - Human HOTAIR; HOXAS; HOXC-AS4; HOXC11-AS1; NCRNA00076 NR_047517.5 21862635 578 HOTAIR colorectal cancer expression In approximately one-quarter of human breast cancers, HOTAIR is highly induced, while its elevated levels are also predictive of metastasis and disease progression in other cancers, such as colon, colorectal, gastrointestinal, pancreatic and liver cancer. chr12 54356096 54362515 - Human HOTAIR; HOXAS; HOXC-AS4; HOXC11-AS1; NCRNA00080 NR_047517.1 24667321 579 HOTAIR colorectal cancer expression Overexpression of the HOTAIR transcript, a cis-lncRNA associated with the HOXD gene cluster, has been associated with hepatocellular carcinoma [32], colorectal cancer [33] and breast cancer [13] by deregulation of HOXD cluster genes chr12 54356096 54362515 - Human HOTAIR; HOXAS; HOXC-AS4; HOXC11-AS1; NCRNA00086 NR_047517.15 22817756 580 HOTAIR colorectal cancer regulation HOTAIR long non-coding RNA is a negative prognostic factor not only in primary tumors, but also in the blood of colorectal cancer patients. chr12 54356096 54362515 - Human HOTAIR; HOXAS; HOXC-AS4; HOXC11-AS1; NCRNA00080 NR_047517.1 24583926 581 HOTAIR endometrial cancer regulation Lentivirus-Mediated?RNA?Interference Targeting the?Long?Noncoding?RNA?HOTAIR Inhibits Proliferation and Invasion of Endometrial Carcinoma Cells In Vitro and In Vivo. chr12 54356096 54362515 - Human HOTAIR; HOXAS; HOXC-AS4; HOXC11-AS1; NCRNA00080 NR_047517.1 24758900 582 HOTAIR endometrial cancer expression The long non-coding RNA HOTAIR is upregulated in endometrial carcinoma and correlates with poor prognosis. chr12 54356096 54362515 - Human HOTAIR; HOXAS; HOXC-AS4; HOXC11-AS1; NCRNA00080 NR_047517.1 24285342 583 HOTAIR epithelial ovarian cancer expression Overexpression of long non-coding RNA HOTAIR predicts poor patient prognosis and promotes tumor metastasis in epithelial ovarian cancer. chr12 54356096 54362515 - Human HOTAIR; HOXAS; HOXC-AS4; HOXC11-AS1; NCRNA00080 NR_047517.1 24662839 584 HOTAIR Esophageal squamous cell cancer expreesion Similarly, patients with high HOTAIR expression suffered a significantly poorer prognosis than those with low expression.? chr12 54356096 54362515 - Human HOTAIR; HOXAS; HOXC-AS4; HOXC11-AS1; NCRNA00080 NR_047517.1 24817925 585 HOTAIR Esophageal squamous cell cancer expreesion The result showed that the expression levels of HOTAIR were upregulated in samples from patients with higher tumor burdens, which were defined as those with larger tumors, advanced clinical staging, increased lymph node tumor burdens and the presence of distant metastases.? chr12 54356096 54362515 - Human HOTAIR; HOXAS; HOXC-AS4; HOXC11-AS1; NCRNA00080 NR_047517.1 24817925 586 HOTAIR Esophageal squamous cell cancer expression Expression of HOTAIR lncRNA is increased in various cancers, and it is also significantly increased in our analysis of ESCC. chr12 54356096 54362515 - Human HOTAIR; HOXAS; HOXC-AS4; HOXC11-AS1; NCRNA00086 NR_047517.1 24222893 587 HOTAIR Esophageal squamous cell cancer expreesion Upregulation of HOTAIR is associated with metastasis of gastric cancer, lung cancer, and esophageal squamous cell carcinoma? chr12 54356096 54362515 - Human HOTAIR; HOXAS; HOXC-AS4; HOXC11-AS1; NCRNA00080 NR_047517.1 24757675 588 HOTAIR gastric cancer expreesion Upregulation of HOTAIR is associated with metastasis of gastric cancer, lung cancer, and esophageal squamous cell carcinoma? chr12 54356096 54362515 - Human HOTAIR; HOXAS; HOXC-AS4; HOXC11-AS1; NCRNA00080 NR_047517.1 24757675 589 HOTAIR gastric cancer regulation Lnc RNA HOTAIR functions as a competing endogenous?RNA?to regulate HER2 expression by sponging miR-331-3p in gastric cancer. chr12 54356096 54362515 - Human HOTAIR; HOXAS; HOXC-AS4; HOXC11-AS1; NCRNA00080 NR_047517.1 24775712 590 HOTAIR gastrointestinal cancer expression In approximately one-quarter of human breast cancers, HOTAIR is highly induced, while its elevated levels are also predictive of metastasis and disease progression in other cancers, such as colon, colorectal, gastrointestinal, pancreatic and liver cancer. chr12 54356096 54362515 - Human HOTAIR; HOXAS; HOXC-AS4; HOXC11-AS1; NCRNA00080 NR_047517.1 24667321 591 HOTAIR gastrointestinal cancer Expression Overexpression of HOTAIR was also strongly associated with high-risk grade and metastasis among GIST specimens. chr12 54356096 54362515 - Human HOTAIR; HOXAS; HOXC-AS4; HOXC11-AS1; NCRNA00085 NR_047517.14 22258453 592 HOTAIR gastrointestinal cancer Expression Upregulation of miR-196a and HOTAIR drive malignant character in gastrointestinal stromal tumors. chr12 54356096 54362515 - Human HOTAIR; HOXAS; HOXC-AS4; HOXC11-AS1; NCRNA00088 NR_047517.17 22258453 593 HOTAIR hepatocelluar carcinoma expression Dysregulation and functional roles of lncRNAs in HCC chr12 54356096 54362515 - Human HOTAIR; HOXAS; HOXC-AS4; HOXC11-AS1; NCRNA00080 NR_047517.1 24183851 594 HOTAIR hepatocelluar carcinoma Expression Overexpression of long non-coding RNA HOTAIR predicts tumor recurrence in hepatocellular carcinoma patients following liver transplantation. chr12 54356096 54362515 - Human HOTAIR; HOXAS; HOXC-AS4; HOXC11-AS1; NCRNA00081 NR_047517.10 21327457 595 HOTAIR hepatocelluar carcinoma Expression The HOTAIR gene was significantly overexpressed in HCC tissues compared with adjacent non-tumour tissues. Patients with high HOTAIR gene expression in their tumours had an increased risk of recurrence after hepatectomy. chr12 54356096 54362515 - Human HOTAIR; HOXAS; HOXC-AS4; HOXC11-AS1; NCRNA00084 NR_047517.13 22289527 596 HOTAIR hepatocelluar carcinoma Expression The high expression level of HOTAIR in HCC could be a candidate biomarker for predicting tumor recurrence in HCC patients who have undergone liver transplant therapy and might be a potential therapeutic target. chr12 54356096 54362515 - Human HOTAIR; HOXAS; HOXC-AS4; HOXC11-AS1; NCRNA00074 NR_047517.3 21327457 597 HOTAIR hepatocelluar carcinoma expression Clinical significance of the expression of long non-coding RNA HOTAIR in primary hepatocellular carcinoma. chr12 54356096 54362515 - Human HOTAIR; HOXAS; HOXC-AS4; HOXC11-AS1; NCRNA00072 NR_047517.1 23292722 598 HOTAIR hepatocelluar carcinoma expression Overexpression of the HOTAIR transcript, a cis-lncRNA associated with the HOXD gene cluster, has been associated with hepatocellular carcinoma [32], colorectal cancer [33] and breast cancer [13] by deregulation of HOXD cluster genes chr12 54356096 54362515 - Human HOTAIR; HOXAS; HOXC-AS4; HOXC11-AS1; NCRNA00086 NR_047517.15 22817756 599 HOTAIR hepatocelluar carcinoma regulation Long non-coding RNA HOTAIR promotes cell migration and invasion via down-regulation of RNA binding motif protein 38 in hepatocellular carcinoma cells. chr12 54356096 54362515 - Human HOTAIR; HOXAS; HOXC-AS4; HOXC11-AS1; NCRNA00080 NR_047517.1 24663081 600 HOTAIR laryngeal squamous cell carcinoma expreesion Inspired observed that HOTAIR was higher expressed in primary LSCC than in adjacent noncancerous tissues. It is noteworthy that over-expression of HOTAIR was related to poor differentiation, lymph node metastasis, or advanced clinical stages of LSCC. The results suggested that HOTAIR promotes the malignant progression of LSCC. chr12 54356096 54362515 - Human HOTAIR; HOXAS; HOXC-AS4; HOXC11-AS1; NCRNA00080 NR_047517.1 24817925 601 HOTAIR liver cancer expression In approximately one-quarter of human breast cancers, HOTAIR is highly induced, while its elevated levels are also predictive of metastasis and disease progression in other cancers, such as colon, colorectal, gastrointestinal, pancreatic and liver cancer. chr12 54356096 54362515 - Human HOTAIR; HOXAS; HOXC-AS4; HOXC11-AS1; NCRNA00080 NR_047517.1 24667321 602 HOTAIR lung adenocarcinoma regulation In this study, the lncRNA HOTAIR was upregualted in lung adenocarcinoma cells grown in 3-D cell culture supplemented with collagen.? chr12 54356096 54362515 - Human HOTAIR; HOXAS; HOXC-AS4; HOXC11-AS1; NCRNA00080 NR_047517.1 24829860 603 HOTAIR lung cancer expreesion Upregulation of HOTAIR is associated with metastasis of gastric cancer, lung cancer, and esophageal squamous cell carcinoma? chr12 54356096 54362515 - Human HOTAIR; HOXAS; HOXC-AS4; HOXC11-AS1; NCRNA00080 NR_047517.1 24757675 604 HOTAIR nasopharyngeal carcinoma expreesion The result showed that, the expression levels of HOTAIR wereup-regulated in NPC tissues than in non-cancerous tissues. Further study demonstrated that HOTAIR was up-regulated in NPC cell lines with high invasive potential and the capacity for migration, invasion and proliferation was suppressed after knocking down HOTAIR expression. chr12 54356096 54362515 - Human HOTAIR; HOXAS; HOXC-AS4; HOXC11-AS1; NCRNA00080 NR_047517.1 24817925 605 HOTAIR non-small cell lung cancer expreesion Long?non-coding?RNA?HOTAIR is a powerful predictor of metastasis and poor prognosis and is associated with epithelial-mesenchymal transition in colon cancer. chr12 54356096 54362515 - Human HOTAIR; HOXAS; HOXC-AS4; HOXC11-AS1; NCRNA00080 NR_047517.1 24840737 606 HOTAIR oesophageal squamous cell carcinoma regulation Long non-coding RNA HOTAIR, a driver of malignancy, predicts negative prognosis and exhibits oncogenic activity in oesophageal squamous cell carcinoma. chr12 54356096 54362515 - Human HOTAIR; HOXAS; HOXC-AS4; HOXC11-AS1; NCRNA00086 NR_047517.1 24022190 607 HOTAIR oral squamous cell carcinoma expreesion Subsequently, they confirmed that the expression levels of HOTAIR, NEAT-1 and UCA1 in metastasized samples was prominent higher than the non-metastatic samples.? chr12 54356096 54362515 - Human HOTAIR; HOXAS; HOXC-AS4; HOXC11-AS1; NCRNA00080 NR_047517.1 24817925 608 HOTAIR pancreas cancer expression In approximately one-quarter of human breast cancers, HOTAIR is highly induced, while its elevated levels are also predictive of metastasis and disease progression in other cancers, such as colon, colorectal, gastrointestinal, pancreatic and liver cancer. chr12 54356096 54362515 - Human HOTAIR; HOXAS; HOXC-AS4; HOXC11-AS1; NCRNA00080 NR_047517.1 24667321 609 HOTAIR rheumatoid arthritis regulation PBMC and exosome-derived Hotair is a critical regulator and potent marker for rheumatoid arthritis. chr12 54356096 54362515 - Human HOTAIR; HOXAS; HOXC-AS4; HOXC11-AS1; NCRNA00080 NR_047517.1 24722995 610 HOTAIR small cell lung cancer regulation Long noncoding RNA HOTAIR is relevant to cellular proliferation, invasiveness, and clinical relapse in small-cell lung cancer. chr12 54356096 54362515 - Human HOTAIR; HOXAS; HOXC-AS4; HOXC11-AS1; NCRNA00080 NR_047517.1 24591352 611 HOTAIR tumor expression Expression of the long non-coding RNAs MEG3, HOTAIR, and MALAT-1 in non-functioning pituitary adenomas and their relationship to tumor behavior. chr12 54356096 54362515 - Human HOTAIR; HOXAS; HOXC-AS4; HOXC11-AS1; NCRNA00080 NR_047517.1 24469926 612 HOTAIR tumor regulation HOTAIR long non-coding RNA is a negative prognostic factor not only in primary tumors, but also in the blood of colorectal cancer patients. chr12 54356096 54362515 - Human HOTAIR; HOXAS; HOXC-AS4; HOXC11-AS1; NCRNA00080 NR_047517.1 24583926 613 HOTTIP hepatocelluar carcinoma expression Currently, upregulated HOTTIP and HOXA13 expressions were associated with the prognosis and progression of the hepatocellular carcinoma (HCC). chr7 27200421 27206520 + Human HOTTIP; HOXA-AS6; HOXA13-AS1; NCRNA00213 NR_037843.3 24531795 614 HOTTIP hepatocelluar carcinoma expression Long noncoding RNA HOTTIP/HOXA13 expression is associated with disease progression and predicts outcome in hepatocellular carcinoma patients. chr7 27200421 27206520 + Human HOTTIP; HOXA-AS6; HOXA13-AS1; NCRNA00213 NR_037843.3 24114970 615 HOTTIP hepatocelluar carcinoma expression lncRNA HOTTIP / HOXA13 expression is associated with disease progression and predicts outcome in hepatocellular carcinoma patients. chr7 27240040 27246139 + Human HOTTIP; HOXA-AS6; HOXA13-AS1; NCRNA00213 NR_037843.2 24114970 616 HTTAS Huntington's disease Expression Levels of HTTAS_v1 are reduced in human HD frontal cortex. In cell systems, overexpression of HTTAS_v1 specifically reduces endogenous HTT transcript levels, while siRNA knockdown of HTTAS_v1 increases HTT transcript levels. chr4 3065198 3076241 - Human HTT-AS1; HTTAS NR_045414.1 21672921 617 HTTAS_v1 Huntington's disease regulation Long ncRNA HTTAS_v1 is regulating the expression of Hungtiontonin (HTT) and is potentially involved in the development of HD. N/A N/A N/A N/A Human HTTAS_v1 N/A 24624135 618 HULC hepatic colorectal metastasis Expression HULC expression is not confined to HCC, but also to those colorectal carcinomas that metastasize to the liver. chr6 8652442 8654079 + Human HULC; LINC00078; NCRNA00081 NR_004855.5 19445043 619 HULC hepatocelluar carcinoma expression Dysregulation and functional roles of lncRNAs in HCC chr6 8652442 8654079 + Human HULC; LINC00078; NCRNA00081 NR_004855.2 24183851 620 HULC hepatocelluar carcinoma regulation Here we focus on two best-characterized lncRNAs-HULC and LALR, which can impact proliferation through targeting various key regulators in different pathways. chr6 8652442 8654079 + Human HULC; LINC00078; NCRNA00081 NR_004855.2 24296588 621 HULC hepatocelluar carcinoma regulation A lncRNA, highly upregulated in liver cancer (HULC), was found to contribute to tumorigenesis of HCC. chr6 8652442 8654079 + Human HULC; LINC00078; NCRNA00081 NR_004855.2 24757675 622 HULC hepatocelluar carcinoma Expression A similar genome-wide differential expression screen in hepatocellular carcinoma (HCC) has uncovered another cancer-associated lncRNA, Highly Upregulated in Liver Cancer, or HULC. chr6 8652442 8654079 + Human HULC; LINC00078; NCRNA00079 NR_004855.3 20951849 623 HULC hepatocelluar carcinoma Expression Highly up-regulated in liver cancer. chr6 8652442 8654079 + Human HULC; LINC00078; NCRNA00080 NR_004855.4 17241883 624 HULC hepatocelluar carcinoma Expression Long non-coding RNA (lncRNA), highly up-regulated in liver cancer (HULC) plays an important role in tumorigenesis. Depletion of HULC resulted in a significant deregulation of several genes involved in liver cancer. Although up-regulation of HULC expression. chr6 8652442 8654079 + Human HULC; LINC00078; NCRNA00082 NR_004855.6 20423907 625 HULC hepatocelluar carcinoma Expression The lncRNA HULC is one of the most upregulated of all genes in hepatocellular carcinoma. chr6 8652442 8654079 + Human HULC; LINC00078; NCRNA00078 NR_004855.2 21802130 626 HULC hepatocelluar carcinoma regulation Moreover, HULC correlated with upregulated hepatitis B virus X protein (HBx) that importantly contributes to HCC and that was able to promote HULC expression. The HULC-mediated downregulation of the tumor suppressor p18 supported the HCC proliferation. chr6 8652442 8654079 + Human HULC; LINC00078; NCRNA00081 NR_004855.2 24531795 627 HULC liver cancer N/A PCGEM1, PCA3 (prostate cancer antigen 3, known also as DD3, differential display code 3) and PCNCR1 (prostate cancer ncRNA 4) are involved in prostate cancer, while HULC (highly up-regulated in liver cancer) is involved with liver cancer. chr6 8652442 8654079 + Human HULC; LINC00078; NCRNA00081 NR_004855.2 24667321 628 HULC liver cancer expression The highly upregulated lncRNA HULC in liver cancer was found in the blood of HCC patients, promising a potential biomarker. chr6 8652442 8654079 + Human HULC; LINC00078; NCRNA00081 NR_004855.2 24531795 629 HYMAI transient neonatal diabetes mellitus Expression In TNDM fibroblasts, the monoallelic expression of both ZAC and HYMAI is relaxed, providing strong supportive evidence that the presence of two unmethylated alleles of this locus is indeed associated with the inappropriate gene expression of neighbouring genes. chr6 144324023 144329867 - Human HYMAI; NCRNA00020 NR_002768.1 11935319 630 IFNG-AS1 multiple sclerosis N/A Tmevpg1 (IFNG-AS1) is another lncRNA that may be involved in MS. chr12 68383225 68415107 + Human IFNG-AS1; Tmevpg1 N/A 12719555 631 IGF2-AS hepatocelluar carcinoma N/A IGF-IR and IGF-IIR antisense genes could significantly restrain the malignant behavior of human hepatoma cells and might be useful in investigating a potential route for hepatocellular carcinoma gene therapy. chr11 2161758 2169896 + Human IGF2-AS; PEG8; IGF2AS; IGF2-AS1 NR_028044.1 12603530 632 IGF2-AS prostat Mutation Association identified by GWAS. chr11 2161758 2169896 + Human IGF2-AS; PEG8; IGF2AS; IGF2-AS1 NR_028044.1 19767753 633 IGF2-AS type 1 diabetes Mutation Association identified by GWAS. chr11 2161758 2169896 + Human IGF2-AS; PEG8; IGF2AS; IGF2-AS1 NR_028044.1 17554260 634 IGF2-AS Wilms' tumor Expression Loss of imprinting of IGF2 sense and antisense transcripts in Wilms' tumor. chr11 2161758 2169896 + Human IGF2-AS; PEG8; IGF2AS; IGF2-AS1 NR_028044.1 12702581 635 IGF2-AS Wilms' tumor Expression PEG8/IGF2AS and IGF2 were found to be overexpressed in Wilms' tumor samples, at levels over ten and a hundred times higher than that in normal kidney tissues neighboring the tumors, respectively. chr11 2161758 2169896 + Human IGF2-AS; PEG8; IGF2AS; IGF2-AS1 NR_028044.1 10731720 636 IPW Prader-Willi syndrome Expression The Prader-Willi syndrome (PWS) is caused by genomic alterations that inactivate imprinted, paternally expressed genes in human chromosome region 15q11-q13. IPW, a paternally expressed gene cloned from this region, is not expressed in individuals with PWS. chr15 25361692 25367623 + Human IPW; NCRNA00002 NR_023915.1 9063754 637 IPW Prader-Willi syndrome Locus IPW (Imprinted gene in the Prader-Willi syndrome region) was isolated using the direct selection method and yeast artificial chromosomes localized to the deletion region. the mRNA product of IPW may play a role in the imprinting process. chr15 25361692 25367623 + Human IPW; NCRNA00002 NR_023915.1 7849716 638 IPW Prader-Willi syndrome mutation Genetic variation in lncRNA genes causes disease and influences susceptibility chr15 25361692 25367623 + Human IPW; NCRNA00002 NR_023915.1 23791884 639 IPW Prader-Willi syndrome expreesion Subsequently, we determined that IPW, along?noncoding?RNA?in the critical region of the PWS locus, is a regulator of the DLK1-DIO3 region, as its overexpression in PWS and parthenogenetic iPSCs resulted in downregulation of MEGs in this locus.? chr15 25361692 25367623 + Human IPW; NCRNA00002 NR_023915.1 24816254 640 Kcna2 antisense RNA neuropathic pain regulation A long noncoding RNA contributes to neuropathic pain by silencing Kcna2 in primary afferent neurons. N/A N/A N/A N/A Human Kcna2 antisense RNA N/A 23792947 641 KCNQ1DN aging Epigenetics Continuously hypermethylated upon aging. chr11 2891263 2893335 + Human KCNQ1DN; BWRT; HSA404617 NR_024627.1 22067257 642 KCNQ1DN Wilms' tumor Expression A novel imprinted gene, KCNQ1DN, within the WT2 critical region of human chromosome 11p15.5 and its reduced expression in Wilms' tumors. chr11 2891263 2893335 + Human KCNQ1DN; BWRT; HSA404617 NR_024627.1 11056398 643 KCNQ1OT1 Beckwith-Wiedemann syndrome Epigenetics In Beckwith-Wiedemann syndrome (BWS), approximately 50% of patients show loss of DNA methylation accompanied by loss of histone H3 Lys9 dimethylation on maternal KCNQ1OT-DMR, namely an imprinting disruption, leading to diminished expression of CDKN1C. chr11 2661768 2721228 - Human KCNQ1OT1; LIT1; KvDMR1; KCNQ10T1; KCNQ1-AS2; KvLQT1-AS; NCRNA00012 NR_002728.3 16575194 644 KCNQ1OT1 Beckwith-Wiedemann syndrome Epigenetics The 5'end of the KCNQ1OT1 gene is hypomethylated in the Beckwith-Wiedemann syndrome. chr11 2661768 2721228 - Human KCNQ1OT1; LIT1; KvDMR1; KCNQ10T1; KCNQ1-AS2; KvLQT1-AS; NCRNA00015 12136243 645 KCNQ1OT1 Beckwith-Wiedemann syndrome Locus In the human and mouse BWS imprinting regions, two major elements for regulation of imprinted gene expression have been identified athe imprinting centers IC1 and IC2.IC2 appears to be the promoter of the paternally expressed probably noncoding transcript. chr11 2661768 2721228 - Human KCNQ1OT1; LIT1; KvDMR1; KCNQ10T1; KCNQ1-AS2; KvLQT1-AS; NCRNA00018 NR_002728.9 15590939 646 KCNQ1OT1 Beckwith-Wiedemann syndrome Locus KvDMR1 and/or its associated antisense RNA (KvLQT1-AS) represents an additional imprinting control element or center in the human 11p15.5 and mouse distal 7 imprinted domains. chr11 2661768 2721228 - Human KCNQ1OT1; LIT1; KvDMR1; KCNQ10T1; KCNQ1-AS2; KvLQT1-AS; NCRNA00013 NR_002728.4 10393948 647 KCNQ1OT1 Beckwith-Wiedemann syndrome Locus The LIT1 CpG island can act as a negative regulator in cis for coordinate imprinting at the centromeric domain, thereby suggesting a role for the LIT1 locus in a BWS pathway leading to functional inactivation of p57(KIP2). chr11 2661768 2721228 - Human KCNQ1OT1; LIT1; KvDMR1; KCNQ10T1; KCNQ1-AS2; KvLQT1-AS; NCRNA00014 10958646 648 KCNQ1OT1 Beckwith-Wiedemann syndrome N/A In vitro fertilization may increase the risk of Beckwith-Wiedemann syndrome related to the abnormal imprinting of the KCN1OT gene. chr11 2661768 2721228 - Human KCNQ1OT1; LIT1; KvDMR1; KCNQ10T1; KCNQ1-AS2; KvLQT1-AS; NCRNA00019 NR_002728.10 12746837 649 KCNQ1OT1 Beckwith-Wiedemann syndrome N/A LIT1 (KCNQ1OT1) may play a role in Beckwith-Wiedemann syndrome. chr11 2661768 2721228 - Human KCNQ1OT1; LIT1; KvDMR1; KCNQ10T1; KCNQ1-AS2; KvLQT1-AS; NCRNA00017 15888726 650 KCNQ1OT1 Beckwith-Wiedemann syndrome regulation Epigenetic deregulation of lncRNAs genes is associated with disease chr11 2661768 2721228 - Human KCNQ1OT1; LIT1; KvDMR1; KCNQ10T1; KCNQ1-AS2; KvLQT1-AS; NCRNA00012 NR_002728.3 23791884 651 KCNQ1OT1 colorectal cancer Epigenetics epigenetic disruption chr11 2661768 2721228 - Human KCNQ1OT1; LIT1; KvDMR1; KCNQ10T1; KCNQ1-AS2; KvLQT1-AS; NCRNA00016 16965397 652 KCNQ1OT1 colorectal cancer expression Recent studies have linked their mis-expression to diverse cancers (ANRIL: prostate cancer, XIST: female cancers, HOTAIR: breast cancer, KCNQ1OT4: colorectal cancer). chr11 2661768 2721228 - Human KCNQ1OT1; LIT1; KvDMR1; KCNQ10T1; KCNQ1-AS2; KvLQT1-AS; NCRNA00012 N/A 23660942 653 KCNQ1OT1 hepatocelluar carcinoma mutation A novel tetranucleotide repeat polymorphism within KCNQ1OT1 confers risk for hepatocellular carcinoma. chr11 2661768 2721228 - Human KCNQ1OT1; LIT1; KvDMR1; KCNQ10T1; KCNQ1-AS2; KvLQT1-AS; NCRNA00012 NR_002728.3 23984860 654 KCNQ1OT1 kidney cancer regulation Oncogene chr11 2661768 2721228 - Human KCNQ1OT1; LIT1; KvDMR1; KCNQ10T1; KCNQ1-AS2; KvLQT1-AS; NCRNA00012 NR_002728.3 24373479 655 KRAS1P cancer regulation Similarly, KRAS and KRAS1P transcript levels were found to be positively correlated, corroborating that pseudogene functions mirror the role of their cognate genes as explained by the miRNA decoy mechanism.? chr6 54770474 54775706 + Human KRAS1P; c-Kras1 N/A 24757675 656 KUCG1 Duchenne muscular dystrophy Mutation Molecular characterization of an X(p21.2;q28) chromosomal inversion in a Duchenne muscular dystrophy patient with mental retardation reveals a novel long non-coding gene on Xq28 chrX 148958633 149008599 + Human KUCG1 JX283354.1 23223008 657 KUCG1 Duchenne muscular dystrophy expression KUCG1 is a 648-bp nuclear lncRNA expressed in a tissue specific manner. Since it is normally expressed in the brain, its deregulation could contribute to the neurological impairment of the patient as already reported for other pathologies. chrX 148958633 149008599 + Human KUCG1 JX283354.1 24685002 658 LALR hepatocelluar carcinoma regulation Here we focus on two best-characterized lncRNAs-HULC and LALR, which can impact proliferation through targeting various key regulators in different pathways. N/A N/A N/A N/A Human LALR N/A 24296588 659 LDMAR photoperiod-sensitive male sterility N/A A lncRNA of 1,236 bases in length, referred to as long-day-specific male-fertility-associated RNA (LDMAR), regulates PSMS (photoperiod-sensitive male sterility) in rice. N/A N/A N/A N/A Rice N/A N/A 22308482 660 LINC00032 melanoma Mutation An analysis of genome-wide DNA copy number alterations in melanoma tumors revealed the loss of the C9orf14 locus, located proximal to CDKN2A, in approximately one-fourth of tumors. chr9 27245682 27282791 - Human LINC00032; C9orf14; NCRNA00032 NR_026679.1 17099875 661 LINC00162 narcolepsy Mutation Association identified by GWAS. chr21 46419126 46424642 - Human LINC00032; C9orf14; NCRNA00032 NR_026679.1 16826516 662 LINC00271 schizophrenia Mutation This gene is associated with susceptibility to schizophrenia. chr6 135818939 136011976 + Human LINC00271; C6orf217; NCRNA00271 NR_026805.1 16773125 663 LINC00271 type 2 diabetes Mutation Association identified by GWAS. chr6 135818939 136011976 + Human LINC00271; C6orf217; NCRNA00271 NR_026805.1 17668382 664 LINC00299 Intellectual and developmental disability mutation Genetic variation in lncRNA genes causes disease and influences susceptibility chr2 8147901 8468549 - Human LINC00299; C2orf46; NCRNA00299 LINC00299; C2orf46; NCRNA00299 23791884 665 LINC00312 nasopharyngeal carcinoma Expression NAG-7 is a novel gene downregulated in human nasopharyngeal carcinoma. chr3 8613468 8615580 + Human LINC00312; NAG7; ERR10; NAG-7; ERR-10; LOH3CR2A; NCRNA00312 NR_024065.2 11780420 666 LINC00312 nasopharyngeal carcinoma Expression NAG7 (LINC00312) gene re-expression could inhibit overproliferation of NPC cell by delaying the progression of G1 into S in cell cycle and inducing cell apoptosis. chr3 8613468 8615580 + Human LINC00312; NAG7; ERR10; NAG-7; ERR-10; LOH3CR2A; NCRNA00312 NR_024065.2 12452030 667 LINC00312 nasopharyngeal carcinoma Interaction NAG7 (LINC00312) promotes human nasopharyngeal carcinoma invasion through inhibition of estrogen receptor alpha and up-regulation of JNK2/AP-1/MMP1 pathways. chr3 8613468 8615580 + Human LINC00312; NAG7; ERR10; NAG-7; ERR-10; LOH3CR2A; NCRNA00312 NR_024065.2 19591174 668 LINC00312 nasopharyngeal carcinoma expression Expression of LINC00312, a long intergenic non-coding RNA, is negatively correlated with tumor size but positively correlated with lymph node metastasis in nasopharyngeal carcinoma. chr3 8613468 8615580 + Human LINC00312; NAG7; ERR10; NAG-7; ERR-10; LOH3CR2A; NCRNA00312 NR_024065.2 23529758 669 Linc00963 prostat regulation Linc00963: a novel, long non-coding RNA involved in the transition of prostate cancer from androgen-dependence to androgen-independence. chr9 129488660 129513686 + Human LINC00963 NR_038955.1 24691949 670 LINC01262 Parkinson's disease expression These included the U1 spliceosomal lncRNA and RP11-462G22.1, each entailing sequence complementarity to numerous microRNAs. chr4 189659605 189661483 + Human LINC01262; RP11-462G22.1 XR_430931.1 24651478 671 LINCMD1 Duchenne muscular dystrophy expression Interestingly, the levels of linc-MD1 are strongly reduced in primary myoblasts of DMD patients and its ectopic expression rescues the myogenic differentiation potential of these cells, restoring the correct expression pattern of MAML1, MEF2C, MYOG and MHC. chr6 N/A N/A N/A Human LINCMD1; linc-MD1 N/A 24685002 672 LincRNA-p21 lung cancer expression lincRNAp21 is required for the global repression of genes that interfere with p53 function regulating cellular apoptosis. lincRNAp21 can mediate gene repression by physically interacting with the protein hnRNP-K, allowing its localization to promoters of genes to be repressed in a p53-dependent manner, and its overexpression in a lung cancer cell line sensitizes the cells to DNA N/A N/A N/A N/A Human N/A N/A 22535282 673 LincRNA-p21 colorectal cancer expression One of them, lincRNA-p21, was regulated by p53 and contributed to apoptosis in mouse embryonic fibroblasts. N/A N/A N/A N/A Mouse LincRNA-p21 N/A 24012455 674 lincRNA-p21 p53-associated pathological states expression Biogenesis, metabolism, and functions of lncRNAs are otherwise interconnected with known pathogenic mechanisms chr17 29057474 29078961 - Mus Trp53cor1; lincRNA-p21 NR_036469.1 23791884 675 LincRNA-p21 tumor regulation Global gene repression in the p53 transcriptional response by binding hnRNP-K, inducing cellular apoptosis. N/A N/A N/A N/A Mus N/A N/A 22996375 676 LincRNA-p21 tumor regulation Thus, similar to its activator p53, lincRNA-p21 may play an important role in tumour suppression by operating as a transcriptional repressor. N/A N/A N/A N/A Mouse LincRNA-p21 N/A 23660942 677 LIPCAR Heart Failure expression Circulating Long Noncoding RNA, LIPCAR, Predicts Survival in Patients With Heart Failure.The mitochondrial long noncoding RNA uc022bqs.1 (LIPCAR) was downregulated early after myocardial infarction but upregulated during later stages. LIPCAR levels identified patients developing cardiac remodeling and were independently to other risk markers associated with future cardiovascular deaths. N/A N/A N/A N/A Human LIPCAR N/A 24663402 678 lnc-AL355149.1-1 nasopharyngeal carcinoma expreesion Results. In primary NPC, upregulation of?lnc-C22orf32-1,?lnc-AL355149.1-1, and?lnc-ZNF674-1 was observed. High levels of?lnc-C22orf32-1 and?lnc-AL355149.1-1 were significantly associated with the male patients N/A N/A N/A N/A Human lnc-AL355149.1-1 N/A 24822202 679 lnc-C22orf32-1 nasopharyngeal carcinoma expreesion Results. In primary NPC, upregulation of?lnc-C22orf32-1,?lnc-AL355149.1-1, and?lnc-ZNF674-1 was observed. High levels of?lnc-C22orf32-1 and?lnc-AL355149.1-1 were significantly associated with the male patients N/A N/A N/A N/A Human lnc-C22orf32-1 N/A 24822202 680 lncRNA-ATB hepatocelluar carcinoma regulation Thus, these findings suggest that?lncRNA-ATB, a mediator of TGF-β signaling, could predispose HCC patients to metastases and may serve as a potential target for antimetastatic therapies. N/A N/A N/A N/A Human lncRNA-ATB N/A 24768205 681 LncRNA-LALR1 liver cancer regulation LncRNA-LALR1 accelerates hepatocyte proliferation during liver regeneration by activating Wnt/尾-Catenin signaling N/A N/A N/A N/A Human LncRNA-LALR1 N/A 23483581 682 lncRNA-LET tumor expression Aberrant Expression of lncRNA-LET in Tumor Tissue. In this study, we found that the lncRNA Low Expression in Tumor (lncRNA-LET) was generally downregulated in hepatocellular carcinomas, colorectal cancers, and squamous-cell lung carcinomas. N/A N/A N/A N/A Human LncRNA-LALR1 N/A 23395002 683 lncRNA-MVIH hepatocelluar carcinoma regulation Dr. Yuan et al. found that lncRNA-MVIH could promote tumor growth and intrahepatic metastasis by contributing to active angiogenesis both?in vitro?and?in vivo?through the inhibition of phosphoglycerate kinase 1 (PGK1) secretion N/A N/A N/A N/A Human lncRNA-MVIH N/A 24757675 684 lncRNA-MVIH hepatocelluar carcinoma expreesion Yuan et al discovered that the lncRNA MVIH (long noncoding RNA associated with microvascular invasion in hepatocellular carcinoma) was overexpressed in hepatocellular carcinoma. N/A N/A N/A N/A Human lncRNA-MVIH N/A 24829860 685 lncRNA-MVIH non-small cell lung cancer regulation Long?non-coding?RNA?MVIH indicates a poor prognosis for non-small cell lung cancer and promotes cell proliferation and invasion. N/A N/A N/A N/A Human lncRNA-MVIH N/A 24793017 686 lnc-ZNF674-1 nasopharyngeal carcinoma expreesion Results. In primary NPC, upregulation of?lnc-C22orf32-1,?lnc-AL355149.1-1, and?lnc-ZNF674-1 was observed. High levels of?lnc-C22orf32-1 and?lnc-AL355149.1-1 were significantly associated with the male patients N/A N/A N/A N/A Human lnc-ZNF674-1 N/A 24822202 687 LOC102635190 Heart Failure expression Quantitative-PCR identified the relative expression of 5 significantly upregulated and 5 downregulated LncRNAs from 10 HF mice. Five LncRNAs were upregulated and 11 downregulated in HF hearts as compared with control hearts. chr6 98224517 98251307 N/A Mus LOC102635190 AK139454.1 24205036 688 LOC389023 psychiatric disease regulation Examples of recently discovered chromatin-bound long non-coding RNAs important for neuronal health and function include the brain-derived neurotrophic factor antisense transcript (Bdnf-AS) which regulates expression of the corresponding sense transcript, and LOC389023 which is associated with human-specific histone methylation signatures at the chromosome 2q14.1 neurodevelopmental risk locus by regulating expression of DPP10, an auxillary subunit for voltage-gated K(+) channels. chr2 115901625 115918920 - Human LOC389023 N/A 23831425 689 Loc554202 breast cancer regulation Long non-coding RNA Loc554202 regulates proliferation and migration in breast cancer cells. N/A N/A N/A N/A Human Loc554202 N/A 24631686 690 LOC728606 prostat expression The most highly up-regulated transcript was LOC728606, a lncRNA now designated PCAT18. PCAT18 is specifically expressed in the prostate compared to 11 other normal tissues (p<0.05) and up-regulated in PCa compared to 15 other neoplasms (p<0.001). N/A N/A N/A N/A Human LOC728606 N/A 24519926 691 LSAMP-AS3 osteosarcoma Mutation These CNAs (copy number alterations) in osteosarcoma often involve the noncoding RNAs LOC285194 and BC040587. chr3 116428635 116435887 + Human LSAMP-AS3; LSAMP-AS1; NCRNA00295 NR_015391.1 20048075 692 LSINCT5 breast cancer Expression LSINCT5 is overexpressed in breast and ovarian cancer cell lines and tumor tissues. N/A N/A N/A N/A Human N/A N/A 21532345 693 LSINCT5 breast cancer expression Ovarian and breast tumours have also been associated with the expression of the LSINCT5 lncRNA; this transcript acts to target several other transcripts, including the antisense RNA NEAT-1 and the PSPC1 gene, which codes for a splicing regulatory factor N/A N/A N/A N/A Human N/A N/A 22817756 694 LSINCT5 ovarian cancer Expression LSINCT5 is overexpressed in breast and ovarian cancer cell lines and tumor tissues. N/A N/A N/A N/A Human N/A N/A 21532345 695 LSINCT5 ovarian cancer expression Ovarian and breast tumours have also been associated with the expression of the LSINCT5 lncRNA; this transcript acts to target several other transcripts, including the antisense RNA NEAT-1 and the PSPC1 gene, which codes for a splicing regulatory factor N/A N/A N/A N/A Human N/A N/A 22817756 696 MALAT1 B-cell neoplasms expression HOTAIR long non-coding RNA is a negative prognostic factor not only in primary tumors, but also in the blood of colorectal cancer patients. chr11 65265233 65273940 + Human MALAT1; HCN; NEAT2; MALAT-1; PRO2853; LINC00047; NCRNA00064 NR_002819.2 24583225 697 MALAT1 bladder cancer regulation Oncogene chr11 65265233 65273940 + Human MALAT1; HCN; NEAT2; MALAT-1; PRO2853; LINC00047; NCRNA00064 NR_002819.2 24373479 698 MALAT1 bladder cancer expression Theseguilty by association studies have found numerous bladder-cancer associated lncRNAs chr11 65265233 65273940 + Human MALAT1; HCN; NEAT2; MALAT-1; PRO2853; LINC00047; NCRNA00051 N/A 24006935 699 MALAT1 breast cancer regulation On a more mechanistic level, recent studies have revealed the contribution of lncRNAs as proto-oncogenes, e.g. GAGE6, as tumor suppressor genes, e.g. 鈥榩15 antisense RNA and lincP21' (36,91), as drivers of metastatic transformation, e.g. HOTAIR in breast cancer, and as regulators of alternative splicing, e.g. MALAT1 chr11 65265233 65273940 + Human MALAT1; HCN; NEAT2; MALAT-1; PRO2853; LINC00047; NCRNA00051 NR_002819.6 22492512 700 MALAT1 breast cancer regulation Sequesters SR splicing factors to regulate alternative splicing. chr11 65265233 65273940 + Human MALAT1; HCN; NEAT2; MALAT-1; PRO2853; LINC00047; NCRNA00051 NR_002819.2 22996375 701 MALAT1 breast cancer regulation invasion & metastasis pancreas, colon, prostate liver, cervix, neuroblastoma osteosarcoma chr11 65265233 65273940 + Human MALAT1; HCN; NEAT2; MALAT-1; PRO2853; LINC00047; NCRNA00064 NR_002819.2 24499465 702 MALAT1 cancer Expression MALAT1 is a highly conserved long ncRNA originally identified as a transcript overexpressed in many cancers. chr11 65265233 65273940 + Human MALAT1; HCN; NEAT2; MALAT-1; PRO2853; LINC00047; NCRNA00055 NR_002819.10 20864030 703 MALAT1 cancer Expression The expression of the long ncRNA MALAT1 correlates with tumor development, progression or survival in lung, liver and breast cancer. chr11 65265233 65273940 + Human MALAT1; HCN; NEAT2; MALAT-1; PRO2853; LINC00047; NCRNA00051 NR_002819.6 20711585 704 MALAT1 cancer expression MALAT1 is upregulated in several cancer types and its overexpression has been linked to an increase in cell proliferation and migration in lung and colorectal cancer cells. chr11 65265233 65273940 + Human MALAT1; HCN; NEAT2; MALAT-1; PRO2853; LINC00047; NCRNA00051 N/A 23660942 705 MALAT1 cancer regulation They found that MALAT1 did not alter alternative splicing but rather actively regulated gene expression including a set of metastasis-associated genes. Consequently, MALAT1-deficient cells were impaired in migration and formed fewer tumor nodules in mouse xenograft. Antisense oligonucleotides (ASO) that block MALAT1 prevented metastasis formation after tumor implantation. chr11 65265233 65273940 + Human MALAT1; HCN; NEAT2; MALAT-1; PRO2853; LINC00047; NCRNA00064 NR_002819.2 24757675 706 MALAT1 cancer regulation MALAT1 (metastasis-associated lung adenocarcinoma transcript 1),another lncRNA associated with various cancers and metastasis (Ji et al. 2003; Lin et al. 2011)锛?, is found to affect the transcriptional and post-transcriptional regulation of cytoskeletal and extracellular matrix genes. chr11 65265233 65273940 + Human MALAT1; HCN; NEAT2; MALAT-1; PRO2853; LINC00047; NCRNA00051 NR_002819.6 23463798 707 MALAT1 cervical cancer Interaction MALAT1 was involved in cervical cancer cell growth, cell cycle progression, and invasion through the regulation of gene expression, such as caspase-3, -8, Bax, Bcl-2, and BclxL. chr11 65265233 65273940 + Human MALAT1; HCN; NEAT2; MALAT-1; PRO2853; LINC00047; NCRNA00059 NR_002819.14 20213048 708 MALAT1 cervical cancer expreesion Overexpressed MALAT1 was found in many solid tumors such as lung cancer, cervical cancer, and HCC. chr11 65265233 65273940 + Human MALAT1; HCN; NEAT2; MALAT-1; PRO2853; LINC00047; NCRNA00064 NR_002819.2 24757675 709 MALAT1 colon cancer regulation Sequesters SR splicing factors to regulate alternative splicing. chr11 65265233 65273940 + Human MALAT1; HCN; NEAT2; MALAT-1; PRO2853; LINC00047; NCRNA00051 NR_002819.2 22996375 710 MALAT1 colorectal cancer N/A The 3' end of MALAT-1 is an important biological motif in the invasion and metastasis of CRC cells. chr11 65265233 65273940 + Human MALAT1; HCN; NEAT2; MALAT-1; PRO2853; LINC00047; NCRNA00061 NR_002819.16 21503572 711 MALAT1 decreased myogenesis expression The myostatin-induced inhibition of the long noncoding RNA Malat1 is associated with decreased myogenesis. chr11 65265233 65273940 + Human MALAT1; HCN; NEAT2; MALAT-1; PRO2853; LINC00047; NCRNA00051 NR_002819.2 23485710 712 MALAT1 Diabetes expression In addition, MALAT1, a conserved lncRNA, was significantly upregulated in an RF/6A cell model of hyperglycemia, in the aqueous humor samples, and in fibrovascular membranes of diabetic patients. chr11 65265233 65273940 + Human MALAT1; HCN; NEAT2; MALAT-1; PRO2853; LINC00047; NCRNA00064 NR_002819.2 24436191 713 MALAT1 endometrial cancer Expression MALAT-1 gene is one of the major genes upregulated in ESS. chr11 65265233 65273940 + Human MALAT1; HCN; NEAT2; MALAT-1; PRO2853; LINC00047; NCRNA00064 NR_002819.19 16441420 714 MALAT1 gallbladder cancer regulation MALAT1 promotes the proliferation and metastasis of gallbladder cancer cells by activating the ERK/MAPK pathway. chr11 65265233 65273940 + Human MALAT1; HCN; NEAT2; MALAT-1; PRO2853; LINC00047; NCRNA00064 NR_002819.2 24658096 715 MALAT1 hepatocelluar carcinoma expression Dysregulation and functional roles of lncRNAs in HCC chr11 65265233 65273940 + Human MALAT1; HCN; NEAT2; MALAT-1; PRO2853; LINC00047; NCRNA00064 NR_002819.2 24183851 716 MALAT1 hepatocelluar carcinoma Expression HCC and HPBL have clearly different patterns of gene expression, with genes IGF2, Fibronectin, DLK1, TGFb1, MALAT1 and MIG6 being over-expressed in HPBL versus HCC chr11 65265233 65273940 + Human MALAT1; HCN; NEAT2; MALAT-1; PRO2853; LINC00047; NCRNA00047 NR_002819.2 17006932 717 MALAT1 hepatocelluar carcinoma Expression HCC and HPBL have clearly different patterns of gene expression, with genes IGF2, Fibronectin, DLK1, TGFb1, MALAT1 and MIG6 being over-expressed in HPBL versus HCC. chr11 65265233 65273940 + Human MALAT1; HCN; NEAT2; MALAT-1; PRO2853; LINC00047; NCRNA00052 NR_002819.7 17006932 718 MALAT1 hepatocelluar carcinoma Expression Long non-coding RNA MALAT-1 overexpression predicts tumor recurrence of hepatocellular carcinoma after liver transplantation. chr11 65265233 65273940 + Human MALAT1; HCN; NEAT2; MALAT-1; PRO2853; LINC00047; NCRNA00057 NR_002819.12 21678027 719 MALAT1 hepatocelluar carcinoma Expression Quantitative analyses indicated a 6-7-fold increased RNA level in HCCs versus uninvolved liver, advancing this as a molecule of interest. chr11 65265233 65273940 + Human MALAT1; HCN; NEAT2; MALAT-1; PRO2853; LINC00047; NCRNA00062 NR_002819.17 16878148 720 MALAT1 hepatocelluar carcinoma Mutation We conducted a case-control study and genotyped two SNPs, rs7763881 in HULC and rs619586 in MALAT1 Furthermore, the variant genotypes of rs619586 was associated with decreased HCC risk with a borderline significance. chr11 65265233 65273940 + Human MALAT1; HCN; NEAT2; MALAT-1; PRO2853; LINC00047; NCRNA00050 NR_002819.5 22493738 721 MALAT1 hepatocelluar carcinoma expreesion Overexpressed MALAT1 was found in many solid tumors such as lung cancer, cervical cancer, and HCC. chr11 65265233 65273940 + Human MALAT1; HCN; NEAT2; MALAT-1; PRO2853; LINC00047; NCRNA00064 NR_002819.2 24757675 722 MALAT1 kidney cancer regulation Oncogene chr11 65265233 65273940 + Human MALAT1; HCN; NEAT2; MALAT-1; PRO2853; LINC00047; NCRNA00064 NR_002819.2 24373479 723 MALAT1 laryngeal squamous cell carcinoma expreesion The result suggested that the MALAT1 was up-regulated in primary LSCC compared with adjacent non-cancerous tissues. chr11 65265233 65273940 + Human MALAT1; HCN; NEAT2; MALAT-1; PRO2853; LINC00047; NCRNA00064 NR_002819.2 24817925 724 MALAT1 liver cancer regulation Sequesters SR splicing factors to regulate alternative splicing. chr11 65265233 65273940 + Human MALAT1; HCN; NEAT2; MALAT-1; PRO2853; LINC00047; NCRNA00051 NR_002819.2 22996375 725 MALAT1 liver cancer regulation Mutual inhibition between YAP and SRSF1 maintains long non-coding RNA, Malat1-induced tumourigenesis in liver cancer. chr11 65265233 65273940 + Human MALAT1; HCN; NEAT2; MALAT-1; PRO2853; LINC00047; NCRNA00064 NR_002819.2 24468535 726 MALAT1 lung adenocarcinoma Expression Metastasis associated lung adenocarcinoma transcript 1 is up-regulated in placenta previa increta/percreta and strongly associated with trophoblast-like cell invasion in vitro. chr11 65265233 65273940 + Human MALAT1; HCN; NEAT2; MALAT-1; PRO2853; LINC00047; NCRNA00060 NR_002819.15 19690017 727 MALAT1 lung cancer Interaction MALAT-1 is a novel class of non-coding RNA that promotes cell motility of lung adenocarcinoma cells through transcriptional and post-transcriptional regulation of motility related gene expression. chr11 65265233 65273940 + Human MALAT1; HCN; NEAT2; MALAT-1; PRO2853; LINC00047; NCRNA00063 NR_002819.18 20937273 728 MALAT1 lung cancer expreesion Overexpressed MALAT1 was found in many solid tumors such as lung cancer, cervical cancer, and HCC. chr11 65265233 65273940 + Human MALAT1; HCN; NEAT2; MALAT-1; PRO2853; LINC00047; NCRNA00064 NR_002819.2 24757675 729 MALAT1 lung cancer expression MALAT1, also known as NEAT2 (nuclear-enriched abundant transcript 2), was initially discovered as a predictive biomarker for metastasis development in lung cancer. chr11 65265233 65273940 + Human MALAT1; HCN; NEAT2; MALAT-1; PRO2853; LINC00047; NCRNA00064 NR_002819.2 24667321 730 MALAT1 lung cancer regulation Sequesters SR splicing factors to regulate alternative splicing. chr11 65265233 65273940 + Human MALAT1; HCN; NEAT2; MALAT-1; PRO2853; LINC00047; NCRNA00051 NR_002819.2 22996375 731 MALAT1 lung cancer regulation The noncoding RNA MALAT1 is a critical regulator of the metastasis phenotype of lung cancer cells. chr11 65265233 65273940 + Human MALAT1; HCN; NEAT2; MALAT-1; PRO2853; LINC00047; NCRNA00051 NR_002819.2 23243023 732 MALAT1 lung cancer regulation invasion & metastasis pancreas, colon, prostate liver, cervix, neuroblastoma osteosarcoma chr11 65265233 65273940 + Human MALAT1; HCN; NEAT2; MALAT-1; PRO2853; LINC00047; NCRNA00064 NR_002819.2 24499465 733 MALAT1 nasopharyngeal carcinoma expreesion The result found that MALAT1 was most highly expressed in 5-8F cells (high rate to be tumor and metastasis), and up-regulated in CNE-2, C666-1 and HONE-1 which is higher malignant and poorly differentiated nasopharyngeal squamous cell carcinoma, while least expressed in NP69 epithelial cells of the eternal life. The data indicated that MALAT1 might be related to the metastasis and differentiation of NPC cells. chr11 65265233 65273940 + Human MALAT1; HCN; NEAT2; MALAT-1; PRO2853; LINC00047; NCRNA00064 NR_002819.2 24817925 734 MALAT1 neuroblastoma Expression We identified a shorter transcriptional initiation site and found that CREB binds to the defined proximal promoter of the MALAT1 gene. The expression of the tumor marker MALAT1 ncRNA is sensitive to cell surface receptor activation by oxytocin in a neuroblastoma cell line. chr11 65265233 65273940 + Human MALAT1; HCN; NEAT2; MALAT-1; PRO2853; LINC00047; NCRNA00056 NR_002819.11 20149803 735 MALAT1 non-small cell lung cancer Expression In NSCLC metastasizing tumors, MALAT-1 expression is three-fold higher than in non-metastasizing tumors. Furthermore, in patients with stage I disease, MALAT-1 expression is closely correlated with poor prognosis. chr11 65265233 65273940 + Human MALAT1; HCN; NEAT2; MALAT-1; PRO2853; LINC00047; NCRNA00058 NR_002819.13 21550244 736 MALAT1 non-small cell lung cancer Expression Increased expression of the lncRNA MALAT-1 has been observed in several types of tumors, including metastatic non-small cell lung cancer. chr11 65265233 65273940 + Human MALAT1; HCN; NEAT2; MALAT-1; PRO2853; LINC00047; NCRNA00048 NR_002819.3 12970751 737 MALAT1 non-small cell lung cancer Expression Specific lncRNAs can serve as predictors of tumor outcome, as shown with the expression of the lncRNA MALAT-1 in early-stage non-small cell lung cancer. chr11 65265233 65273940 + Human MALAT1; HCN; NEAT2; MALAT-1; PRO2853; LINC00047; NCRNA00049 NR_002819.4 21903344 738 MALAT1 non-small cell lung cancer Expression The long noncoding MALAT-1 RNA indicates a poor prognosis in non-small cell lung cancer and induces migration and tumor growth. chr11 65265233 65273940 + Human MALAT1; HCN; NEAT2; MALAT-1; PRO2853; LINC00047; NCRNA00065 NR_002819.20 22088988 739 MALAT1 non-small cell lung cancer N/A MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer. chr11 65265233 65273940 + Human MALAT1; HCN; NEAT2; MALAT-1; PRO2853; LINC00047; NCRNA00053 NR_002819.8 12970751 740 MALAT1 non-small cell lung cancer expression lncRNA-associated disruption to alternative splicing has also been reported in non-small cell lung cancer by virtue of overexpression of MALAT1 chr11 65265233 65273940 + Human MALAT1; HCN; NEAT2; MALAT-1; PRO2853; LINC00047; NCRNA00051 NR_002819.6 22817756 741 MALAT1 osteosarcoma Expression Osteosarcoma patients' survival is significantly associated with MALAT-1 expression levels. chr11 65265233 65273940 + Human MALAT1; HCN; NEAT2; MALAT-1; PRO2853; LINC00047; NCRNA00054 NR_002819.9 20951849 742 MALAT1 osteosarcoma regulation Sequesters SR splicing factors to regulate alternative splicing. chr11 65265233 65273940 + Human MALAT1; HCN; NEAT2; MALAT-1; PRO2853; LINC00047; NCRNA00051 NR_002819.2 22996375 743 MALAT1 pancreas cancer regulation Sequesters SR splicing factors to regulate alternative splicing. chr11 65265233 65273940 + Human MALAT1; HCN; NEAT2; MALAT-1; PRO2853; LINC00047; NCRNA00051 NR_002819.2 22996375 744 MALAT1 prostat regulation Putative marker chr11 65265233 65273940 + Human MALAT1; HCN; NEAT2; MALAT-1; PRO2853; LINC00047; NCRNA00064 NR_002819.2 24373479 745 MALAT1 prostat regulation Sequesters SR splicing factors to regulate alternative splicing. chr11 65265233 65273940 + Human MALAT1; HCN; NEAT2; MALAT-1; PRO2853; LINC00047; NCRNA00051 NR_002819.2 22996375 746 MALAT1 small cell lung cancer expression For other LncRNAs, specific targets have yet to be identified. This is the case of MALAT1, a LncRNA whose expression is three times higher in metastasizing early-stage non-small cell lung cancer vs. non-metastasizing tumours chr11 65265233 65273940 + Human MALAT1; HCN; NEAT2; MALAT-1; PRO2853; LINC00047; NCRNA00051 NR_002819.6 22928560 747 MALAT1 TDP-43-associated pathological states expression Biogenesis, metabolism, and functions of lncRNAs are otherwise interconnected with known pathogenic mechanisms chr11 65265233 65273940 + Human MALAT1; HCN; NEAT2; MALAT-1; PRO2853; LINC00047; NCRNA00064 NR_002819.2 23791884 748 MALAT1 tumor expression Expression of the long non-coding RNAs MEG3, HOTAIR, and MALAT-1 in non-functioning pituitary adenomas and their relationship to tumor behavior. chr11 65265233 65273940 + Human MALAT1; HCN; NEAT2; MALAT-1; PRO2853; LINC00047; NCRNA00064 NR_002819.2 24469926 749 MALAT1 tumor regulation MALAT1 plays a role in cell migration and tumor metastasis, as demonstrated by knockout of MALAT1 in lung cancer cell lines (Gutschner et al., 2013). chr11 65265233 65273940 + Human MALAT1; HCN; NEAT2; MALAT-1; PRO2853; LINC00047; NCRNA00064 NR_002819.2 24721780 750 MALAT1 uterus cancer regulation Sequesters SR splicing factors to regulate alternative splicing. chr11 65265233 65273940 + Human MALAT1; HCN; NEAT2; MALAT-1; PRO2853; LINC00047; NCRNA00051 NR_002819.2 22996375 751 MALAT1 uterus cancer regulation invasion & metastasis pancreas, colon, prostate liver, cervix, neuroblastoma osteosarcoma chr11 65265233 65273940 + Human MALAT1; HCN; NEAT2; MALAT-1; PRO2853; LINC00047; NCRNA00064 NR_002819.2 24499465 752 MAP3K14 Pancreatic ductal adenocarcinoma Expression Differential expression chr17 43340488 43394414 - Human MAP3K14; HS; NIK; HSNIK; FTDCR1B NM_003954.3 22078386 753 MEG3 acute myeloid leukemia Epigenetics MEG3 hypermethylation occurred in 15 MDS patients (34.9%), and in 20 AML patients (47.6%). chr14 101292445 101327363 + Human MEG3; GTL2; FP504; prebp1; PRO0518; PRO2160; LINC00023; NCRNA00035 NR_002766.14 19595458 754 MEG3 bladder cancer regulation Tumour suppressor chr14 101292445 101327363 + Human MEG3; GTL2; FP504; prebp1; PRO0518; PRO2160; LINC00023; NCRNA00028 NR_002766.2 24373479 755 MEG3 bladder cancer Expression MEG3 expression is lost. chr14 101292445 101327363 + Human MEG3; GTL2; FP504; prebp1; PRO0518; PRO2160; LINC00023; NCRNA00028 NR_002766.7 14602737 756 MEG3 bladder cancer expression Theseguilty by association studies have found numerous bladder-cancer associated lncRNAs chr14 101292445 101327363 + Human MEG3; GTL2; FP504; prebp1; PRO0518; PRO2160; LINC00023; NCRNA00034 N/A 24006935 757 MEG3 bladder cancer regulation Downregulated MEG3 activates autophagy and increases cell proliferation in bladder cancer. chr14 101292445 101327363 + Human MEG3; GTL2; FP504; prebp1; PRO0518; PRO2160; LINC00023; NCRNA00028 NR_002766.2 23295831 758 MEG3 breast cancer Expression MEG3 expression is lost. chr14 101292445 101327363 + Human MEG3; GTL2; FP504; prebp1; PRO0518; PRO2160; LINC00023; NCRNA00028 NR_002766.7 14602737 759 MEG3 cancer N/A A pituitary-derived MEG3 isoform functions as a growth suppressor in tumor cells. chr14 101292445 101327363 + Human MEG3; GTL2; FP504; prebp1; PRO0518; PRO2160; LINC00023; NCRNA00023 NR_002766.2 14602737 760 MEG3 cancer N/A MEG3 could represent a tumor suppressor gene located in chromosome 14q32 and its association with tumorigenesis is growing every day. chr14 101292445 101327363 + Human MEG3; GTL2; FP504; prebp1; PRO0518; PRO2160; LINC00023; NCRNA00034 NR_002766.13 21400503 761 MEG3 cancer N/A MEG3 functions as a novel lncRNA tumor suppressor. chr14 101292445 101327363 + Human MEG3; GTL2; FP504; prebp1; PRO0518; PRO2160; LINC00023; NCRNA00027 NR_002766.6 22393162 762 MEG3 chronic myeloid leukemia Expression MEG3 expression is lost. chr14 101292445 101327363 + Human MEG3; GTL2; FP504; prebp1; PRO0518; PRO2160; LINC00023; NCRNA00028 NR_002766.7 14602737 763 MEG3 colon cancer Expression MEG3 expression is lost. chr14 101292445 101327363 + Human MEG3; GTL2; FP504; prebp1; PRO0518; PRO2160; LINC00023; NCRNA00028 NR_002766.7 14602737 764 MEG3 gastric cancer expression Downregulated long noncoding RNA MEG3 is associated with poor prognosis and promotes cell proliferation in gastric cancer. chr14 101292445 101327363 + Human MEG3; GTL2; FP504; prebp1; PRO0518; PRO2160; LINC00023; NCRNA00028 NR_002766.2 24006224 765 MEG3 gastric cancer regulation Downregulated long noncoding RNA MEG3 is associated with poor prognosis and promotes cell proliferation in gastric cancer. chr14 101292445 101327363 + Human MEG3; GTL2; FP504; prebp1; PRO0518; PRO2160; LINC00023; NCRNA00034 N/A 24006224 766 MEG3 glioma Expression Overexpression of the long non-coding RNA MEG3 impairs in vitro glioma cell proliferation. chr14 101292445 101327363 + Human MEG3; GTL2; FP504; prebp1; PRO0518; PRO2160; LINC00023; NCRNA00031 NR_002766.10 22234798 767 MEG3 hepatocelluar carcinoma expression Braconi et al. found that the expression of maternally expressed gene 3 (MEG3) is markedly reduced in four human HCC cell lines compared with normal hepatocytes and enforced expression of MEG3 in HCC cells significantly induce apoptosis. chr14 101292445 101327363 + Human MEG3; GTL2; FP504; prebp1; PRO0518; PRO2160; LINC00023; NCRNA00028 NR_002766.2 24296588 768 MEG3 hepatocelluar carcinoma Expression Enforced expression of MEG3 in HCC cells significantly decreased both anchorage-dependent and -independent cell growth, and induced apoptosis. Methylation-dependent tissue-specific regulation of the lncRNA MEG3 by miR-29a may contribute to HCC growth. chr14 101292445 101327363 + Human MEG3; GTL2; FP504; prebp1; PRO0518; PRO2160; LINC00023; NCRNA00036 NR_002766.15 21625215 769 MEG3 hepatocelluar carcinoma regulation Expression of MEG3 in tumor cells results in growth suppression, p53 protein increase, and activation of p53 downstream targets. chr14 101292445 101327363 + Human MEG3; GTL2; FP504; prebp1; PRO0518; PRO2160; LINC00023; NCRNA00028 NR_002766.2 24757675 770 MEG3 heroin abuse Mutation Intriguingly a genome-wide association study has implicated MEG3 in the vulnerability to heroin addiction. chr14 101292445 101327363 + Human MEG3; GTL2; FP504; prebp1; PRO0518; PRO2160; LINC00023; NCRNA00030 NR_002766.9 21128942 771 MEG3 Huntington's disease expression LncRNAs TUG1 (necessary for retinal development), and NEAT-1 (a structural component of nuclear paraspeckles) are upregulated in HD caudate, while the brain-specific tumor-suppressor MEG3 is downregulated in HD. chr14 101292445 101327363 + Human MEG3; GTL2; FP504; prebp1; PRO0518; PRO2160; LINC00023; NCRNA00028 NR_002766.2 23346095 772 MEG3 kidney cancer expression Tumour suppressor chr14 101292445 101327363 + Human MEG3; GTL2; FP504; prebp1; PRO0518; PRO2160; LINC00023; NCRNA00028 NR_002766.2 24373479 773 MEG3 lung cancer Expression MEG3 expression is lost. chr14 101292445 101327363 + Human MEG3; GTL2; FP504; prebp1; PRO0518; PRO2160; LINC00023; NCRNA00028 NR_002766.7 14602737 774 MEG3 Meningioma Epigenetics Maternally expressed gene 3, an imprinted noncoding RNA gene, is associated with meningioma pathogenesis and progression. chr14 101292445 101327363 + Human MEG3; GTL2; FP504; prebp1; PRO0518; PRO2160; LINC00023; NCRNA00025 NR_002766.4 20179190 775 MEG3 Meningioma regulation MEG3: a novel long noncoding potentially tumour-suppressing RNA in meningiomas. chr14 101292445 101327363 + Human MEG3; GTL2; FP504; prebp1; PRO0518; PRO2160; LINC00023; NCRNA00028 NR_002766.2 23307326 776 MEG3 myelodysplastic syndrome Epigenetics MEG3 hypermethylation occurred in 15 MDS patients (34.9%), and in 20 AML patients (47.6%). chr14 101292445 101327363 + Human MEG3; GTL2; FP504; prebp1; PRO0518; PRO2160; LINC00023; NCRNA00033 NR_002766.12 19595458 777 MEG3 neuroblastoma Epigenetics MEG3-DMR is completely methylated in neuroblastoma cell lines. chr14 101292445 101327363 + Human MEG3; GTL2; FP504; prebp1; PRO0518; PRO2160; LINC00023; NCRNA00028 NR_002766.7 15798773 778 MEG3 nonfunctioning pituitary adenomas Expression Maternally Expressed Gene 3 (MEG3), which is specifically associated with clinically non-functioning pituitary adenomas of a gonadotroph lineage. chr14 101292445 101327363 + Human MEG3; GTL2; FP504; prebp1; PRO0518; PRO2160; LINC00023; NCRNA00024 NR_002766.3 20211686 779 MEG3 Pituitary adenoma Epigenetics Hypermethylation of the promoter region is associated with the loss of MEG3 gene expression in human pituitary tumors. chr14 101292445 101327363 + Human MEG3; GTL2; FP504; prebp1; PRO0518; PRO2160; LINC00023; NCRNA00026 NR_002766.5 15644399 780 MEG3 Pituitary adenoma Epigenetics Selective loss of MEG3 expression and intergenic differentially methylated region hypermethylation in the MEG3/DLK1 locus in human clinically nonfunctioning pituitary adenomas. chr14 101292445 101327363 + Human MEG3; GTL2; FP504; prebp1; PRO0518; PRO2160; LINC00023; NCRNA00029 NR_002766.8 18628527 781 MEG3 Pituitary adenoma Expression The DLK1-MEG3 locus is silenced in NFAs (nonfunctioning adenomas). The DLK1-MEG3 locus plays a tumor suppressor role in human NFAs. chr14 101292445 101327363 + Human MEG3; GTL2; FP504; prebp1; PRO0518; PRO2160; LINC00023; NCRNA00032 NR_002766.11 21871428 782 MEG3 Pituitary adenoma expreesion Another potential angiogenic lncRNA, Maternally expressed gene 3 (MEG3) was found to be silenced in pituitary adenomas.? chr14 101292445 101327363 + Human MEG3; GTL2; FP504; prebp1; PRO0518; PRO2160; LINC00023; NCRNA00028 NR_002766.2 24829860 783 MEG3 prostat Expression MEG3 expression is lost. chr14 101292445 101327363 + Human MEG3; GTL2; FP504; prebp1; PRO0518; PRO2160; LINC00023; NCRNA00028 NR_002766.7 14602737 784 MEG3 tumor expression Expression of the long non-coding RNAs MEG3, HOTAIR, and MALAT-1 in non-functioning pituitary adenomas and their relationship to tumor behavior. chr14 101292445 101327363 + Human MEG3; GTL2; FP504; prebp1; PRO0518; PRO2160; LINC00023; NCRNA00028 NR_002766.2 24469926 785 MEG3 type 1 diabetes Locus The imprinted DLK1-MEG3 gene region on chromosome 14q32.2 alters susceptibility to type 1 diabetes. chr14 101292445 101327363 + Human MEG3; GTL2; FP504; prebp1; PRO0518; PRO2160; LINC00023; NCRNA00028 NR_002766.7 19966805 786 MESTIT1 Silver-Russell syndrome N/A Association chr7 130126898 130131013 - Human MESTIT1; MEST-IT; PEG1-AS; MEST-AS1; MEST-IT1; NCRNA00040 NR_004382.1 12746419 787 MIAT cancer regulation Another lncRNA serving as oncogene is retinal noncoding RNA 2 (RNCR2). chr22 27053446 27072441 + Human MIAT; RNCR2; GOMAFU; C22orf35; LINC00066; NCRNA00067 NR_003491.2 24757675 788 MIAT drug abuse Expression MIAT turned out to be one of the top twenty-five, of nearly 39,000, transcripts differentially expressed in the nucleus accumbens,a midbrain region pivotal in drug abuse, in a case-control study of human heroin and cocaine abusers. chr22 27053446 27072441 + Human MIAT; RNCR2; GOMAFU; C22orf35; LINC00066; NCRNA00067 NR_003491.3 20951849 789 MIAT heroin abuse Expression The lncRNA MIAT is upregulated in heroin abusers. chr22 27053446 27072441 + Human MIAT; RNCR2; GOMAFU; C22orf35; LINC00066; NCRNA00066 NR_003491.2 21128942 790 MIAT myocardial infarction mutation MIAT lincRNA Variants Confer Susceptibility to Myocardial Infarction chr22 27053446 27072441 + Human MIAT; RNCR2; GOMAFU; C22orf35; LINC00066; NCRNA00067 NR_003491.3 23104877 791 MIAT myocardial infarction Expression The altered expression of MIAT by the SNP may play some role in the pathogenesis of MI. chr22 27053446 27072441 + Human MIAT; RNCR2; GOMAFU; C22orf35; LINC00066; NCRNA00069 NR_003491.5 17066261 792 MIAT myocardial infarction Mutation In vitro functional analyses revealed that the minor variant of one SNP in exon 5 increased transcriptional level of MIAT. Moreover, unidentified nuclear protein(s) bound more intensely to risk allele than non-risk allele. These results indicate that the altered expression of MIAT by the SNP may play some role in the pathogenesis of MI. chr22 27053446 27072441 + Human MIAT; RNCR2; GOMAFU; C22orf35; LINC00066; NCRNA00070 NR_003491.6 17066261 793 MIAT myocardial infarction Mutation SNPs associated with myocardial infarction localized to a haplotype block that encompassed the last 3 exons of MIAT. chr22 27053446 27072441 + Human MIAT; RNCR2; GOMAFU; C22orf35; LINC00066; NCRNA00068 NR_003491.4 20951849 794 MIAT myocardial infarction regulation A myocardial infarction-associated transcript (MIAT), also known as RNCR2 or Gomafu, is a long intergenic non-coding RNA that presents many genetic variants implicated in different processes. A large scale case-control association study regarding cardiovascular disease demonstrates that a MIAT variant (rs2301523) confers susceptibility to myocardial infarction. chr22 27053446 27072441 + Human MIAT; RNCR2; GOMAFU; C22orf35; LINC00066; NCRNA00067 NR_003491.2 24113581 795 MIAT schizophrenia expression Finally, we show that Gomafu is downregulated in post-mortem cortical gray matter from the superior temporal gyrus in SZ. chr22 27053446 27072441 + Human MIAT; RNCR2; GOMAFU; C22orf35; LINC00066; NCRNA00067 NR_003491.2 23628989 796 MINA Esophageal squamous cell cancer regulation Dysfunction of MDIG was found in several types of solid cancers including gastric carcinoma, esophageal squamous cell carcinoma, and lung cancer. Overexpression of MDIG was observed in hepatocellular carcinoma.? chr3 97941817 97972451 - Human MINA; ROX; MDIG; NO52; MINA53 XR_241516.2 24757675 797 MINA gastric cancer regulation Dysfunction of MDIG was found in several types of solid cancers including gastric carcinoma, esophageal squamous cell carcinoma, and lung cancer. Overexpression of MDIG was observed in hepatocellular carcinoma.? chr3 97941817 97972451 - Human MINA; ROX; MDIG; NO52; MINA53 XR_241516.2 24757675 798 MINA hepatocelluar carcinoma expreesion Dysfunction of MDIG was found in several types of solid cancers including gastric carcinoma, esophageal squamous cell carcinoma, and lung cancer. Overexpression of MDIG was observed in hepatocellular carcinoma.? chr3 97941817 97972451 - Human MINA; ROX; MDIG; NO52; MINA53 XR_241516.2 24757675 799 MINA lung cancer regulation Dysfunction of MDIG was found in several types of solid cancers including gastric carcinoma, esophageal squamous cell carcinoma, and lung cancer. Overexpression of MDIG was observed in hepatocellular carcinoma.? chr3 97941817 97972451 - Human MINA; ROX; MDIG; NO52; MINA53 XR_241516.2 24757675 800 MIR100HG myopia Locus LOC399959 was identified within a 200-kb DNA encompassing rs577948. chr11 121959811 122073770 - Human MIR100HG NR_024430.1 19779542 801 MIR155HG chronic lymphocytic leukemia Interaction MYB transcriptionally regulates the miR-155 host gene in chronic lymphocytic leukemia. chr21 26934457 26947480 + Human MIR155HG; BIC; MIRHG2; NCRNA00172 NR_001458.3 21296997 802 MIR17HG cancer Locus Aurora kinase A induces miR-17-92 cluster through regulation of E2F1 transcription factor. chr13 92000074 92006829 + Human MIR17HG; MIHG1; MIRH1; FGLDS2; MIRHG1; C13orf25; LINC00048; miR-17-92; NCRNA00048 NR_027350.1 20300951 803 MIR17HG lymphoma Locus C13orf25 (MIR17HG) is a target for 13q31-q32 amplification in malignant lymphoma. chr13 92000074 92006829 + Human MIR17HG; MIHG1; MIRH1; FGLDS2; MIRHG1; C13orf25; LINC00048; miR-17-92; NCRNA00048 NR_027350.1 15126345 804 MIR17HG syndromic developmental defect Locus Here we report the identification of germline hemizygous deletions of MIR17HG, encoding the miR-17~92 polycistronic miRNA cluster, in individuals with microcephaly, short stature and digital abnormalities. chr13 92000074 92006829 + Human MIR17HG; MIHG1; MIRH1; FGLDS2; MIRHG1; C13orf25; LINC00048; miR-17-92; NCRNA00048 NR_027350.1 21892160 805 MIR31HG breast cancer Epigenetics miR-31 and its host gene lncRNA LOC554202 (MIR31HG) are regulated by promoter hypermethylation in triple-negative breast cancer.Both miR-31 and the host gene LOC554202 are down-regulated in the TNBC cell lines of basal subtype and over-expressed in the luminal counterparts. chr9 21454267 21559697 - Human MIR31HG NR_027054.1 22289355 806 MIR7-3HG hepatocelluar carcinoma expression Besides, another study showed that liver cancer-downregulated lncRNA uc002mbe.2 could be induced by trichostatin A (TSA) treatment and its expression is positively correlated with the apoptotic effect of TSA in HCC cells. chr19 4769105 4772556 + Human MIR7-3HG; Huh7; PGSF1; C19orf30; LINC00306; NCRNA00306; uc002mbe.2 NR_027148.1 24296588 807 MKRN3-AS1 Prader-Willi syndrome Epigenetics ZNF127 and ZNF127AS are imprinted genes that may be associated with some of the clinical features of the polygenic Prader-Willi syndrome. chr15 23812411 23814804 - Human MKRN3-AS1; FNZ127; MKRN3AS; MKRN3-AS; ZNF127AS; NCRNA00009 10196367 808 MYCNOS neuroblastoma Expression Both DeltaMYCN and MYCNOS are expressed in all NBs examined. In NBs with MYCN-amplification, these transcripts are significantly higher expressed. the ratio of MYCNOS:MYCN expression is directly correlated with NB disease stage (p = 0.007). In the more advanced NB stages and NBs with MYCN-amplification, relatively more MYCNOS is present as compared to MYCN. Expression of the antisense gene MYCNOS might be relevant to the progression of NB. chr2 16080020 16081845 - Human MYCNOS; NCYM; NYCM; MYCN-AS1 NR_026766.1 19615087 809 NAMA papillary thyroid carcinoma Expression Identification of a novel noncoding RNA gene, NAMA, that is downregulated in papillary thyroid carcinoma with BRAF mutation and associated with growth arrest. chr9 102117692 102137509 - Human NAMA N/A 17415708 810 ncRAN neuroblastoma regulation It is now becoming increasingly evident that N-myc also regulates the expression of long noncoding RNAs such as T-UCRs and ncRAN. chr17 74553852 74561430 + Human ncRAN AB447886.1 22936790 811 NDM29 neuroblastoma Expression The synthesis of a pol III-transcribed noncoding (nc) RNA (NDM29) strongly restricts NB development by promoting cell differentiation, a drop of malignancy processes. NDM29 expression leads to NB cell differentiation. N/A N/A N/A N/A Human N/A N/A 20581224 812 NEAT-1 AIDS expression We found NEAT-1 to be one of several lncRNAs whose expression is changed by HIV-1 infection, and we have characterized its role in HIV-1 replication. chr11 65190269 65194003 + Human NEAT-1; TncRNA; LINC00084; NCRNA00084 NR_028272.1 23362321 813 NEAT-1 amyotrophic lateral sclerosis regulation The long non-coding RNA nuclear-enriched abundant transcript 1_2 induces paraspeckle formation in the motor neuron during the early phase of amyotrophic lateral sclerosis. chr11 65190269 65194003 + Human NEAT-1; TncRNA; LINC00084; NCRNA00084 N/A 23835137 814 NEAT-1 frontotemporal lobar degeneration Interaction Analysis of RNA binding by TDP-43 in brains from subjects with FTLD revealed that the greatest increases in binding were to the MALAT1 and NEAT-1 noncoding RNAs. chr11 65190269 65194003 + Human NEAT-1; TncRNA; LINC00084; NCRNA00084 NR_028272.1 20581224 815 NEAT-1 Huntington's disease expression LncRNAs TUG1 (necessary for retinal development), and NEAT-1 (a structural component of nuclear paraspeckles) are upregulated in HD caudate, while the brain-specific tumor-suppressor MEG3 is downregulated in HD. chr11 65190269 65194003 + Human NEAT-1; TncRNA; LINC00084; NCRNA00084 NR_028272.1 23346095 816 NEAT-1 Intrauterine Growth Restriction expression The long non-coding RNA NEAT-1 is increased in IUGR placentas, leading to potential new hypotheses of IUGR origin/development. chr11 65190269 65194003 + Human NEAT-1; TncRNA; LINC00084; NCRNA00084 NR_028272.1 24280234 817 NEAT-1 TDP-43-associated pathological states expression Biogenesis, metabolism, and functions of lncRNAs are otherwise interconnected with known pathogenic mechanisms chr11 65190269 65194003 + Human NEAT-1; TncRNA; LINC00084; NCRNA00084 NR_028272.1 23791884 818 NEAT-1 oral squamous cell carcinoma expreesion Subsequently, they confirmed that the expression levels of HOTAIR, NEAT-1 and UCA2 in metastasized samples was prominent higher than the non-metastatic samples.? chr11 65190269 65194003 + Human NEAT-1; TncRNA; LINC00084; NCRNA00084 NR_028272.1 24817925 819 np_17856 progressive kidney injury regulation Real-time PCR confirmed these findings and revealed the functional link between Smad3-dependent lncRNAs np_5318/np_17856 and progressive kidney injury. N/A N/A N/A N/A Mus np_17856 N/A 24262754 820 np_5318 progressive kidney injury regulation Real-time PCR confirmed these findings and revealed the functional link between Smad3-dependent lncRNAs np_5318/np_17856 and progressive kidney injury. N/A N/A N/A N/A Mus np_5318 N/A 24262754 821 NPPA-AS1 cardiovascular disease N/A The NPPA-AS lncRNA has been shown to be a modulator of the alternative splicing of the NPPA gene. This lncRNA thus has potential to be involved in cardiovascular disease chr1 11900376 11907673 + Human NPPA-AS1; NPPAAS; NPPA-AS NR_037806.1 22817756 822 NPTN-IT1 colorectal cancer expression In this study, we found that the lncRNA Low Expression in Tumor (lncRNA-LET) was generally downregulated in hepatocellular carcinomas, colorectal cancers, and squamous-cell lung carcinomas. chr15 73859365 73861635 - Human NPTN-IT1; lncRNA-LET AK055007.1 23395002 823 NPTN-IT1 hepatocelluar carcinoma expression Importantly, another lncRNA-LET (lncRNA low expression in tumor) is found to play a critical role in hypoxia-induced metastasis in HCC chr15 73859365 73861635 - Human NPTN-IT1; lncRNA-LET AK055007.1 24296588 824 NPTN-IT1 hepatocelluar carcinoma expression In this study, we found that the lncRNA Low Expression in Tumor (lncRNA-LET) was generally downregulated in hepatocellular carcinomas, colorectal cancers, and squamous-cell lung carcinomas. chr15 73859365 73861635 - Human NPTN-IT1; lncRNA-LET AK055007.1 23395002 825 NPTN-IT1 squamous-cell lung carcinomas expression In this study, we found that the lncRNA Low Expression in Tumor (lncRNA-LET) was generally downregulated in hepatocellular carcinomas, colorectal cancers, and squamous-cell lung carcinomas. chr15 73859365 73861635 - Human NPTN-IT1; lncRNA-LET AK055007.1 23395002 826 NRON Down's syndrome Expression NRON is a lncRNA that mediates the cytoplasmic to nuclear shuttling of the NFAT transcription factor . In animal models, deregulation of the DSCR1 and DYRK1A genes act synergistically to prevent nuclear occupancy of NFATc transcription factors leading to reduced NFATc activity and to many features of DS, suggesting a potential link between NRON activity and DS pathophysiology. 9q33.3; 9 129270966 129481601 - Human NRON; NCRNA00194 NR_045006.1 16141075 827 PAN Kaposi's sarcoma expression KSHV infected cells express a highly abundant long noncoding transcript referred to as polyadenylated nuclear RNA (PAN RNA). N/A N/A N/A N/A Human CG17964; CG32005; CG34403; cTCF; d-TCF; Dm Pan; Dmel\CG34403; dTcf; dTCF; DTcf; DTCF; IA5; l(4)102ABb; l(4)13; Lef; LEF-1; LEF/TCF; LEF/TCF-1; lef1; Lef1; LEF1; LEF1/TCF; Pan; PAN; pan.dTCF; tcf; Tcf; TCF; Tcf-1; Tcf/LEF; TCF/LEF; TCF/LEF1 NM_105536.3 23468496 828 PANDA p53-associated pathological states expression Biogenesis, metabolism, and functions of lncRNAs are otherwise interconnected with known pathogenic mechanisms chr6 36641398 36642903 - Human PANDAR;PANDA JF803844.1 23791884 829 PANDAR cancer expression Another DNA damage-responsive, p53-induced lncRNA that lies upstream of p21, PANDA (P21 associated ncRNA DNA damage activated), is also implicated in the repression of pro-apoptotic genes, such as FAS and BIK, by acting as a decoy for the transcription factor NF-YA. In some cancer types, p53 mutations have been found that maintain the protein's ability to induce the PANDA pathway (and its antiapoptotic effects) while abolishing its ability to induce p21 and its promotion of cell-cycle arrest, thus leading to increased tumor cell survival (Hung et al. 2011). chr6 36641398 36642903 - Human PANDAR;PANDA JF803844.1 23463798 830 PCA3 prostat expression Diagnostic marker chr9 79379354 79402465 + Human PCA3; DD3; NCRNA00023 NR_015342.1 24373479 831 PCA3 prostat Expression A PCA3 score threshold of 20 may have the highest utility for selecting men with clinically insignificant prostate cancer in whom active surveillance may be appropriate; a PCA3 score threshold of 50 may be used to identify men at high risk of harbouring significant prostate cancer who are candidates for RP. chr9 79379354 79402465 + Human PCA3; DD3; NCRNA00023 NR_015342.5 21883822 832 PCA3 prostat Expression It was found that the levels of the mRNA expression of DD3(PCA3) were significantly higher (p<0.045) in patients with PCa than in patients with benign prostatic hyperplasia. chr9 79379354 79402465 + Human PCA3; DD3; NCRNA00026 NR_015342.8 20332487 833 PCA3 prostat Expression Measurement of lncRNA PCA3 in patient urine samples has been shown to allow more sensitive and specific diagnosis of prostate cancer than the widely used marker prostate-specific antigen (PSA). chr9 79379354 79402465 + Human PCA3; DD3; NCRNA00019 NR_015342.1 15245811 834 PCA3 prostat Expression PCA3 is a highly prostate cancer-specific gene. chr9 79379354 79402465 + Human PCA3; DD3; NCRNA00021 NR_015342.3 14607216 835 PCA3 prostat Expression PCA3 is one of the most prostate cancer-specific genes yet described, and this makes DD3 a promising marker for the early diagnosis of prostate cancer and provides a powerful tool for the development of new treatment strategies for prostate cancer patients. chr9 79379354 79402465 + Human PCA3; DD3; NCRNA00020 NR_015342.2 10606244 836 PCA3 prostat Expression PCA3 mRNA is prostate cancer specific and shows increased expression in prostate cancer. chr9 79379354 79402465 + Human PCA3; DD3; NCRNA00025 NR_015342.7 20114043 837 PCA3 prostat Expression PCA3 scores were significantly lower in low-volume disease and insignificant PCa. Higher PCA3 scores were associated with aggressive disease. chr9 79379354 79402465 + Human PCA3; DD3; NCRNA00028 NR_015342.10 20980098 838 PCA3 prostat Expression Patients with a positive biopsy showed significantly higher PCA3 values. chr9 79379354 79402465 + Human PCA3; DD3; NCRNA00027 NR_015342.9 20424427 839 PCA3 prostat Expression The PCA3 assay is insensitive to pre-analytical factors, performs well analytically and correctly classifies a high percent of subjects with known prostate cancer status across research sites. chr9 79379354 79402465 + Human PCA3; DD3; NCRNA00022 NR_015342.4 18054202 840 PCA3 prostat Expression The probability of a positive repeat biopsy increases with rising PCA3 scores. The PCA3 score was superior to %fPSA for predicting repeat prostate biopsy outcome and may be indicative of clinical stage and significance of pCa. chr9 79379354 79402465 + Human PCA3; DD3; NCRNA00030 NR_015342.12 18602209 841 PCA3 prostat Expression Upregulation of two new PCA3 isoforms in PCa tissues improves discrimination between PCa and BPH. chr9 79379354 79402465 + Human PCA3; DD3; NCRNA00024 NR_015342.6 19319183 842 PCA3 prostat Mutation The presence of the (TAAA)n short tandem repeat polymorphisms in the PCA3 promoter region may be a risk factor for prostate cancer in the Chinese population. chr9 79379354 79402465 + Human PCA3; DD3; NCRNA00029 NR_015342.11 21655300 843 PCA3 prostat N/A PCGEM1, PCA3 (prostate cancer antigen 3, known also as DD3, differential display code 3) and PCNCR1 (prostate cancer ncRNA 2) are involved in prostate cancer, while HULC (highly up-regulated in liver cancer) is involved with liver cancer. chr9 79379354 79402465 + Human PCA3; DD3; NCRNA00023 NR_015342.1 24667321 844 PCAT1 cancer regulation PCAT1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in cancer. chr8 128025399 128033259 + Human PCAT1; PCAT1 NR_045262.1 24473064 845 PCAT1 prostat regulation They described PCAT1,a novel PCa lincRNA on 8q24, in the locality of well-characterized PCa risk-related SNPs and the c-MYC oncogene. chr8 128025399 128033259 + Human PCAT1; PCAT1 NR_045262.1 24146262 846 PCAT1 prostat expression Putative marker and oncogene chr8 128025399 128033259 + Human PCAT1; PCAT1 NR_045262.1 24373479 847 PCAT1 prostat Expression PCAT1 is markedly overexpressed in a subset of prostate cancers, particularly metastases, and may contribute to cell proliferation in these tumors. chr8 128025399 128033259 + Human PCAT1; PCAT1 NR_045262.1 21804560 848 PCAT1 prostat Interaction PCAT1 is a prostate-specific regulator of cell proliferation and show that it is a target of the Polycomb Repressive Complex 2 (PRC2). Patterns of PCAT1 and PRC2 expression stratified patient tissues into molecular subtypes distinguished by expression signatures of PCAT1-repressed target genes. chr8 128025399 128033259 + Human PCAT1; PCAT1 NR_045262.1 21804560 849 PCAT1 prostat regulation The prostate cancer-associated ncRNA transcript 1 lncRNA PCAT1, SchlAP1 (second chromosome locus associated with prostate-1), and CTBP1-AS indicate cancer cell invasiveness and metastasis in prostate cancer progression. chr8 128025399 128033259 + Human PCAT1; PCAT1 NR_045262.1 24531795 850 PCAT1 prostat regulation The prostate cancer-associated ncRNA transcript 1 lncRNA PCAT1, SchlAP1 (second chromosome locus associated with prostate-1), and CTBP1-AS indicate cancer cell invasiveness and metastasis in prostate cancer progression. chr8 128025399 128033259 + Human PCAT1; PCAT1 NR_045262.1 24531795 851 PCAT1 prostat regulation For example, a recent RNA-Seq study in prostate cancer tissues and cell lines uncovered a lncRNA, PCAT1, that promotes cell proliferation and is a target of PRC2 regulation. chr8 128025399 128033259 + Human PCAT1; PCAT1 NR_045262.1 21804560 852 PCGEM1 prostat regulation One of the earliest lncRNAs described in PCa, was PCGEM1(prostate cancer gene expression marker 1), a prostate-specific transcript encoded on 2q32 (40). One of the earliest lncRNAs described in PCa, was PCGEM1 (prostate cancer gene expression marker 1), a prostate-specific transcript encoded on 2q32 (40). chr2 193614571 193641625 + Human PCGEM1; LINC00071; NCRNA00076 NR_002769.1 24146262 853 PCGEM1 prostat regulation High-risk and predictive marker Oncogene chr2 193614571 193641625 + Human PCGEM1; LINC00071; NCRNA00076 NR_002769.1 24373479 854 PCGEM1 prostat Expression Elevated expression of PCGEM1, a prostate-specific gene with cell growth-promoting function, is associated with high-risk prostate cancer patients. chr2 193614571 193641625 + Human PCGEM1; LINC00071; NCRNA00076 NR_002769.6 14724589 855 PCGEM1 prostat Expression Expression profiles of genes in CRPC support a role for the transcriptional activity of the PCGEM1. chr2 193614571 193641625 + Human PCGEM1; LINC00071; NCRNA00075 NR_002769.5 20868494 856 PCGEM1 prostat Expression PCGEM1 was originally discovered in a genome-wide gene expression screen as a cDNA sequence with prostate cancer overexpression and highly specific localization to glandular epithelial cells. chr2 193614571 193641625 + Human PCGEM1; LINC00071; NCRNA00073 NR_002769.3 20951849 857 PCGEM1 prostat Expression PCGEM1, a prostate-specific gene, is overexpressed in prostate cancer. chr2 193614571 193641625 + Human PCGEM1; LINC00071; NCRNA00077 NR_002769.7 11050243 858 PCGEM1 prostat Expression The biomarkers had sensitivities ranging from 91% to 100%. Clinical specificities evaluated with the BPH tissue were the following: hTERT mRNA (93%), DD3 mRNA (57%), Survivin (29%) and PCGEM1 (14%). chr2 193614571 193641625 + Human PCGEM1; LINC00071; NCRNA00072 NR_002769.2 16515751 859 PCGEM1 prostat Interaction Phytosterol inhibition of PCGEM1 and cell growth and the overexpression of caveolin-1, suggests that poor disease prognosis anchors on the ability of caveolin-1 to regulate downstream oncogene(s) and apoptosis genes. chr2 193614571 193641625 + Human PCGEM1; LINC00071; NCRNA00074 NR_002769.4 19186008 860 PCGEM1 prostat N/A A prostate-specific and prostate cancer-associated noncoding gene, PCGEM1 regulates apoptosis. chr2 193614571 193641625 + Human PCGEM1; LINC00071; NCRNA00075 NR_002769.5 16569192 861 PCGEM1 prostat N/A PCGEM1, PCA3 (prostate cancer antigen 3, known also as DD3, differential display code 3) and PCNCR1 (prostate cancer ncRNA 1) are involved in prostate cancer, while HULC (highly up-regulated in liver cancer) is involved with liver cancer. chr2 193614571 193641625 + Human PCGEM1; LINC00071; NCRNA00076 NR_002769.1 24667321 862 PCGEM1 prostat expression Here we report that two lncRNAs highly overexpressed in aggressive prostate cancer, PRNCR1 (also known as PCAT8) and PCGEM1, bind successively to the androgen receptor and strongly enhance both ligand-dependent and ligand-independent androgen-receptor-mediated gene activation programs and proliferation in prostate cancer cells. chr2 193614571 193641625 + Human PCGEM1; PCAT9; LINC00071; NCRNA00071 N/A 23945587 863 PCGEM1 prostat mutation We found a significantly decreased risk of PCa for rs6434568 AC and AC/AA genotype, as well as rs16834898 AC and AC/CC genotype, compared with the CC and AA genotypes, respectively. chr2 193614571 193641625 + Human PCGEM1; LINC00071; NCRNA00072 NR_002769.1 23459097 864 PCGEM1 prostat regulation The focus of this Nature report13 is on two PCa-associated lncRNAs: PCGEM1 and PRNCR1. They cooperate in regulating the function of the male hormone receptor, the androgen receptor (AR), which plays central role in PCa onset and progression. AR pathway is activated in advanced CaPs including castration-resistant prostate cancer (CRPC). chr2 193614571 193641625 + Human PCGEM1; LINC00071; NCRNA00076 NR_002769.1 24713835 865 PCNA-AS1 tumor regulation Antisense long non-coding RNA PCNA-AS1 promotes tumor growth by regulating proliferating cell nuclear antigen in hepatocellular carcinoma. chr20 5119586 5119969 + Human PCNA-AS1; PCNAAS; PCNA-AS NR_028370.1 24704293 866 PCNCR1 prostat N/A Accumulating evidence indicated that prostate cancer non-coding RNA 1 (PCNCR1) lncRNA was identified in a gene deserton chromosome 8q24.2 and is associated with susceptibility to prostate cancer N/A N/A N/A N/A Human N/A N/A 22535282 867 PCNCR1 prostat N/A PCGEM1, PCA3 (prostate cancer antigen 3, known also as DD3, differential display code 3) and PCNCR1 (prostate cancer ncRNA 3) are involved in prostate cancer, while HULC (highly up-regulated in liver cancer) is involved with liver cancer. N/A N/A N/A N/A Human PCNCR1 N/A 24667321 868 PDZRN3-AS1 type 2 diabetes Mutation SNP rs11128347 (C>G) in PDZRN3 is associated with African-Americans with type 2 diabetes. chr3 73545921 73691649 + Human PDZRN3-AS1; N/A 21546767 869 PINC breast cancer N/A In a finding of relevance to breast cancer pathogenesis, the mammary gland lncRNA PINC, whose genomic structure is substantially different between primates and rodents has been shown to function in both cell survival and cell cycle progression. chr1 73391385 73407569 + Mouse Pinc NR_003202.1 20951849 870 PINK1-AS glucose metabolism disorder expression As the name suggests, PINK1 is induced by PTEN, which is an important inhibitor of insulin signalling. PINK1 depletion has been associated with diabetes status, impaired glucose uptake in neuronal cell lines and with mitochondrial gene expression in adipocytes , raising the possibility that disruption to naPINK1 may impact on glucose metabolism. chr1 20804687 20999762 + Human PINK1-AS; NAPINK1; PINK1AS; PINK1-AS1 22817756 871 PINK1-AS Parkinson's disease Interaction Mutations in the PTEN induced putative kinase 1 (PINK1) are implicated in early-onset Parkinson's disease. Welective targeting of naPINK1 results in loss of the PINK1 splice variant in neuronal cell lines. chr1 20804687 20999762 + Human PINK1-AS; NAPINK1; PINK1AS; PINK1-AS1 17362513 872 PISRT1 blepharophimosis syndrome Mutation The blepharophimosis syndrome (BPES) is driven by dysregulation of the FOXL2 gene, numerous extragenic mutations have been reported in patients. One particular deletion occurring 283 kb away from FOXL2 disrupts a lncRNA, PISRT1, that was shown by chromatin confirmation capture to physically loop with FOXL2. chr3 138951834 138952364 - Human PISRT1; NCRNA00195 NR_027070.1 20930520 873 PPP3CB Pancreatic ductal adenocarcinoma Expression Differential expression chr10 75196563 75255782 - Human PPP3CB; CNA2; CALNB; CALNA2; PP2Bbeta NM_001142353.1 22078386 874 PRINS psoriasis Expression The anti-apoptotic protein G1P3 is overexpressed in psoriasis and regulated by the non-coding RNA, PRINS. chr10 24536051 24544975 + Human PRINS; NCRNA00074 NC_000010.10 from=24536051&to=24544975&report=genbank 20377629 875 PRINS psoriasis N/A PRINS is a psoriasis susceptibility-related noncoding RNA gene. chr10 24536051 24544975 + Human PRINS; NCRNA00074 NC_000010.10 from=24536051&to=24544975&report=genbank 15855153 876 PRINS psoriasis expression In an effort to identify novel susceptibility factors for the hyperproliferative skin disorder psoriasis, Sonkoly et al. analyzed differential gene expression of unaffected epidermis from psoriasis patients compared to specimens from healthy subjects and identified a novel lncRNA called psoriasis susceptibility-related RNA gene induced by stress (PRINS) involved in psoriasis susceptibility chr10 24536051 24544975 + Human PRINS; NCRNA00074 NC_000010.10 from=24536051&to=24544975&report=genbank 24115003 877 PRNCR1 prostat regulation That same year, Chung et al reported PCa susceptibility SNPs within a 13 kb intron-less lincRNA also on 8q24, which they termed PRNCR1. chr8 N/A N/A N/A Human PRNCR1; PCAT8 NR_109833.1 24146262 878 PRNCR1 prostat regulation Susceptibility marker oncogene N/A N/A N/A N/A Human PCNCR1 N/A 24373479 879 PRNCR1 prostat expression Here we report that two lncRNAs highly overexpressed in aggressive prostate cancer, PRNCR1 (also known as PCAT8) and PCGEM1, bind successively to the androgen receptor and strongly enhance both ligand-dependent and ligand-independent androgen-receptor-mediated gene activation programs and proliferation in prostate cancer cells. N/A N/A N/A N/A Human PRNCR1; PCAT8 N/A 23945587 880 PRNCR1 prostat regulation The focus of this Nature report13 is on two PCa-associated lncRNAs: PCGEM1 and PRNCR1. They cooperate in regulating the function of the male hormone receptor, the androgen receptor (AR), which plays central role in PCa onset and progression. AR pathway is activated in advanced CaPs including castration-resistant prostate cancer (CRPC). N/A N/A N/A N/A Human PCNCR1 N/A 24713835 881 PSORS1C3 psoriasis N/A Psoriasis susceptibility 1 candidate 3 chr6 31141512 31145676 - Human PSORS1C3; AB023059.1; NCRNA00196 NR_026816.1 15848982 882 PSORS1C3 psoriasis Mutation The PSORS1C3*582A allele, an SNP in the 3'-untranslated region of the PSORS1C3 gene, was a major psoriasis vulgaris susceptibility allele in the Chinese population, and the association was much stronger in patients with early-onset psoriasis vulgaris. chr6 31141512 31145676 - Human PSORS1C3; AB023059.1; NCRNA00196 NR_026816.1 16965413 883 PTCSC papillary thyroid carcinoma Locus papillary thyroid carcinoma susceptibility candidate chr8 134067204 134067204 + Human PSORS1C3; AB023059.1; NCRNA00196 NR_026816.1 19147577 884 PTCSC3 papillary thyroid carcinoma expreesion The study showed that the expression of PTCSC3 in six thyroid cancer cell lines is lower and no expression was detected in any of them.? chr14 36135710 36176651 - Human PTCSC3 NR_049735.2 24817925 885 PTCSC3 papillary thyroid carcinoma mutation A thyroid-specific lncRNA, termed PTC susceptibility candidate 3 (PTCSC3), that was strongly downregulated in PTC was identified in this region and it was found that the repression was caused by the associated SNP. chr14 36604916 36645857 - Human PTCSC3 N/A 23660942 886 PTENP1 cancer regulation PTENP1 pseudogene belongs to the group of competing endogenous RNAs (ceRNAs). It may act as “decoy” by protecting PTEN mRNA from binding to common miRNA and therefore allowing expression of the tumor suppressor protein.? chr9 33673502 33677418 - Human PTENP1; PTH2; PTEN2; PTEN-rs; PTENpg1; psiPTEN BX374997.2 24757675 887 PTENP1 prostat regulation Oncogene; tumour suppressor chr9 33673502 33677418 - Human PTENP1; PTH2; PTEN2; PTEN-rs; PTENpg1; psiPTEN BX374997.2 24373479 888 PTENP1 tumor regulation An example of this mechanism is represented by the tumour suppressor gene PTEN and its pseudogene PTENP1. chr9 33673502 33677418 - Human PTENP1; PTH2; PTEN2; PTEN-rs; PTENpg1; psiPTEN N/A 23660942 889 PTENpg1 tumor regulation PTEN is a tumor-suppressor gene that has been shown to be under the regulatory control of a PTEN pseudogene expressed noncoding RNA, PTENpg1. chr9 33673502 33677418 - Human PTENP1; PTH2; PTEN2; PTEN-rs; PTENpg1; psiPTEN BX374997.2 23435381 890 PTHLH brachydactyly expression Silencing of the lncRNA, PTHLH, or SOX9 revealed a feedback mechanism involving an expression-dependent network in humans. In the BDE patients, the human lncRNA was upregulated by the disrupted chromosomal association. chr12 28111017 28124916 - Human PTHLH; HHM; PLP; BDE2; PTHR; PTHRP NG_023197.1 23093776 891 PVT1 breast cancer Expression Amplification of PVT1 contributes to the pathophysiology of ovarian and breast cancer. chr8 128806779 129113499 + Human PVT1; LINC00079; NCRNA00083 NR_003367.6 17908964 892 PVT1 Burkitt's lymphomas Mutation PVT1 is frequently involved in the translocations occurring in variant Burkitt's lymphomas and murine plasmacytomas. chr8 128806779 129113499 + Human PVT1; LINC00079; NCRNA00088 NR_003367.11 17503467 893 PVT1 cancer Expression The PVT gene frequently amplifies with MYC in tumor cells. chr8 128806779 129113499 + Human PVT1; LINC00079; NCRNA00087 NR_003367.10 2725491 894 PVT1 cleft lip Mutation Association identified by GWAS (rs987525,A>G). chr8 128806779 129113499 + Human PVT1; LINC00079; NCRNA00082 NR_003367.5 19270707 895 PVT1 diabetic nephropathy Interaction PVT1 may mediate the development and progression of diabetic nephropathy through mechanisms involving ECM accumulation. chr8 128806779 129113499 + Human PVT1; LINC00079; NCRNA00086 NR_003367.9 21526116 896 PVT1 diabetic nephropathy regulation Role of MicroRNA 1207-5P and Its Host Gene, the Long Non-Coding RNA Pvt1, as Mediators of Extracellular Matrix Accumulation in the Kidney: Implications for Diabetic Nephropathy. chr8 128806779 129113499 + Human PVT1; LINC00079; NCRNA00088 NR_003367.2 24204837 897 PVT1 Hodgkin's lymphoma N/A PVT1 is a new susceptibility loci for this disease. chr8 128806779 129113499 + Human PVT1; LINC00079; NCRNA00081 NR_003367.4 21037568 898 PVT1 lymphoma N/A Burkitt lymphoma association chr8 128806779 129113499 + Human PVT1; LINC00079; NCRNA00080 NR_003367.3 3024964 899 PVT1 lymphoma N/A Burkitt lymphoma association chr8 128806779 129113499 + Human PVT1; LINC00079; NCRNA00093 NR_003367.16 2470097 900 PVT1 murine plasmacytomas Mutation PVT1 is frequently involved in the translocations occurring in variant Burkitt's lymphomas and murine plasmacytomas. chr8 128806779 129113499 + Human PVT1; LINC00079; NCRNA00079 NR_003367.2 17503467 901 PVT1 ovarian cancer Expression Amplification of PVT1 contributes to the pathophysiology of ovarian and breast cancer. chr8 128806779 129113499 + Human PVT1; LINC00079; NCRNA00084 NR_003367.7 17908964 902 PVT1 pancreas cancer Expression PVT1 gene as a regulator of Gemcitabine sensitivity and showed that functional inactivation of the PVT1 gene led to enhanced Gemcitabine sensitivity in human pancreatic cancer ASPC-1 cells. chr8 128806779 129113499 + Human PVT1; LINC00079; NCRNA00085 NR_003367.8 21316338 903 PVT1 prostat Mutation The risk allele (G) of rs378854 (A>G) reduces binding of the transcription factor YY1 in vitro. The region surrounding rs378854 interacts with the MYC and PVT1 promoters.Expression of the PVT1 oncogene in normal prostate tissue increased with the presence of the risk allele of rs378854, while expression of MYC was not affected. chr8 128806779 129113499 + Human PVT1; LINC00079; NCRNA00094 NR_003367.17 21814516 904 PVT1 renal cancer Mutation Variants (rs13447075, A>C;rs2648862, A>C) in the plasmacytoma variant translocation gene (PVT1) are associated with end-stage renal disease attributed to type 1 diabetes. chr8 128806779 129113499 + Human PVT1; LINC00079; NCRNA00091 NR_003367.14 17881614 905 PVT1 type 1 diabetes Mutation There is association between variants (rs2720709, A>G) in the plasmacytoma variant translocation 1 gene (PVT1) and end-stage renal disease (ESRD) attributed to both type 1 and type 2 diabetes. chr8 128806779 129113499 + Human PVT1; LINC00079; NCRNA00089 NR_003367.12 21526116 906 PVT1 type 2 diabetes Mutation Identification of PVT1 (rs2720709, A>G) as a candidate gene for end-stage renal disease in type 2 diabetes using a pooling-based genome-wide single nucleotide polymorphism association study. chr8 128806779 129113499 + Human PVT1; LINC00079; NCRNA00090 NR_003367.13 17395743 907 PVT1 type 2 diabetes Mutation There is association between variants (rs2720709, A>G) in the plasmacytoma variant translocation 1 gene (PVT1) and end-stage renal disease (ESRD) attributed to both type 1 and type 2 diabetes. chr8 128806779 129113499 + Human PVT1; LINC00079; NCRNA00092 NR_003367.15 21526116 908 REST/CoREST-regulated lncRNAs Huntington's disease expression Biogenesis, metabolism, and functions of lncRNAs are otherwise interconnected with known pathogenic mechanisms N/A N/A N/A N/A Human REST/CoREST-regulated lncRNAs N/A 23791884 909 RMST rhabdomyosarcoma Expression NCRMS (RMST) on chromosome 12q21 shows differential expression between rhabdomyosarcoma subtypes. chr12 97858799 97927544 + Human RMST; NCRMS; LINC00054; NCRNA00054 NR_024037.1 12082533 910 RNA polymerase III-dependent lncRNAs Diffuse cerebral hypomyelination with cerebellar atrophy and hypoplasia of the corpus callosum expression Biogenesis, metabolism, and functions of lncRNAs are otherwise interconnected with known pathogenic mechanisms N/A N/A N/A N/A Human RNA polymerase III-dependent lncRNAs N/A 23791884 911 RNA-a Opitz–Kaveggia syndrome regulation A recent study indicated that a subset of long ncRNAs, called activating long ncRNAs (RNA-a), is associated with Opitz–Kaveggia (also known as FG) syndrome, a X-linked intellectual disability syndrome, characterized by various neuronal pathologies as well as developmental abnormalities. N/A N/A N/A N/A Human RNA-a N/A 24624135 912 RNase MRP Cartilage Hair Hypoplaisia mutation Point mutations in RNase MRP cause human Cartilage Hair Hypoplaisia (CHH), and several disease-causing mutations map to RMRP-S1 and -S2. SHAPE chemical probing identified two alternative secondary structures altered by disease mutations. N/A N/A N/A N/A Human RNase MRP N/A 24009312 913 RP1-179N16.3 nasopharyngeal carcinoma expression Six lncRNAs (AF086415, AK095147, RP1-179N16.3, MUDENG, AK056098 and AK294006) were confirmed by qPCR. N/A N/A N/A N/A Human RP1-179N16.3 N/A 24379026 914 RP4-620F22.3 enterovirus 74 infection expression A general consistency between the qPCR and microarray analysis results was confirmed in four lncRNAs (AP000688.29, AC002511.1, RP5-843L14.1, and RP4-620F22.3) in terms of regulation direction and significance. Specifically, a 3.31-fold down-regulation N/A N/A N/A N/A Human N/A N/A 23220233 915 RP5-843L14.1 enterovirus 73 infection expression A general consistency between the qPCR and microarray analysis results was confirmed in four lncRNAs (AP000688.29, AC002511.1, RP5-843L14.1, and RP4-620F22.3) in terms of regulation direction and significance. Specifically, a 3.31-fold down-regulation N/A N/A N/A N/A Human N/A N/A 23220233 916 RRP1B cancer Epigenetics RRP1B, a tumor progression and metastasis susceptibility candidate gene, is potentially a dynamic modulator of transcription and chromatin structure. chr21 45079432 45115960 + Human RRP1B; Nnp1; RRP1; NNP1L; KIAA0179 NM_015056.2 19710015 917 RUNXOR hematopoietic malignancies regulation RUNXOR utilizes its 3'-terminal fragment to directly interact with the RUNX1 promoter and enhancers and participates in the orchestration of an intrachromosomal loop. The 3' region of RUNXOR also participates in?long-range interchromosomal interactions with chromatin regions that are involved in multiple RUNX1 translocations. N/A N/A N/A N/A Human RUNXOR N/A 24752773 918 SCAANT1 Spinocerebellar ataxia type 7 Expression CTCF is required for SCAANT1 expression. Loss of SCAANT1 derepressed ataxin-7 sense transcription in a cis-dependent fashion and was accompanied by chromatin remodeling. chr3 63897194 63897448 - Human RRP1B; Nnp1; RRP1; NNP1L; KIAA0179 NM_015056.2 21689595 919 SCAANT1 Spinocerebellar ataxia type 7 regulation Genomic context links lncRNAs to disease genes/loci and related pathways chr3 63897194 63897448 - Human RRP1B; Nnp1; RRP1; NNP1L; KIAA0179 NM_015056.2 23791884 920 SCAANT1 Spinocerebellar ataxia type 7 expression Long ncRNA SCAANT1 is implicated in a type of polyglutamine disorder, spinocerebellar ataxia type 7 (SCA7). chr3 63897194 63897448 - Human SCAANT1; RRP1B; Nnp1; RRP1; NNP1L; KIAA0179 NM_015056.2 24624135 921 SCAANT1 Spinocerebellar ataxia type 7 mutation For example, SCA7/ATXN7 antisense RNA 1 (SCAANT1) is an lncRNA transcribed antisense to the gene mutated in spinocerebellar ataxia type 7 (ATXN7), and it functions as a repressor of ATXN7 transcription chr3 63897194 63897448 - Human RRP1B; Nnp1; RRP1; NNP1L; KIAA0179 NM_015056.2 22814587 922 Scarb2 Heart Failure expression Quantitative-PCR identified the relative expression of 5 significantly upregulated and 5 downregulated LncRNAs from 10 HF mice. Five LncRNAs were upregulated and 18 downregulated in HF hearts as compared with control hearts. chr5 92443873 92505608 - Mus Scarb2; LGP85; Cd36l2; LIMP-2; MLGP85; 9330185J12Rik AK036863.1 24205036 923 SCHLAP1 prostat expreesion Prensner et al found that the lncRNA SChLAP1 was overexpresed in prostate tumors and where it is critical for tumor cell metastasis. chr2 180692104 180916939 + Human SCHLAP1; PCAT11; PCAT114; LINC00913 NR_104319.1 24829860 924 Sema3g ischemia/reperfusion expression Classification and validation of deregulated LncRNAs in ischemia/reperfusion-treated mouse livers. chr14 31217873 31230352 + Mus Sema3g; AK087277 AK087277.1 24312245 925 SLC7A2-IT1A/B Progressive encephalopathy with severe infantile anorexia mutation Genetic variation in lncRNA genes causes disease and influences susceptibility N/A N/A N/A N/A Human SLC7A2-IT1A/B N/A 23791884 926 SNHG11 obesity Mutation New gene associated with obesity. chr20 37075297 37079564 + Human SNHG11; C20orf198; LINC00101; NCRNA0010 NR_003239.1 20532202 927 SNHG16 bladder cancer regulation putative diagnostic, prognostic, and predictive marker chr17 76557764 76565348 + Human SNHG16; ncRAN NR_038108.1 24373479 928 SNHG16 colorectal cancer expression Down-regulation of ncRAN, a long non-coding RNA, contributes to colorectal cancer cell migration and invasion and predicts poor overall survival for colorectal cancer patients. chr17 76557764 76565348 + Human SNHG16; ncRAN NR_038108.1 24519959 929 SNHG3 Alzheimer's disease Expression We selected three differential signature genes specific for the early stage (Nudt19, Arl16, Aph1b), five common to both groups (Slc15a2, Agpat5, Sox2ot, 2210015, D19Rik, Wdfy1), and seven specific for late stage. chr1 28832455 28837404 + Human SNHG3; U17HG; RNU17C; RNU17D; U17HG-A; U17HG-AB; NCRNA00014 NR_036473.1 21961160 930 SNHG4 myelodysplastic syndrome Mutation Association identified by GWAS. chr5 138609441 138618873 + Human SNHG4; U19H; NCRNA00059 NR_003141.3 19240791 931 SNHG5 lymphoma Locus snhg5 is located at the breakpoint of chromosomal translocation t(3;6)(q27;q15) involved in human B-cell lymphoma. chr6 86386725 86388451 - Human SNHG5; U50HG; C6orf160; LINC00044; bA33E24.2; NCRNA00044 NR_003038.2 10792466 932 SOX2-OT Esophageal squamous cell cancer expreesion The results revealed a significant co-upregulation of SOX2OT along with SOX2 and OCT4 in tumor samples, compared to the non-tumor tissues obtained from the margin of same tumors. Therefore, the SOX2 gene might be a indicator for the early diagnosis of ESCC. chr3 181328151 181459009 + Human SOX2-OT; SOX2OT; NCRNA00043 NR_004053.2 24817925 933 SOX2-OT Alzheimer's disease Expression We selected three differential signature genes specific for the early stage (Nudt19, Arl16, Aph1b), five common to both groups (Slc15a2, Agpat5, Sox2ot, 2210015, D19Rik, Wdfy1), and seven specific for late stage (D14Ertd449, Tia1, Txnl4, 1810014B01Rik). chr3 181328151 181459009 + Human SOX2-OT; SOX2OT; NCRNA00043 NR_004053.2 21961160 934 SOX2-OT Neurodevelopmental syndromes associated with the SOX2 locus regulation Genomic context links lncRNAs to disease genes/loci and related pathways chr3 181328151 181459009 + Human SOX2-OT; SOX2OT; NCRNA00043 NR_004053.2 23791884 935 Sox4 ischemia/reperfusion expression Classification and validation of deregulated LncRNAs in ischemia/reperfusion-treated mouse livers. chr13 28950716 28953682 - Mus Sox4; AK054386 AK054386.1 24312245 936 SPRY4-IT1 Esophageal squamous cell cancer expreesion Long?noncoding?RNA?SPRY4-IT1 is upregulated in esophageal squamous cell carcinoma and associated with poor prognosis. chr5 141697185 141697887 - Human SPRY4-IT1 N/A 24810925 937 SPRY4-IT1 melanoma N/A The melanoma-upregulated long noncoding RNA SPRY4-IT1 modulates apoptosis and invasion. chr5 141697185 141697887 - Human SPRY4-IT1 N/A 21558391 938 SPRY4-IT1 melanoma expression Another elegant study by Khaitan et al. utilized a non-coding RNA microarray approach to identify differentially regulated lncRNAs in melanoma cells and identified a 687 bp single exon lncRNA named SPRY4-IT1 which was highly up-regulated in melanoma patient samples and cell lines. chr5 141697185 141697887 - Human SPRY4-IT1 N/A 24115003 939 SPRY4-IT1 melanoma expression The lncRNA, SPRY4-IT1, which is up-regulated in human melanomas compared to melanocytes and keratinocytes, affects cell dynamics, including increased rate of wound closure upon ectopic expression. chr5 141697185 141697887 - Human SPRY4-IT1 N/A 22492512 940 SRA1 breast cancer regulation Co-activator of steroid Receptors & other transcription Factors; associate with metastasis chr5 139929653 139937678 - Human SRA1; SRA; SRAP; STRAA1; pp7686 NM_001035235.3 24499465 941 SRA1 breast cancer Expression Our results demonstrate that full-length SRA-RNAs likely to encode stable proteins are widely expressed in breast cancer cell lines. chr5 139929653 139937678 - Human SRA1; SRA; SRAP; STRAA1; pp7688 NM_001035235.7 12565891 942 SRA1 breast cancer Expression We recently reported a decreased estrogen receptor activity in breast cancer cells overexpressing SRAP, suggesting antagonist roles played by SRA1 RNA and SRAP. chr5 139929653 139937678 - Human SRA1; SRA; SRAP; STRAA1; pp7686 NM_001035235.5 16848684 943 SRA1 breast cancer Locus We have previously found that both fully-spliced SRAP-coding and intron-1-containing non-coding SRA RNAs co-exist in breast cancer cell lines. chr5 139929653 139937678 - Human SRA1; SRA; SRAP; STRAA1; pp7684 NM_001035235.3 19483093 944 SRA1 breast cancer N/A Disturbance of the balance between SRAP1-coding and non-coding SRA1 RNAs in breast tumor tissues might be involved in breast tumorigenesis. chr5 139929653 139937678 - Human SRA1; SRA; SRAP; STRAA1; pp7687 NM_001035235.6 20079837 945 SRA1 cardiomyopathy N/A SRA1 results independently in a phenotype of myocardial contractile dysfunction. chr5 139929653 139937678 - Human SRA1; SRA; SRAP; STRAA1; pp7687 NM_001035235.6 19064678 946 SRA1 Human Dilated Cardiomyopathy expression RA also is present in a 600-kb linkage disequilibrium block associated with human dilated cardiomyopathy in 3 independent populations. chr5 139929653 139937678 - Human SRA1; SRA; SRAP; STRAA1; pp7686 NM_001035235.5 23104877 947 SRA1 ovarian cancer regulation Co-activator of steroid Receptors & other transcription Factors; associate with metastasis chr5 139929653 139937678 - Human SRA1; SRA; SRAP; STRAA1; pp7686 NM_001035235.3 24499465 948 SRA1 uterus cancer regulation Co-activator of steroid Receptors & other transcription Factors; associate with metastasis chr5 139929653 139937678 - Human SRA1; SRA; SRAP; STRAA1; pp7686 NM_001035235.3 24499465 949 Srsf9 ischemia/reperfusion expression Classification and validation of deregulated LncRNAs in ischemia/reperfusion-treated mouse livers. chr5 115327177 115333080 + Mus Srsf9; NR-036616 NR_036616.1 24312245 950 SUMO1P3 gastric cancer expreesion Pseudogene-expressed lncRNAs are a major member of the lncRNA family. Recently, our group reported that small ubiquitin-like modifier (SUMO) 1 pseudogene 3, SUMO1P3, was markedly up-regulated in gastric cancer tissues compared with paired adjacent non-tumor tissues. chr1 160317265 160318474 + Human SUMO1P3 NR_002190.1 24833871 951 SUMO1P3 gastric cancer regulation Up-regulation of SUMO1 pseudogene 3 (SUMO1P3) in gastric cancer and its clinical association. chr1 160287055 160288264 + Human SUMO1P3 N/A 23996296 952 TC0100223 cancer expression Notably, three candidates (TC0100223, TC0101686 and TC0101441) were aberrantly expressed in ERα-positive compared to ERα-negative EOC tissues, showing correlations with some malignant cancer phenotypes such as advanced FIGO stage and/or high histological grade. N/A N/A N/A N/A Human TC0100223 N/A 24481591 953 TC0101441 cancer expression Notably, three candidates (TC0100223, TC0101686 and TC0101441) were aberrantly expressed in ERα-positive compared to ERα-negative EOC tissues, showing correlations with some malignant cancer phenotypes such as advanced FIGO stage and/or high histological grade. N/A N/A N/A N/A Human TC0101441 N/A 24481591 954 TC0101686 cancer expression Notably, three candidates (TC0100223, TC0101686 and TC0101441) were aberrantly expressed in ERα-positive compared to ERα-negative EOC tissues, showing correlations with some malignant cancer phenotypes such as advanced FIGO stage and/or high histological grade. N/A N/A N/A N/A Human TC0101686 N/A 24481591 955 TCL6 leukemia N/A T-cell leukemia/lymphoma 6 chr14 96117515 96139789 + Human TCL6; TNG1; TNG2 NR_028288.1 10851082 956 TCL6 lymphoma N/A T-cell leukemia/lymphoma 6 chr14 96117515 96139789 + Human TCL6; TNG1; TNG2 NR_028288.1 10851082 957 TDRG1 testicular cancer Expression The significantly reduced expression of the TDRG1 in patients with seminoma or teratoma indicates that TDRG1 may be a candidate cancer suppressor gene. chr6 40346163 40347631 + Human TDRG1; LINC00532 NR_024015.1 21243750 958 TERC dyskeratosis congenita Mutation Mutations that alter the equilibrium between different conformational states of TERCs result in disease states such as dyskeratosis congenita, presumably through disruptions of the RNA scaffold structure into which are plugged modular binding sites for telomeric regulatory proteins. chr3 169482398 169482848 - Human TERC; TR; hTR; TRC3; DKCA1; SCARNA19 NR_001566.1 14630939 959 TERC prostat expression TERC is expressed in all human tissues regardless of telomerase activity, whereas TERT is highly expressed in >90% of tumor cells chr3 169482398 169482848 - Human TERC; TR; hTR; TRC3; DKCA1; SCARNA19 NR_001566.1 24146262 960 TERRA cancer regulation In many cancer cells TERRA is downregulated, providing a possible link to the longevity of cancer cells by telomerase-mediated lengthening of chromosomal ends. N/A N/A N/A N/A Mouse TERRA N/A 23660942 961 THRIL Kawasaki disease expression Finally, THRIL expression was correlated with the severity of symptoms in patients with Kawasaki disease, an acute inflammatory disease of childhood. chr12 N/A N/A N/A Human THRIL NR_110375.1 24371310 962 THRIL Kawasaki disease regulation Finally, THRIL expression was correlated with the severity of symptoms in patients with Kawasaki disease, an acute inflammatory disease of childhood. chr12 N/A N/A N/A Human THRIL; Linc1992; BRI3BP-AS1 AK025766.1 24371310 963 TINCR squamous cell carcinoma expression Interestingly, the lncRNA TINCR, which is highly induced during keratinocyte differentiation, is repressed in squamous cell carcinoma specimens compared to normal adjacent epidermis. chr19 5558178 5568005 - Human TINCR; PLAC2; LINC00036; NCRNA00036 NR_027064.1 24115003 964 TRAF3IP2-AS1 schizophrenia N/A Association chr6 111804675 111923498 + Human TRAF3IP2-AS1; C6UAS; C6orf3; NCRNA00248; TRAF3IP2-AS2 NR_034108.1 10903453 965 Trp53cor1 cancer regulation They identified lincRNA-p21 as a direct p53 target. Furthermore, they found that lincRNA-p21 is critical in regulating many of the genes that are repressed in response to p53 activity and they found that lincRNA-p21 associates with hnRNP-K. The lincRNA-p21/hnRNP-K interaction was found to be necessary for hnRNP-K genomic localization at sites of gene repression. chr17 29057474 29078961 - Mus Trp53cor1; lincRNA-p21 NR_036469.1 24829860 966 Trp53cor1 cancer expression lincRNA-p21 (named for its vicinity to the CDKN1A/p21 locus) is upregulated by p53 upon DNA damage and implicated in downstream repressive effects of the p53 pathway, particularly on genes regulating apoptosis, possibly by directing the recruitment of hnRNP-K to its genomic targets. chr17 29057474 29078961 - Mus Trp53cor1; lincRNA-p21 NR_036469.1 23463798 967 Trp53cor1 colorectal cancer regulation LincRNA-p21 enhances the sensitivity of radiotherapy for human colorectal cancer by targeting the Wnt/β-catenin signaling pathway. chr17 29057474 29078961 - Mus Trp53cor1; lincRNA-p21 NR_036469.1 24573322 968 Trp53cor1 colorectal cancer regulation LincRNA-p21 enhances the sensitivity of radiotherapy for human colorectal cancer by targeting the Wnt/β-catenin signaling pathway. chr17 29057474 29078961 - Mus Trp53cor1; lincRNA-p21 NR_036469.1 24573322 969 Trp53cor1 tumor regulation ANRIL, GAS5 and lincRNA-p23 are involved in the escape of growth suppression by regulating tumor suppressor genes (ANRIL) or apoptosis regulators. chr17 29057474 29078961 - Mus Trp53cor1; lincRNA-p21 NR_036469.1 24667321 970 Trp53cor1 tumor regulation Global gene regulation p53 repression via hnRNP-K; inducing cellular apoptosis chr17 29057474 29078961 - Mus Trp53cor1; lincRNA-p21 NR_036469.1 24499465 971 Trpm3 Heart Failure expression Quantitative-PCR identified the relative expression of 5 significantly upregulated and 5 downregulated LncRNAs from 10 HF mice. Five LncRNAs were upregulated and 25 downregulated in HF hearts as compared with control hearts. chr19 22040865 22989897 + Mus Trpm3; MLSN2; LTRPC3; AU018608; 9330180E14; 6330504P12Rik; B930001P07Rik AK139989.1 24205036 972 T-UCRs neuroblastoma regulation It is now becoming increasingly evident that N-myc also regulates the expression of long noncoding RNAs such as T-UCRs and ncRAN. N/A N/A N/A N/A Human N/A N/A 22936790 973 TUG1 B-cell neoplasms expression HOTAIR long non-coding RNA is a negative prognostic factor not only in primary tumors, but also in the blood of colorectal cancer patients. chr22 31365634 31375381 + Human TUG1; TI-227H; LINC00080; NCRNA00080 NR_002323.1 24583225 974 TUG1 bladder cancer regulation Putative diagnostic and prognostic marker; oncogene chr22 31365634 31375381 + Human TUG1; TI-227H; LINC00080; NCRNA00080 NR_002323.1 24373479 975 TUG1 bladder cancer expression Theseguilty by association studies have found numerous bladder-cancer associated lncRNAs chr22 31365634 31375381 + Human TUG1; TI-227H; LINC00080; NCRNA00080 N/A 24006935 976 TUG1 bladder cancer expression Long intergenic non-coding RNA TUG1 is overexpressed in urothelial carcinoma of the bladder. chr22 31365634 31375381 + Human TUG1; TI-227H; LINC00080; NCRNA00080 NR_002323.1 22961206 977 TUG1 Huntington's disease expression LncRNAs TUG1 (necessary for retinal development), and NEAT-1 (a structural component of nuclear paraspeckles) are upregulated in HD caudate, while the brain-specific tumor-suppressor MEG3 is downregulated in HD. chr22 31365634 31375381 + Human TUG1; TI-227H; LINC00080; NCRNA00080 NR_002323.1 23346095 978 TUG1 Huntington's disease Expression TUG1 is upregulated in Huntington's disease brains, which is from the reanalysis of the Affymetrix U133A and B microarray data on normal and HD brains in this review. chr22 31365634 31375381 + Human TUG1; TI-227H; LINC00080; NCRNA00080 NR_002323.1 22202438 979 TUG1 non-small cell lung cancer regulation P53-regulated?long?non-coding?RNA?TUG1 affects cell proliferation in human non-small cell lung cancer, partly through epigenetically regulating HOXB7 expression. chr22 31365634 31375381 + Human TUG1; TI-227H; LINC00080; NCRNA00080 NR_002323.1 24853421 980 TUSC8 cervical cancer expression Low expression of long noncoding XLOC_010588 indicates a poor prognosis and promotes proliferation through upregulation of c-Myc in cervical cancer. chr13 44400250 44405984 - Human TUSC8; LINC01071; XLOC_010588 NR_104174.1 24667250 981 U1 spliceosomal lncRNA Parkinson's disease expression These included the U1 spliceosomal lncRNA and RP11-462G22.1, each entailing sequence complementarity to numerous microRNAs. N/A N/A N/A N/A Human U1 spliceosomal lncRNA N/A 24651478 982 Ube3a-as Angelman syndrome Locus Ube3a-as is a lncRNA transcribed antisense to the maternally expressed Ube3a gene, a candidate gene for AS, suggesting that Ube3a-as may be responsible for repressing paternal Ube3a expression. N/A N/A N/A N/A Human N/A N/A 20380817 983 UBE3A-AS1 Angelman syndrome expression Prader–Willi and Angelman syndromes, due to UBE3A expression, are affected due to the presence of a 20-kb NAT, which shares complementary sequences of UBE3A N/A N/A N/A N/A Human UBE3A-AS1 N/A 23781896 984 UBE3A-AS1 Angelman syndrome mutation Although in the majority of human tissues, both copies of the UBE3A gene are expressed, in neurons one copy is silenced by UBE3A-AS1 (ubiquitin-protein ligase E3A antisense RNA 1). In patients suffering from Angelman syndrome, the other (active) allele has either been deleted or inactivated. N/A N/A N/A N/A Human UBE3A-AS1 N/A 24667321 985 UBE3A-AS1 Prader-Willi syndrome expression Prader–Willi and Angelman syndromes, due to UBE3A expression, are affected due to the presence of a 20-kb NAT, which shares complementary sequences of UBE3A N/A N/A N/A N/A Human UBE3A-AS1 N/A 23781896 986 UBE3A-ATS Angelman syndrome regulation Genomic context links lncRNAs to disease genes/loci and related pathways N/A N/A N/A N/A Human UBE3A-ATS N/A 23791884 987 UBE3A-ATS Angelman syndrome regulation LncRNAs are also associated with imprinting disorders, such as ubiquitin protein ligase E3A (UBE3A)-ATS in Angelman syndrome. N/A N/A N/A N/A Human UBE3A-ATS N/A 23562612 988 uc.115- Heart Failure expression Quantitative-PCR identified the relative expression of 5 significantly upregulated and 5 downregulated LncRNAs from 10 HF mice. Five LncRNAs were upregulated and 10 downregulated in HF hearts as compared with control hearts. N/A N/A N/A N/A Mus uc.115- N/A 24205036 989 uc.184+ Heart Failure expression Quantitative-PCR identified the relative expression of 5 significantly upregulated and 5 downregulated LncRNAs from 10 HF mice. Five LncRNAs were upregulated and 19 downregulated in HF hearts as compared with control hearts. N/A N/A N/A N/A Mus uc.184+ N/A 24205036 990 UCA1 bladder cancer expression Diagnostic marker oncogene chr19 15939757 15946230 + Human UCA1; CUDR; LINC00178; NCRNA00178 NR_015379.3 24373479 991 UCA1 bladder cancer Expression In adult human tissues, UCA1 gene was not expressed except in the heart and spleen. The expression level of UCA1 was increased in 8 common tumor tissues as compared with that in the corresponding normal tissues. chr19 15939757 15946230 + Human UCA1; CUDR; LINC00178; NCRNA00178 NR_015379.3 20117985 992 UCA1 bladder cancer Expression Overexpression of UCA1a(CUDR) significantly enhanced proliferation, migration and invasion of the bladder cancer cell line UM-UC-2. chr19 15939757 15946230 + Human UCA1; CUDR; LINC00178; NCRNA00178 NR_015379.3 22576688 993 UCA1 bladder cancer Expression UCA1 was identified as a novel noncoding RNA gene dramatically up-regulated in TCC (bladder transitional cell carcinoma) and it is the most TCC-specific gene yet identified. chr19 15939757 15946230 + Human UCA1; CUDR; LINC00178; NCRNA00178 NR_015379.3 16914571 994 UCA1 bladder cancer Expression UCA1, a non-protein-coding RNA up-regulated in bladder carcinoma and embryo, influencing cell growth and promoting invasion. chr19 15939757 15946230 + Human UCA1; CUDR; LINC00178; NCRNA00178 NR_015379.3 18501714 995 UCA1 bladder cancer Expression With a high level of sensitivity and specificity, UCA1 is a promising urinary marker for the diagnosis of bladder cancer. chr19 15939757 15946230 + Human UCA1; CUDR; LINC00178; NCRNA00178 NR_015379.3 22490897 996 UCA1 bladder cancer Interaction Long non-coding RNA UCA1 regulated cell cycle distribution via CREB through PI3-K dependent pathway in bladder carcinoma cells. chr19 15939757 15946230 + Human UCA1; CUDR; LINC00178; NCRNA00178 NR_015379.3 22289355 997 UCA1 bladder cancer expression Theseguilty by association studies have found numerous bladder-cancer associated lncRNAs chr19 15939757 15946230 + Human UCA1; CUDR; LINC00178; NCRNA00178 N/A 24006935 998 UCA1 bladder cancer expression Upregulation of long non-coding RNA urothelial carcinoma associated 1 by CCAAT/enhancer binding protein α contributes to bladder cancer cell growth and reduced apoptosis. chr19 15939757 15946230 + Human UCA1; CUDR; LINC00178; NCRNA00178 NR_015379.3 24648007 999 UCA1 bladder cancer regulation Long non-coding RNA UCA1 increases chemoresistance of bladder cancer cells by regulating Wnt signaling. chr19 15939757 15946230 + Human UCA1; CUDR; LINC00178; NCRNA00178 NR_015379.3 24495014 1000 UCA1 oral squamous cell carcinoma expreesion Subsequently, they confirmed that the expression levels of HOTAIR, NEAT-1 and UCA3 in metastasized samples was prominent higher than the non-metastatic samples.? chr19 15939757 15946230 + Human UCA1; CUDR; LINC00178; NCRNA00178 NR_015379.3 24817925 1001 UCA1 pancreaticobiliary maljunction Expression Gene expression profiling reveals upregulated UCA1 and BMF in gallbladder epithelia of children with pancreaticobiliary maljunction. chr19 15939757 15946230 + Human UCA1; CUDR; LINC00178; NCRNA00178 NR_015379.3 21593646 1002 UCA1 squamous carcinoma Expression Cancer up-regulated drug resistant (CUDR) gene, was found to be overexpressed in a doxorubicin-resistant subline of human squamous carcinoma A431 and A10A cells. chr19 15939757 15946230 + Human UCA1; CUDR; LINC00178; NCRNA00178 NR_015379.3 17416635 1003 UCA1 tongue squamous cell carcinomas expreesion Meaningfully, the expression levels of UCA1 lncRNA were dramatically higher in TSCC tissues than those in paired ANTs.? chr19 15939757 15946230 + Human UCA1; CUDR; LINC00178; NCRNA00178 NR_015379.3 24817925 1004 UCA1 tumor regulation Long non-coding RNA UCA1 promotes breast tumor growth by suppression of p27 (Kip1). chr19 15939757 15946230 + Human UCA1; CUDR; LINC00178; NCRNA00178 NR_015379.3 24457952 1005 UCH1LAS Parkinson's disease regulation Genomic context links lncRNAs to disease genes/loci and related pathways N/A N/A N/A N/A Human UCH1LAS; RP11-124A7.2 N/A 23791884 1006 VL30 LTRs hepatocelluar carcinoma expression Trim24 (Tif1) and Trim33 (Tif1) interact to form a co-repressor complex that suppresses murine hepatocellular carcinoma. Here we show that Trim24 and Trim33 cooperatively repress retinoic acid receptor-dependent activity of VL30-class endogenous retroviruses (ERVs) in liver. In Trim24-knockout hepatocytes, VL30 derepression leads to accumulation of reverse-transcribed VL30 cDNA in the cytoplasm that correlates with activation of the viral-defense interferon responses mimicking the preneoplastic inflammatory state seen in human liver following exogenous viral infection. Furthermore, upon derepression, VL30 long terminal repeats (LTRs) act as promoter and enhancer elements deregulating expression of neighboring genes and generating enhancer RNAs that are required for LTR enhancer activity in hepatocytes in vivo. N/A N/A N/A N/A Mus N/A N/A 23377542 1007 WRAP53 cancer Expression A natural antisense transcript of TP53, WRAP53, was strongly augmented by idarubicin and etoposide. chr17 7589389 7606820 + Human WRAP53; DKCB3; TCAB1; WDR79 NM_001143990.1 21441950 1008 WRAP53 cancer N/A WRAP53 promotes cancer cell survival and is a potential target for cancer therapy. chr17 7589389 7606820 + Human WRAP53; DKCB3; TCAB1; WDR79 NM_001143990.1 21368886 1009 WRAP53 dyskeratosis congenita Mutation Disruption of telomerase trafficking by WRAP53 mutation causes dyskeratosis congenita. chr17 7589389 7606820 + Human WRAP53; DKCB3; TCAB1; WDR79 NM_001143990.1 21205863 1010 WT1-AS acute myeloid leukemia Epigenetics The incidence of WIT-1 methylation in primary refractory AML was significantly higher than that noted in chemosensitive AML. chr11 32457285 32461636 + Human WT1-AS; WIT1; WIT-1; WT1AS; WT1-AS1; dJ74J1.3 NR_023920.3 10340388 1011 WT1-AS acute myeloid leukemia Interaction In AML, there is often abnormal splicing of WT1-AS, which may play a role in the development of this malignancy. chr11 32457285 32461636 + Human WT1-AS; WIT1; WIT-1; WT1AS; WT1-AS1; dJ74J1.2 NR_023920.2 17940140 1012 WT1-AS Wilms' tumor Epigenetics A CTCF-binding silencer regulates the imprinted genes AWT1 and WT1-AS and exhibits sequential epigenetic defects during Wilms' tumourigenesis. chr11 32457285 32461636 + Human WT1-AS; WIT1; WIT-1; WT1AS; WT1-AS1; dJ74J1.1 NR_023920.1 17210670 1013 WT1-AS Wilms' tumor Interaction WT1 is a gene that is mutated in Wilms' tumor (WT) and acute myeloid leukaemia (AML) and has an antisense transcript (WT1-AS), which was found to regulate WT1 protein levels. chr11 32457285 32461636 + Human WT1-AS; WIT1; WIT-1; WT1AS; WT1-AS1; dJ74J1.4 NR_023920.4 17940140 1014 Wt1os ischemia/reperfusion expression Classification and validation of deregulated LncRNAs in ischemia/reperfusion-treated mouse livers. chr2 105076538 105126510, - Mus Wt1os; NR-015462 NR_015462.1 24312245 1015 XIST bladder cancer regulation Putative diagnostic and prognostic marker chrX 73040495 73072588 - Human XIST; SXI1; swd66; DXS1089; DXS399E; LINC00001; NCRNA00002 NR_001564.2 24373479 1016 XIST breast cancer Mutation The intratumoral and intertumoral variability in XIST RNA domain number in BRCA1 tumors correlates with chromosomal genetic abnormalities, including gains, losses, reduplications, and rearrangements of the X-chromosome. chrX 73040495 73072588 - Human XIST; SXI1; swd66; DXS1089; DXS399E; LINC00001; NCRNA00002 NR_001564.3 17545591 1017 XIST cancer regulation Dysfunction of XIST may trigger the chromatin instability and promote caner development. chrX 73040495 73072588 - Human XIST; SXI1; swd66; DXS1089; DXS399E; LINC00001; NCRNA00002 NR_001564.2 24757675 1018 XIST cancer regulation The lncRNA Xist was found to be a potent tumor suppressor of hematologic malignancies?in vivo. chrX 73040495 73072588 - Human XIST; SXI1; swd66; DXS1089; DXS399E; LINC00001; NCRNA00002 NR_001564.2 24829860 1019 XIST female cancers expression Recent studies have linked their mis-expression to diverse cancers (ANRIL: prostate cancer, XIST: female cancers, HOTAIR: breast cancer, KCNQ1OT2: colorectal cancer). chrX 73040495 73072588 - Human XIST; SXI1; swd66; DXS1089; DXS399E; LINC00001; NCRNA00002 N/A 23660942 1020 XIST Klinefelter's syndrome Epigenetics Severe XIST hypomethylation clearly distinguishes (SRY+) 46,XX-maleness from Klinefelter syndrome. chrX 73040495 73072588 - Human XIST; SXI1; swd66; DXS1089; DXS399E; LINC00001; NCRNA00004 NR_001564.5 19812237 1021 XIST Klinefelter's syndrome Expression We demonstrated by quantitative RT-PCR an active XIST RNA expression in blood lymphocytes from Klinefelter patients, comparable to that observed in control females and over 30,000-fold greater than in control males. chrX 73040495 73072588 - Human XIST; SXI1; swd66; DXS1089; DXS399E; LINC00001; NCRNA00001 NR_001564.2 18854511 1022 XIST testicular cancer Expression XIST expression was common in seminomatous testicular germ cell tumors but not in nonseminomatous testicular germ cell tumors. chrX 73040495 73072588 - Human XIST; SXI1; swd66; DXS1089; DXS399E; LINC00001; NCRNA00003 NR_001564.4 12629412 1023 Yiya cancer Expression Expression profiling revealed a general and regulated expression pattern of Yiya in major tissues, and more interestingly, identified elevated mRNA levels in different cancers. chr1 214098092 214099997 + Human LINC00538; Yiya NR_046189.1 22258142 1024 ZFAT-AS1 autoimmune disease Mutation SNPs in the promoter of a B cell-specific antisense transcript, SAS-ZFAT (ZFAT-AS1), determine susceptibility to autoimmune thyroid disease. chr8 135610314 135612932 + Human ZFAT-AS1; ZFATAS; ZFAT-AS; SAS-ZFAT; NCRNA00070 NR_002438.1 15294872 1025 Zim3 Heart Failure expression Quantitative-PCR identified the relative expression of 5 significantly upregulated and 5 downregulated LncRNAs from 10 HF mice. Five LncRNAs were upregulated and 13 downregulated in HF hearts as compared with control hearts. chr7 6955685 6976662 - Mus Zim3; 1700128I23Rik NR_036631 24205036 1026 ZNFX1-AS1 breast cancer Expression SNORD-host RNA Zfas1 is a regulator of mammary development and a potential marker for breast cancer.ZFAS1 is highly expressed in the mammary gland and is down-regulated in breast tumors compared to normal tissue. ZFAS1 is a putative tumor suppressor gene. chr20 47894715 47905797 + Human ZNFX1-AS1; HSUP1; HSUP2; ZFAS1; C20orf199; NCRNA00275 NR_003604.2 21460236 1027 ZNFX1-AS1 breast cancer Locus SNORD-host RNA Zfas1 is a regulator of mammary development and a potential marker for breast cancer. ZFAS1 as a putative tumor suppressor gene. chr20 47894715 47905797 + Human ZNFX1-AS1; HSUP1; HSUP2; ZFAS1; C20orf199; NCRNA00275 NR_003604.2 21460236 1028 ZNFX1-AS1 ductal carcinoma Expression Human ZFAS1 levels are reduced in ductal carcinoma relative to normal breast tissue. chr20 47894715 47905797 + Human ZNFX1-AS1; HSUP1; HSUP2; ZFAS1; C20orf199; NCRNA00275 NR_003604.2 21460236 1029 PVT1 gastric cancer N/A Overexpression of long non-coding RNA PVT1 in gastric cancer cells promotes the development of multidrug resistance N/A N/A N/A N/A N/A N/A N/A 25956062 1030 LINC01133 lung squamous cell cancer N/A LSCC patients with higher expression level of LINC01133 had shorter survival time. LINC01133 is upregulated in lung squamous cell cancer and predicts survival N/A N/A N/A N/A N/A N/A N/A 25908174 1031 lnc-LCE5A-1 Head and neck squamous cell carcinoma N/A Ectopic expression of lnc-LCE5A-1 increased the expression of CDH-1 in HNSCC cells, while decreasing the expression of OCT-4, NANOG, and VIM. N/A N/A N/A N/A N/A N/A N/A 25904139 1032 lnc-KCTD6-3 Head and neck squamous cell carcinoma N/A Overexpression of lnc-KCTD6-3 reduced the expression of NANOG N/A N/A N/A N/A N/A N/A N/A 25904139 1033 UCA1 gastric cancer N/A UCA1 expression was remarkably increased in gastric cancer tissues and cell lines compared with that in the normal control; high UCA1 expression correlated with worse differentiation, tumor size, invasion depth and TNM stage in gastric cancer; increased UCA1 expression contributed to poor overall survival and disease-free survival of patients. N/A N/A N/A N/A N/A N/A N/A 25903045 1034 HOTAIR oral squamous cell carcinoma N/A Long non-coding RNA HOTAIR promotes tumor cell invasion and metastasis by recruiting EZH2 and repressing E-cadherin in oral squamous cell carcinoma. N/A N/A N/A N/A N/A N/A N/A 25901533 1035 antisense to Uchl1 (AS Uchl1) Parkinson's disease N/A Uch1 RNA levels are strongly down-regulated in neurochemical models of PD in vitro and in vivo N/A N/A N/A N/A N/A N/A N/A 25883552 1036 H19 breast cancer N/A H19 lncRNA mediates 17beta-estradiol-induced cell proliferation in MCF-7 breast cancer cells; H19 lncRNA was much higher in estrogen receptor (ER)-positive MCF-7 breast cancer cells than in ER-negative MDA-MB-231 cells N/A N/A N/A N/A N/A N/A N/A 25846769 1037 SPRY4-IT1 gastric cancer N/A SPRY4-IT1 expression was elevated in GC tissues and cell lines N/A N/A N/A N/A N/A N/A N/A 25835973 1038 LOC728228 lung cancer N/A LOC728228 was upregulated relative to its expression in control untransformed16HBE (16HBE-N) cells. N/A N/A N/A N/A N/A N/A N/A 25820656 1039 MALAT1 glioblastoma N/A Extensive microRNA-mediated crosstalk between lncRNAs and mRNAs in mouse WIF1 re-expression in glioblastoma inhibits migration through attenuation of non-canonical WNT signaling by downregulating the lncRNA MALAT1. N/A N/A N/A N/A N/A N/A N/A 25772239 1040 H19 coronary artery disease N/A Re-expression of H19 has been observed in patients with atherosclerosis. Common polymorphisms of H19 are associated with the risk and severity of CAD in a Chinese population. N/A N/A N/A N/A N/A N/A N/A 25772106 1041 tumour suppressor candidate 7 (TUSC7) gastric cancer N/A TUSC7 was downregulated in GC samples and was an independent prognostic indicator of disease-free survival (DFS) and disease-specific survival (DSS) in GC patients; TUSC7 was a direct transcriptional target of p53 via interaction of p53 with the putative p53-response element in the upstream region of TUSC7 N/A N/A N/A N/A N/A N/A N/A 25765901 1042 HIF1A-AS1 Cardiovascular disease N/A Clopidogrel reduces apoptosis and promotes proliferation of human vascular endothelial cells induced by palmitic acid via suppression of the long non-coding RNA HIF1A-AS1 in vitro. N/A N/A N/A N/A N/A N/A N/A 25761653 1043 UCA1 hepatocellular carcinoma N/A Upregulated lncRNA-UCA1 contributes to progression of hepatocellular carcinoma through inhibition of miR-216b and activation of FGFR1/ERK signaling pathway. N/A N/A N/A N/A N/A N/A N/A 25760077 1044 lncRNA-ATB colorectal cancer N/A High lncRNA-ATB expression was significantly associated with greater tumor size, depth of tumor invasion, lymphatic invasion, vascular invasion, and lymph node metastasis. Additionally, levels of lncRNA-ATB expression were significantly higher in patients with hematogenous metastases. N/A N/A N/A N/A N/A N/A N/A 25750289 1045 Arid2-IR renal inflammation N/A Arid2-IR is a novel lncRNA that functions to promote NF-KB-dependent renal inflammation. Overexpression of Arid2-IR promoted interleukin-1-induced NF-B signaling and inflammatory cytokine expression without alteration of TGF-beta1-induced fibrotic response. N/A N/A N/A N/A N/A N/A N/A 25743111 1046 TINCR gastric cancer N/A TINCR is strongly upregulated in human gastric carcinoma (GC), where it was found to contribute to oncogenesis and cancer progression. TINCR overexpression is induced by nuclear transcription factor SP1. TINCR contributes to the oncogenic potential of GC and may constitute a potential therapeutic target in this disease. N/A N/A N/A N/A N/A N/A N/A 25728677 1047 NRON AIDS N/A The lncRNA NRON modulates HIV-1 replication in a NFAT-dependent manner and is differentially regulated by early and late viral proteins. Its expression was significantly altered following HIV-1 infection. Its levels were reduced by the early viral accessory protein Nef and increased by the late protein Vpu. N/A N/A N/A N/A N/A N/A N/A 25728138 1048 MALAT2-activated long noncoding RNA gastric cancer N/A MALAT2-activated long noncoding RNA indicates a biomarker of poor prognosis in gastric cancer. MALAT2 was frequently over-expressed in cancer tissues and this over-expression was found to significantly correlate with lymph node metastasis and tumor stage. N/A N/A N/A N/A N/A N/A N/A 25721209 1049 DRAIC/PCAT29 prostate cancer, bladder cancer, low-grade gliomas, lung adenocarcinoma, stomach adenocarcinoma, renal clear cell carcinoma, hepatocellular carcinoma, skin melanoma N/A The lncRNA DRAIC/PCAT29 Locus Constitutes a Tumor-Suppressive Nexus. Prostate cancers persisting in patients after androgen deprivation therapy (ADT) select for decreased DRAIC expression, and higher levels of DRAIC in prostate cancer are associated with longer disease-free survival (DFS). DRAIC expression predicts good prognosis in a wide range of malignancies, including bladder cancer, low-grade gliomas, lung adenocarcinoma, stomach adenocarcinoma, renal clear cell carcinoma, hepatocellular carcinoma, skin melanoma, and stomach adenocarcinoma. N/A N/A N/A N/A N/A N/A N/A 25700553 1050 DANCR postmenopausal osteoporosis N/A DANCR promoted the expression of IL6 and TNF-alpha at both mRNA level and protein level in MNCs. DANCR level was correlated with IL6 and TNF-alpha in postmenopausal women with low BMD N/A N/A N/A N/A N/A N/A N/A 25660720 1051 MRAK052686 Nonalcoholic fatty liver disease (NAFLD) N/A Berberine ameliorates nonalcoholic fatty liver disease by a global modulation of hepatic mRNA and lncRNA expression profiles. MRAK052686, was found strongly correlated with the antioxidant factor Nrf2, and both genes were down-regulated by the steatotic liver. The reduced expression of MRAK052686 and Nrf2 was completely reversed by BBR treatment, suggesting a new mechanism accounting for the therapeutic effect of BBR. N/A N/A N/A N/A N/A N/A N/A 25623289 1052 Abhd11os neurodegenerative diseases N/A The striatal long noncoding RNA Abhd11os is neuroprotective against an N-terminal fragment of mutant huntingtin in vivo. Abhd11os overexpression produces neuroprotection against an N-terminal fragment of mutant huntingtin, whereas Abhd11os knockdown is protoxic. N/A N/A N/A N/A N/A N/A N/A 25619660 1053 HOTAIR gastric Cancer N/A HOTAIR Long Noncoding RNA Promotes Gastric Cancer Metastasis through Suppression of Poly r(C)-Binding Protein (PCBP) 1. Our findings provide mechanistic evidence for HOTAIR overexpression and PCBP1 downregulation and the ensuing malignant phenotype in both cultured and xenograft gastric cancer cells. N/A N/A N/A N/A N/A N/A N/A 25612617 1054 MALAT1 renal cell carcinoma (RCC) N/A Long Noncoding RNA MALAT1 Promotes Aggressive Renal Cell Carcinoma through Ezh2 and Interacts with miR-205. MALAT1 expression was higher in human RCC tissues, where it was associated with reduced patient survival. N/A N/A N/A N/A N/A N/A N/A 25600645 1055 Androgen Receptor Coregulator CTBP1-AS Polycystic Ovary Syndrome N/A C-Terminal binding protein 1 antisense (CTBP1-AS) was a novel long noncoding RNA (lncRNA) to regulate AR activity. Expression level of CTBP1-AS in peripheral blood leukocytes was significantly higher in women with PCOS than that in controls after adjustment for age and body mass index (BMI). N/A N/A N/A N/A N/A N/A N/A 25552498 1056 long stress-induced non-coding transcript 5 (LSINCT5) gastric cancer,colorectal cancer N/A The expression of LSINCT5 is significantly upregulated in gastrointestinal cancer tissues and cell lines relative to their normal counterparts. Increased LSINCT5 expression was correlated with a larger tumor size, deeper tumor depth, and advanced clinical stage. Gastric cancer (GC) and colorectal cancer (CRC) patients with higher LSINCT5 expression levels have worse disease-free survival (DFS) and disease-specific survival (DSS) rates. N/A N/A N/A N/A N/A N/A N/A 25526476 1057 NBAT-1 neuroblastoma N/A The risk-associated long noncoding RNA NBAT-1 controls neuroblastoma progression by regulating cell proliferation and neuronal differentiation. Loss of NBAT-1 increases cellular proliferation and invasion. N/A N/A N/A N/A N/A N/A N/A 25517750 1058 prostate cancer gene expression marker 1 (PCGEM1) prostate cancer N/A PCGEM1 overexpression is highly associated with prostate tumors. CGEM1 tumorigenic potential has been recently shown to be in part due to its ability to activate androgen receptor (AR). Here, we report a novel function of PCGEM1 that provides growth advantages for cancer cells by regulating tumor metabolism via c-Myc activation. PCGEM1 promotes glucose uptake for aerobic glycolysis, coupling with the pentose phosphate shunt to facilitate biosynthesis of nucleotide and lipid, and generates NADPH for redox homeostasis. N/A N/A N/A N/A N/A N/A N/A 25512540 1059 SChLAP1 prostate cancer N/A SChLAP1 expression increases with prostate cancer progression,and high SChLAP1 expression by ISH is associated with poor outcome after radical prostatectomy in patients with clinically localized prostate cancer by both univariate and multivariate Cox regression analyses. N/A N/A N/A N/A N/A N/A N/A 25499224 1060 Ube3a-ATS Angelman syndrome N/A ASO treatment achieved specific reduction of Ube3a-ATS and sustained unsilencing of paternal Ube3a in neurons in vitro and in vivo. Partial restoration of UBE3A protein in an Angelman syndrome mouse model ameliorated some cognitive deficits associated with the disease. N/A N/A N/A N/A N/A N/A N/A 25470045 1061 SChLAP1 prostate cancer N/A The long non-coding RNA SChLAP1 was identified as the highest-ranked overexpressed gene in cancers with metastatic progression. N/A N/A N/A N/A N/A N/A N/A 25456366 1062 PCA3 prostate cancer N/A By PCR-based cloning and sequencing in paired peripheral blood leukocytes and prostate tissues,5 PCA3 TAAA STR polymorphisms and 8 genotypes were found in both peripheral blood leukocytes and prostate tissues, the carriers with more TAAA repeats were associated with increased risk for PCa than individuals having less TAAA repeats N/A N/A N/A N/A N/A N/A N/A 25445501 1063 linc-POU3F3 glioma N/A By using real-time PCR and gain-/loss-of-function studies,the authors revealed that linc-POU3F3 levels were extraordinarily associated with the tumor WHO grade.In related biochemical assays, overexpression of linc-POU3F3 promotes cell viability and proliferation in glioma cells, whereas knockdown of linc-POU3F3 showed the opposite effect. As expected, they also found that linc-POU3F3 expression was negatively correlated with the mRNA level of POU3F3. N/A N/A N/A N/A N/A N/A N/A 25445282 1064 BCAR4 breast cancer N/A BCAR4 binding of SNIP1 and PNUTS in response to CCL21 releases the SNIP1's inhibition of p300-dependent histone acetylation, which in turn enables the BCAR4-recruited PNUTS to bind H3K18ac and relieve inhibition of RNA Pol II via activation of the PP1 phosphatase. N/A N/A N/A N/A N/A N/A N/A 25416949 1065 MALAT1 multiple myeloma N/A MALAT1 was overexpressed in the newly diagnosed patients compared with post-treatment patients and healthy individuals. The expression of MALAT1 strongly correlated with disease status, and the magnitude of change in MALAT1 post-treatment had prognostic relevance. The patients with early progression had a significantly smaller change in MALAT1 after treatment. N/A N/A N/A N/A N/A N/A N/A 25369863 1066 Neat1 infertility N/A Neat1 knockout (KO) mice stochastically fail to become pregnant despite normal ovulation. Unilateral transplantation of wild-type ovaries or the administration of progesterone partially rescued the phenotype, suggesting that corpus luteum dysfunction and concomitant low progesterone were the primary causes of the decreased fertility. In contrast to the faint expression observed in most of the adult tissues, Neat1 was highly expressed in the corpus luteum, and the formation of luteal tissue was severely impaired in nearly half of the Neat1 KO mice N/A N/A N/A N/A N/A N/A N/A 25359727 1067 MALAT1 diabetes mellitus N/A MALAT1 expression is significantly upregulated in the retinas of STZ-induced diabetic rats and db/db mice. MALAT1 knockdown could obviously ameliorate DR in vivo, as shown by pericyte loss, capillary degeneration, microvascular leakage, and retinal inflammation. Moreover, MALAT1 knockdown could regulate retinal endothelial cell proliferation, migration, and tube formation in vitro. The crosstalk between MALAT1 and p38 MAPK signaling pathway is involved in the regulation of endothelial cell function. N/A N/A N/A N/A N/A N/A N/A 25356875 1068 ENST00000480739 pancreatic ductal adenocarcinoma N/A the ENST00000480739 expression level was remarkably N/A N/A N/A N/A N/A N/A N/A 25314054 1069 lnc-SCA7 spinocerebellar ataxia type 7 (SCA7) N/A STAGA is required for the transcription initiation of miR-124, which in turn mediates the post-transcriptional cross-talk between lnc-SCA7, a conserved long noncoding RNA,and ATXN7 mRNA. In SCA7, mutations in ATXN7 disrupt these regulatory interactions and result in a neuron-specific increase in ATXN7 expression. Strikingly, in mice this increase is most prominent in the SCA7 disease-relevant tissues, namely the retina and cerebellum. N/A N/A N/A N/A N/A N/A N/A 25306109 1070 HOST2 epithelial ovarian cancer N/A EOC-specific lncRNA-HOST2, which acts as a miRNA sponge, sequesters let-7b to maintain the expression of oncogenes and further maintains EOC biological functions. N/A N/A N/A N/A N/A N/A N/A 25292198 1071 GAPLINC gastric cancer N/A GAPLINC is a 924-bp-long lncRNA that is highly expressed in gastric cancer tissues. GAPLINC suppression and with gene expression profiling in gastric cancer cells revealed alterations in cell migration pathways, with CD44 expression the most highly correlated. Manipulating GAPLINC N/A N/A N/A N/A N/A N/A N/A 25277524 1072 RP5-833A20.1 atherosclerosis N/A Using microarray analysis, the authors found that long noncoding RNA RP5-833A20.1 expression was upregulated, whereas nuclear factor IA (NFIA) expression was downregulated in human acute monocytic leukemia macrophage-derived foam cells. Moreover, they showed that long noncoding RNA RP5-833A20.1 maydecreases NFIA expression by inducing hsa-miR-382-5p expression in vitro. N/A N/A N/A N/A N/A N/A N/A 25265644 1073 lincRNA-RoR triple-negative breast cancer N/A LincRNA-RoR is upregulated in TNBC and in metastatic disease and knockdown restores miR-145 expression.The lincRNA-RoR/miR-145/ARF6 pathway is critical to TNBC metastasis and could serve as biomarkers or therapeutic targets for improving survival. N/A N/A N/A N/A N/A N/A N/A 25253741 1074 AC006050.3-003 lung squamous cell carcinoma N/A The expression of lncRNA AC006050.3-003 was significantly lower in PR samples compared to the PD samples in another 60 lung squamous cell carcinoma patients. Receiver operating characteristic curve analysis revealed that lncRNA AC006050.3-003 was a valuable biomarker for differentiating PR patients from PD patients with an area under the curve of 0.887 (95% confidence interval 0.779, 0.954). N/A N/A N/A N/A N/A N/A N/A 25250788 1075 LOC285194 esophageal squamous cell carcinoma (ESCC) N/A LOC285194 expression was significantly down-regulated in ESCC tumor tissues when compared with the adjacent normal tissues. Low expression of LOC285194 was associated with larger tumor size, advanced TNM stage, more lymph node metastases and distant metastases. N/A N/A N/A N/A N/A N/A N/A 25169763 1076 AB074278 bladder cancer N/A We implicate upregulation of AB074278 in apoptosis avoidance and the maintenance of a proproliferative state in cancer through a potential interaction with EMP1, a tumor suppressor and a negative regulator of cell proliferation. N/A N/A N/A N/A N/A N/A N/A 25165097 1077 Xist membranous nephropathy (MN) N/A Urinary Xist is significantly elevated in urine samples from patients with different types of glomerular nephritis, including MN, compared to normal counterparts. N/A N/A N/A N/A N/A N/A N/A 25157805 1078 lincRNA-p21 atherosclerosis N/A The expression of lincRNA-p21 was dramatically downregulated in atherosclerotic plaques of ApoE(-/-) mice, an animal model for atherosclerosis. LincRNA-p21 represses cell proliferation and induces apoptosis in vascular smooth muscle cells and mouse mononuclear macrophage cells in vitro N/A N/A N/A N/A N/A N/A N/A 25156994 1079 cyclin-dependent kinase inhibitor 2B antisense RNA (CDKN2B-AS) endometriosis N/A Rs10965235 SNP in the CDKN2B-AS gene was significantly associated with endometriosis in this Korean population. N/A N/A N/A N/A N/A N/A N/A 25154675 1080 wingless-type MMTV integration site family member 4 (WNT4) endometriosis N/A Rs10965235 SNP in the rs16826658 SNP near the WNT4 gene was significantly associated with endometriosis in this Korean population. N/A N/A N/A N/A N/A N/A N/A 25154675 1081 HOX transcript antisense RNA (HOTAIR) renal carcinoma N/A Suppressed expression of long non-coding RNA HOTAIR inhibits proliferation and tumourigenicity of renal carcinoma cells. N/A N/A N/A N/A N/A N/A N/A 25149152 1082 Urothelial cancer associated 1 (UCA1) carcinoma of the urinary bladder N/A UCA1 expression was found in T24 cell line and also found to be significantly higher in the cancer group as compared to the controls N/A N/A N/A N/A N/A N/A N/A 25123267 1083 HA117 Hirschsprung's disease N/A HA117 expression in stenotic segment was higher compared to proximal anastomosis and dilated segment (p < 0.05); HA117 may be a factor exerting an anti-differentiation or anti-maturation role in the genesis of HSCR. N/A N/A N/A N/A N/A N/A N/A 25120773 1084 HOTAIR laryngeal squamous cell carcinoma N/A The expression of exosomal miR-21 and HOTAIR was significantly higher in patients with laryngeal squamous cell carcinomaLSCC than those with vocal cord polyps; The patients with lymph node metastasis had higher serum exosomal miR-21 and HOTAIR expressions than those without. N/A N/A N/A N/A N/A N/A N/A 25099764 1085 miR-21 laryngeal squamous cell carcinoma N/A The expression of exosomal miR-21 and HOTAIR was significantly higher in patients with laryngeal squamous cell carcinomaLSCC than those with vocal cord polyps; The patients with lymph node metastasis had higher serum exosomal miR-21 and HOTAIR expressions than those without. N/A N/A N/A N/A N/A N/A N/A 25099764 1086 TARID cancer N/A Long noncoding RNA TARID directs demethylation and activation of the tumor suppressor TCF21 via GADD45A. N/A N/A N/A N/A N/A N/A N/A 25087872 1087 PVT1 hepatocellular carcinoma N/A Oncofetal long noncoding RNA PVT1 promotes proliferation and stem cell-like property of hepatocellular carcinoma cells by stabilizing NOP2 N/A N/A N/A N/A N/A N/A N/A 25043274 1088 PVT1 cancer N/A A single supernumerary segment encompassing all four genes(Myc gene or the region encompassing Pvt1, Ccdc26 and Gsdmc ) successfully promotes cancer; PVT1 RNA and MYC protein expression correlated in primary human tumours, and copy number of PVT1 was co-increased in more than 98% of MYC-copy-increase cancers. N/A N/A N/A N/A N/A N/A N/A 25043044 1089 hypoxia inducible factor 1A antisense RNA 2 acute myocardial infarction N/A Level of hypoxia inducible factor 1A antisense RNA 2 was higher in patients with MI than in healthy volunteers (P<0.01) N/A N/A N/A N/A N/A N/A N/A 25035150 1090 cyclin-dependent kinase inhibitor 2B antisense RNA 1 (ANRIL) acute myocardial infarction N/A Level of ANRIL was lower in patients with MI (P=0.003)Patients with ST-segment-elevation MI had lower level of ANRIL (P<0.001)when compared with patients with non-ST-segment-elevation MI. N/A N/A N/A N/A N/A N/A N/A 25035150 1091 member 1 opposite strand/antisense transcript 1 (KCNQ1OT1) acute myocardial infarction N/A Level of KCNQ1OT1 was higher in patients with MI than in healthy volunteers (P<0.01);Patients with ST-segment-elevation MI had lower levels of KCNQ1OT1 (P<0.001)when compared with patients with non-ST-segment-elevation N/A N/A N/A N/A N/A N/A N/A 25035150 1092 metastasis-associated lung adenocarcinoma transcript 1 acute myocardial infarction N/A Level of metastasis-associated lung adenocarcinoma transcript 1 was higher in patients with MI than in healthy volunteers (P<0.01); Patients with ST-segment-elevation MI had lower levels of metastasis-associated lung adenocarcinoma transcript 1 (P=0.005) when compared with patients with non-ST-segment-elevation N/A N/A N/A N/A N/A N/A N/A 25035150 1093 myocardial infarction-associated transcript acute myocardial infarction N/A Patients with ST-segment-elevation MI had lower levels of myocardial infarction-associated transcript (P<0.001)when compared with patients with non-ST-segment-elevation N/A N/A N/A N/A N/A N/A N/A 25035150 1094 XLOC_004562 H. pylori-related diseases N/A Using qPCR,the five lncRNAs were found differentially expressed in H. pylori-infected gastric epithelial cells N/A N/A N/A N/A N/A N/A N/A 25420666 1095 XLOC_005912 H. pylori-related diseases N/A Using qPCR,the five lncRNAs were found differentially expressed in H. pylori-infected gastric epithelial cells N/A N/A N/A N/A N/A N/A N/A 25420666 1096 XLOC_000620 H. pylori-related diseases N/A Using qPCR,the five lncRNAs were found differentially expressed in H. pylori-infected gastric epithelial cells N/A N/A N/A N/A N/A N/A N/A 25420666 1097 XLOC_004122 H. pylori-related diseases N/A Using qPCR,the five lncRNAs were found differentially expressed in H. pylori-infected gastric epithelial cells N/A N/A N/A N/A N/A N/A N/A 25420666 1098 XLOC_014388 H. pylori-related diseases N/A Using qPCR,the five lncRNAs were found differentially expressed in H. pylori-infected gastric epithelial cells N/A N/A N/A N/A N/A N/A N/A 25420666 1099 Asb3 cardiovascular and renal disease N/A The protein expression status of 4 target genes, Asb3, Chac2, Pex11b, and Sp5, were differentially expressed between the relevant strain comparisons, thereby suggesting that the differentially expressed lncRNAs associated with these genes are candidate genetic determinants of blood pressure N/A N/A N/A N/A N/A N/A N/A 25385761 1100 Chac2 cardiovascular and renal disease N/A The protein expression status of 4 target genes, Asb3, Chac2, Pex11b, and Sp5, were differentially expressed between the relevant strain comparisons, thereby suggesting that the differentially expressed lncRNAs associated with these genes are candidate genetic determinants of blood pressure N/A N/A N/A N/A N/A N/A N/A 25385761 1101 Pex11b cardiovascular and renal disease N/A The protein expression status of 4 target genes, Asb3, Chac2, Pex11b, and Sp5, were differentially expressed between the relevant strain comparisons, thereby suggesting that the differentially expressed lncRNAs associated with these genes are candidate genetic determinants of blood pressure N/A N/A N/A N/A N/A N/A N/A 25385761 1102 Sp5 cardiovascular and renal disease N/A The protein expression status of 4 target genes, Asb3, Chac2, Pex11b, and Sp5, were differentially expressed between the relevant strain comparisons, thereby suggesting that the differentially expressed lncRNAs associated with these genes are candidate genetic determinants of blood pressure N/A N/A N/A N/A N/A N/A N/A 25385761